Protein Kinase Stress-Related Proteins and Methods of Use in Plants

ABSTRACT

A transgenic plant transformed by a Protein Kinase Stress-Related Protein (PKSRP) coding nucleic acid, wherein expression of the nucleic acid sequence in the plant results in increased tolerance to environmental stress as compared to a wild type variety of the plant. Also provided are agricultural products, including seeds, produced by the transgenic plants. Also provided are isolated PKSRPs, and isolated nucleic acid coding PKSRPs, and vectors and host cells containing the latter.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of allowed U.S. patent applicationSer. No. 10/768,863, filed Jan. 30, 2004, which is a divisional of U.S.patent application Ser. No. 09/828,313, filed Apr. 6, 2001 and now U.S.Pat. No. 6,867,351, which claims the priority benefit of U.S.Provisional Application Ser. No. 60/196,001 filed Apr. 7, 2000.

BACKGROUND OF THE INVENTION

1. Field of the Invention

This invention relates generally to nucleic acid sequences encodingproteins that are associated with abiotic stress responses and abioticstress tolerance in plants. In particular, this invention relates tonucleic acid sequences encoding proteins that confer drought, cold,and/or salt tolerance to plants.

2. Background Art

Abiotic environmental stresses, such as drought stress, salinity stress,heat stress, and cold stress, are major limiting factors of plant growthand productivity. Crop losses and crop yield losses of major crops suchas rice, maize (corn) and wheat caused by these stresses represent asignificant economic and political factor and contribute to foodshortages in many underdeveloped countries.

Plants are typically exposed during their life cycle to conditions ofreduced environmental water content. Most plants have evolved strategiesto protect themselves against these conditions of desiccation. However,if the severity and duration of the drought conditions are too great,the effects on plant development, growth and yield of most crop plantsare profound. Furthermore, most of the crop plants are very susceptibleto higher salt concentrations in the soil. Continuous exposure todrought and high salt causes major alterations in the plant metabolism.These great changes in metabolism ultimately lead to cell death andconsequently yield losses.

Developing stress-tolerant plants is a strategy that has the potentialto solve or mediate at least some of these problems. However,traditional plant breeding strategies to develop new lines of plantsthat exhibit resistance (tolerance) to these types of stresses arerelatively slow and require specific resistant lines for crossing withthe desired line. Limited germplasm resources for stress tolerance andincompatibility in crosses between distantly related plant speciesrepresent significant problems encountered in conventional breeding.Additionally, the cellular processes leading to drought, cold and salttolerance in model, drought- and/or salt-tolerant plants are complex innature and involve multiple mechanisms of cellular adaptation andnumerous metabolic pathways. This multi-component nature of stresstolerance has not only made breeding for tolerance largely unsuccessful,but has also limited the ability to genetically engineer stresstolerance plants using biotechnological methods.

Drought, cold as well as salt stresses have a common theme important forplant growth and that is water availability. Plants are exposed duringtheir entire life cycle to conditions of reduced environmental watercontent. Most plants have evolved strategies to protect themselvesagainst these conditions of desiccation. However, if the severity andduration of the drought conditions are too great, the effects on plantdevelopment, growth and yield of most crop plants are profound. Sincehigh salt content in some soils result in less available water for cellintake, its effect is similar to those observed under droughtconditions. Additionally, under freezing temperatures, plant cells loosewater as a result of ice formation that starts in the apoplast andwithdraws water from the symplast. Commonly, a plant's molecularresponse mechanisms to each of these stress conditions are common andprotein kinases play an essential role in these molecular mechanisms.

Protein kinases represent a super family and the members of this familycatalyze the reversible transfer of a phosphate group of ATP to serine,threonine and tyrosine amino acid side chains on target proteins.Protein kinases are primary elements in signaling processes in plantsand have been reported to play crucial roles in perception andtransduction of signals that allow a cell (and the plant) to respond toenvironmental stimuli. In particular, receptor protein kinases (RPKs)represent one group of protein kinases that activate a complex array ofintracellular signaling pathways in response to the extracellularenvironment (Van der Gear et al., 1994 Annu. Rev. Cell Biol.10:251-337). RPKs are single-pass transmembrane proteins that contain anamino-terminal signal sequence, extracellular domains unique to eachreceptor, and a cytoplasmic kinase domain. Ligand binding induces homo-or hetero-dimerization of RPKs, and the resultant close proximity of thecytoplasmic domains results in kinase activation bytransphosphorylation. Although plants have many proteins similar toRPKs, no ligand has been identified for these receptor-like kinases(RLKs). The majority of plant RLKs that have been identified belong tothe family of Serine/Threonine (Ser/Thr) kinases, and most haveextracellular Leucine-rich repeats (Becraft, P W. 1998 Trends Plant Sci.3:384-388).

Another type of protein kinase is the Ca+-dependent protein kinase(CDPK). This type of kinase has a calmodulin-like domain at the COOHterminus which allows response to Ca+ signals directly withoutcalmodulin being present. Currently, CDPKs are the most prevalentSer/Thr protein kinases found in higher plants. Although theirphysiological roles remain unclear, they are induced by cold, droughtand abscisic acid (ABA) (Knight et al., 1991 Nature 352:524; Schroeder,J I and Thuleau, P., 1991 Plant Cell 3:555; Bush, D. S., 1995 Annu. Rev.Plant Phys. Plant Mol. Biol. 46:95; Urao, T. et al., 1994 Mol. Gen.Genet. 244:331).

Another type of signaling mechanism involves members of the conservedSNF1 Serine/Threonine protein kinase family. These kinases playessential roles in eukaryotic glucose and stress signaling. PlantSNF1-like kinases participate in the control of key metabolic enzymes,including HMGR, nitrate reductase, sucrose synthase, and sucrosephosphate synthase (SPS). Genetic and biochemical data indicate thatsugar-dependent regulation of SNF1 kinases involves several othersensory and signaling components in yeast, plants and animals.

Additionally, members of the Mitogen-Activated Protein Kinase (MAPK)family have been implicated in the actions of numerous environmentalstresses in animals, yeasts and plants. It has been demonstrated thatboth MAPK-like kinase activity and mRNA levels of the components of MAPKcascades increase in response to environmental stress and plant hormonesignal transduction. MAP kinases are components of sequential kinasecascades, which are activated by phosphorylation of threonine andtyrosine residues by intermediate upstream MAP kinase kinases (MAPKKs).The MAPKKs are themselves activated by phosphorylation of serine andthreonine residues by upstream kinases (MAPKKKs). A number of MAP Kinasegenes have been reported in higher plants.

SUMMARY OF THE INVENTION

This invention fulfills in part the need to identify new, unique proteinkinases capable of conferring stress tolerance to plants uponover-expression. The present invention provides a transgenic plant celltransformed by a Protein Kinase Stress-Related Protein (PKSRP) codingnucleic acid, wherein expression of the nucleic acid sequence in theplant cell results in increased tolerance to environmental stress ascompared to a wild type variety of the plant cell. Namely, describedherein are the protein kinases: 1) Ser/Thr Kinase and other type ofkinases (PK-6, PK-7, PK-8 and PK-9); 2) Calcium dependent proteinkinases (CDPK-1 and CDPK-2), 3) Casein Kinase homologs (CK-1, CK-2 andCK-3), and 4) MAP-Kinases (MPK-2, MPK-3, MPK-4 and MPK-5), all fromPhyscomitrella patens.

The invention provides in some embodiments that the PKSRP and codingnucleic acid are that found in members of the genus Physcomitrella. Inanother preferred embodiment, the nucleic acid and protein are from aPhyscomitrella patens. The invention provides that the environmentalstress can be salinity, drought, temperature, metal, chemical,pathogenic and oxidative stresses, or combinations thereof. In preferredembodiments, the environmental stress can be drought or coldtemperature.

The invention further provides a seed produced by a transgenic planttransformed by a PKSRP coding nucleic acid, wherein the plant is truebreeding for increased tolerance to environmental stress as compared toa wild type variety of the plant. The invention further provides a seedproduced by a transgenic plant expressing a PKSRP, wherein the plant istrue breeding for increased tolerance to environmental stress ascompared to a wild type variety of the plant.

The invention further provides an agricultural product produced by anyof the below-described transgenic plants, plant parts or seeds. Theinvention further provides an isolated PKSRP as described below. Theinvention further provides an isolated PKSRP coding nucleic acid,wherein the PKSRP coding nucleic acid codes for a PKSRP as describedbelow.

The invention further provides an isolated recombinant expression vectorcomprising a PKSRP coding nucleic acid as described below, whereinexpression of the vector in a host cell results in increased toleranceto environmental stress as compared to a wild type variety of the hostcell. The invention further provides a host cell containing the vectorand a plant containing the host cell.

The invention further provides a method of producing a transgenic plantwith a PKSRP coding nucleic acid, wherein expression of the nucleic acidin the plant results in increased tolerance to environmental stress ascompared to a wild type variety of the plant comprising: (a)transforming a plant cell with an expression vector comprising a PKSRPcoding nucleic acid, and (b) generating from the plant cell a transgenicplant with an increased tolerance to environmental stress as compared toa wild type variety of the plant. In preferred embodiments, the PKSRPand PKSRP coding nucleic acid are as described below.

The present invention further provides a method of identifying a novelPKSRP, comprising (a) raising a specific antibody response to a PKSRP,or fragment thereof, as described below; (b) screening putative PKSRPmaterial with the antibody, wherein specific binding of the antibody tothe material indicates the presence of a potentially novel PKSRP; and(c) identifying from the bound material a novel PKSRP in comparison toknown PKSRP. Alternatively, hybridization with nucleic acid probes asdescribed below can be used to identify novel PKSRP nucleic acids.

The present invention also provides methods of modifying stresstolerance of a plant comprising, modifying the expression of a PKSRPnucleic acid in the plant, wherein the PKSRP is as described below. Theinvention provides that this method can be performed such that thestress tolerance is either increased or decreased. Preferably, stresstolerance is increased in a plant via increasing expression of a PKSRPnucleic acid.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows a diagram of the plant expression vector pBPSSC022containing the super promoter driving the expression of SEQ ID NOs: 14,15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 and 26 (“Desired Gene”). Thecomponents are: NPTII kanamycin resistance gene (Bevan M, Nucleic AcidsRes. 26: 8711-21, 1984), AtAct2-i promoter (An Y Q et al., Plant J 10:107-121 1996), OCS3 terminator (During K, Transgenic Res. 3: 138-140,1994), NOSpA terminator (Jefferson et al., EMBO J. 6:3901-7 1987).

FIG. 2 shows the results of a drought stress test with over-expressingPpPK-6 transgenic plants and wild-type Arabidopsis lines. The transgeniclines display a tolerant phenotype. Individual transformant lines areshown.

FIG. 3 shows the results of a drought stress test with over-expressingPpPK-7 transgenic plants and wild-type Arabidopsis lines. The transgeniclines display a tolerant phenotype. Individual transformant lines areshown.

FIG. 4 shows the results of a freezing stress test with over-expressingPpPK-7 transgenic plants and wild-type Arabidopsis lines. The transgeniclines display a tolerant phenotype. Individual transformant lines areshown.

FIG. 5 shows the results of a drought stress test with over-expressingPpPK-9 transgenic plants and wild-type Arabidopsis lines. The transgeniclines display a tolerant phenotype. Individual transformant lines areshown.

FIG. 6 shows the results of a freezing stress test with over-expressingPpPK-9 transgenic plants and wild-type Arabidopsis lines. The transgeniclines display a tolerant phenotype. Individual transformant lines areshown.

FIG. 7 shows the results of a drought stress test with over-expressingPpCK-1 transgenic plants and wild-type Arabidopsis lines. The transgeniclines display a tolerant phenotype. Individual transformant lines areshown.

FIG. 8 shows the results of a freezing stress test with over-expressingPpCK-1 transgenic plants and wild-type Arabidopsis lines. The transgeniclines display a tolerant phenotype. Individual transformant lines areshown.

FIG. 9 shows the results of a drought stress test with over-expressingPpCK-2 transgenic plants and wild-type Arabidopsis lines. The transgeniclines display a tolerant phenotype. Individual transformant lines areshown.

FIG. 10 shows the results of a drought stress test with over-expressingPpCK-3 transgenic plants and wild-type Arabidopsis lines. The transgeniclines display a tolerant phenotype. Individual transformant lines areshown.

FIG. 11 shows the results of a drought stress test with over-expressingPpMPK-2 transgenic plants and wild-type Arabidopsis lines. Thetransgenic lines display a tolerant phenotype. Individual transformantlines are shown.

FIG. 12 shows the results of a freezing stress test with over-expressingPpMPK-2 transgenic plants and wild-type Arabidopsis lines. Thetransgenic lines display a tolerant phenotype. Individual transformantlines are shown.

FIG. 13 shows the results of a drought stress test with over-expressingPpMPK-3 transgenic plants and wild-type Arabidopsis lines. Thetransgenic lines display a tolerant phenotype. Individual transformantlines are shown.

FIG. 14 shows the results of a freezing stress test with over-expressingPpMPK-3 transgenic plants and wild-type Arabidopsis lines. Thetransgenic lines display a tolerant phenotype. Individual transformantlines are shown.

FIG. 15 shows the results of a drought stress test with over-expressingPpMPK-4 transgenic plants and wild-type Arabidopsis lines. Thetransgenic lines display a tolerant phenotype. Individual transformantlines are shown.

FIG. 16 shows the results of a drought stress test with over-expressingPpMPK-5 transgenic plants and wild-type Arabidopsis lines. Thetransgenic lines display a tolerant phenotype. Individual transformantlines are shown.

FIG. 17 shows the results of a drought stress test with over-expressingPpCPK-1 transgenic plants and wild-type Arabidopsis lines. Thetransgenic lines display a tolerant phenotype. Individual transformantlines are shown.

FIG. 18 shows the results of a drought stress test with over-expressingPpCPK-2 transgenic plants and wild-type Arabidopsis lines. Thetransgenic lines display a tolerant phenotype. Individual transformantlines are shown.

DETAILED DESCRIPTION OF THE INVENTION

The present invention may be understood more readily by reference to thefollowing detailed description of the preferred embodiments of theinvention and the Examples included herein. However, before the presentcompounds, compositions, and methods are disclosed and described, it isto be understood that this invention is not limited to specific nucleicacids, specific polypeptides, specific cell types, specific host cells,specific conditions, or specific methods, etc., as such may, of course,vary, and the numerous modifications and variations therein will beapparent to those skilled in the art. It is also to be understood thatthe terminology used herein is for the purpose of describing specificembodiments only and is not intended to be limiting. In particular, thedesignation of the amino acid sequences as protein “Protein KinaseStress-Related Proteins” (PKSRPs), in no way limits the functionality ofthose sequences.

The present invention provides a transgenic plant cell transformed by aPKSRP coding nucleic acid, wherein expression of the nucleic acidsequence in the plant cell results in increased tolerance toenvironmental stress as compared to a wild type variety of the plantcell. The invention further provides transgenic plant parts andtransgenic plants containing the plant cells described herein. Alsoprovided is a plant seed produced by a transgenic plant transformed by aPKSRP coding nucleic acid, wherein the seed contains the PKSRP codingnucleic acid, and wherein the plant is true breeding for increasedtolerance to environmental stress as compared to a wild type variety ofthe plant. The invention further provides a seed produced by atransgenic plant expressing a PKSRP, wherein the seed contains thePKSRP, and wherein the plant is true breeding for increased tolerance toenvironmental stress as compared to a wild type variety of the plant.The invention also provides an agricultural product produced by any ofthe below-described transgenic plants, plant parts and plant seeds.

As used herein, the term “variety” refers to a group of plants within aspecies that share constant characters that separate them from thetypical form and from other possible varieties within that species.While possessing at least one distinctive trait, a variety is alsocharacterized by some variation between individuals within the variety,based primarily on the Mendelian segregation of traits among the progenyof succeeding generations. A variety is considered “true breeding” for aparticular trait if it is genetically homozygous for that trait to theextent that, when the true-breeding variety is self-pollinated, asignificant amount of independent segregation of the trait among theprogeny is not observed. In the present invention, the trait arises fromthe transgenic expression of one or more DNA sequences introduced into aplant variety.

The present invention describes for the first time that thePhyscomitrella patens PKSRPs, PK-6, PK-7, PK-8, PK-9, CK-1, CK-2, CK-3,MPK-2, MPK-3, MPK-4, MPK-5, CPK-1 and CPK-2, are useful for increasing aplant's tolerance to environmental stress. Accordingly, the presentinvention provides isolated PKSRPs selected from the group consisting ofPK-6, PK-7, PK-8, PK-9, CK-1, CK-2, CK-3, MPK-2, MPK-3, MPK-4, MPK-5,CPK-1 and CPK-2, and homologs thereof. In preferred embodiments, thePKSRP is selected from 1) Protein Kinase-6 (PK-6) protein as defined inSEQ ID NO:27; 2) Protein Kinase-7 (PK-7) protein as defined in SEQ IDNO:28; 3) Protein Kinase-8 (PK-8) protein as defined in SEQ ID NO:29; 4)Protein Kinase-9 (PK-9) protein as defined in SEQ ID NO:30; 5) CaseinKinase homologue (CK-1) protein as defined in SEQ ID NO:31; 6) CaseinKinase homologue-2 (CK-2) protein as defined in SEQ ID NO:32; 7) CaseinKinase homologue-3 (CK-3) protein as defined in SEQ ID NO:33; 8) MAPKinase-2 (MPK-2) protein as defined in SEQ ID NO:34; 9) MAP Kinase-3(MPK-3) protein as defined in SEQ ID NO:35; 10) MAP Kinase-4 (MPK-4)protein as defined in SEQ ID NO:36; 11) MAP Kinase-5 (MPK-5) protein asdefined in SEQ ID NO:37, 12) Calcium dependent protein kinase-1 (CPK-1)protein as defined in SEQ ID NO:38; 13) Calcium dependent proteinkinase-2 (CPK-2) protein as defined in SEQ ID NO:39; and homologs andorthologs thereof. Homologs and orthologs of the amino acid sequencesare defined below.

The PKSRPs of the present invention are preferably produced byrecombinant DNA techniques. For example, a nucleic acid moleculeencoding the protein is cloned into an expression vector (as describedbelow), the expression vector is introduced into a host cell (asdescribed below) and the PKSRP is expressed in the host cell. The PKSRPcan then be isolated from the cells by an appropriate purificationscheme using standard protein purification techniques. Alternative torecombinant expression, a PKSRP polypeptide, or peptide can besynthesized chemically using standard peptide synthesis techniques.Moreover, native PKSRP can be isolated from cells (e.g., Physcomitrellapatens), for example using an anti-PKSRP antibody, which can be producedby standard techniques utilizing a PKSRP or fragment thereof.

The invention further provides an isolated PKSRP coding nucleic acid.The present invention includes PKSRP coding nucleic acids that encodePKSRPs as described herein. In preferred embodiments, the PKSRP codingnucleic acid is selected from 1) Protein Kinase-6 (PK-6) nucleic acid asdefined in SEQ ID NO: 14; 2) Protein Kinase-7 (PK-7) nucleic acid asdefined in SEQ ID NO:15; 3) Protein Kinase-8 (PK-8) nucleic acid asdefined in SEQ ID NO:16; 4) Protein Kinase-9 (PK-9) nucleic acid asdefined in SEQ ID NO:17; 5) Casein Kinase homolog (CK-1) nucleic acid asdefined in SEQ ID NO:18; 6) Casein Kinase homolog-2 (CK-2) nucleic acidas defined in SEQ ID NO:19; 7) Casein Kinase homolog-3 (CK-3) nucleicacid as defined in SEQ ID NO:20; 8) MAP Kinase-2 (MPK-2) nucleic acid asdefined in SEQ ID NO:21; 9) MAP Kinase-3 (MPK-3) nucleic acid as definedin SEQ ID NO:22; 10) MAP Kinase-4 (MPK-4) nucleic acid as defined in SEQID NO:23; 11) MAP Kinase-5 (MPK-5) nucleic acid as defined in SEQ IDNO:24; 12) Calcium dependent protein kinase-1 (CPK-1) nucleic acid asdefined in SEQ ID NO:25; 13) Calcium dependent protein kinase-2 (CPK-2)nucleic acid as defined in SEQ ID NO:26 and homologs and orthologsthereof. Homologs and orthologs of the nucleotide sequences are definedbelow. In one preferred embodiment, the nucleic acid and protein areisolated from the plant genus Physcomitrella. In another preferredembodiment, the nucleic acid and protein are from a Physcomitrellapatens (P. patens) plant.

As used herein, the term “environmental stress” refers to anysub-optimal growing condition and includes, but is not limited to,sub-optimal conditions associated with salinity, drought, temperature,metal, chemical, pathogenic and oxidative stresses, or combinationsthereof. In preferred embodiments, the environmental stress can besalinity, drought, or temperature, or combinations thereof, and inparticular, can be high salinity, low water content or low temperature.It is also to be understood that as used in the specification and in theclaims, “a” or “an” can mean one or more, depending upon the context inwhich it is used. Thus, for example, reference to “a cell” can mean thatat least one cell can be utilized.

As also used herein, the terms “nucleic acid” and “nucleic acidmolecule” are intended to include DNA molecules (e.g., cDNA or genomicDNA) and RNA molecules (e.g., mRNA) and analogs of the DNA or RNAgenerated using nucleotide analogs. This term also encompassesuntranslated sequence located at both the 3′ and 5′ ends of the codingregion of the gene: at least about 1000 nucleotides of sequence upstreamfrom the 5′ end of the coding region and at least about 200 nucleotidesof sequence downstream from the 3′ end of the coding region of the gene.The nucleic acid molecule can be single-stranded or double-stranded, butpreferably is double-stranded DNA.

An “isolated” nucleic acid molecule is one that is substantiallyseparated from other nucleic acid molecules which are present in thenatural source of the nucleic acid. Preferably, an “isolated” nucleicacid is free of some of the sequences which naturally flank the nucleicacid (i.e., sequences located at the 5′ and 3′ ends of the nucleic acid)in the genomic DNA of the organism from which the nucleic acid isderived. For example, in various embodiments, the isolated PKSRP nucleicacid molecule can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb,0.5 kb or 0.1 kb of nucleotide sequences which naturally flank thenucleic acid molecule in genomic DNA of the cell from which the nucleicacid is derived (e.g., a Physcomitrella patens cell). Moreover, an“isolated” nucleic acid molecule, such as a cDNA molecule, can be freefrom some of the other cellular material with which it is naturallyassociated, or culture medium when produced by recombinant techniques,or chemical precursors or other chemicals when chemically synthesized.

A nucleic acid molecule of the present invention, e.g., a nucleic acidmolecule having a nucleotide sequence of SEQ ID NO: 14, SEQ ID NO:15,SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20,SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25 orSEQ ID NO:26, or a portion thereof, can be isolated using standardmolecular biology techniques and the sequence information providedherein. For example, a P. patens PKSRP cDNA can be isolated from a P.patens library using all or portion of one of the sequences of SEQ IDNO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6,SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQID NO:12 and SEQ ID NO:13. Moreover, a nucleic acid moleculeencompassing all or a portion of one of the sequences of SEQ ID NO:1,SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ IDNO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12and SEQ ID NO:13 can be isolated by the polymerase chain reaction usingoligonucleotide primers designed based upon this sequence. For example,mRNA can be isolated from plant cells (e.g., by theguanidinium-thiocyanate extraction procedure of Chirgwin et al., 1979Biochemistry 18:5294-5299) and cDNA can be prepared using reversetranscriptase (e.g., Moloney MLV reverse transcriptase, available fromGibco/BRt, Bethesda, Md.; or AMV reverse transcriptase, available fromSeikagaku America, Inc., St. Petersburg, Fla.). Syntheticoligonucleotide primers for polymerase chain reaction amplification canbe designed based upon one of the nucleotide sequences shown in SEQ IDNO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6,SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQID NO:12 and SEQ ID NO:13. A nucleic acid molecule of the invention canbe amplified using cDNA or, alternatively, genomic DNA, as a templateand appropriate oligonucleotide primers according to standard PCRamplification techniques. The nucleic acid molecule so amplified can becloned into an appropriate vector and characterized by DNA sequenceanalysis. Furthermore, oligonucleotides corresponding to a PKSRPnucleotide sequence can be prepared by standard synthetic techniques,e.g., using an automated DNA synthesizer.

In a preferred embodiment, an isolated nucleic acid molecule of theinvention comprises one of the nucleotide sequences shown in SEQ IDNO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ IDNO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ IDNO:24, SEQ ID NO:25 and SEQ ID NO:26. These cDNAs comprise sequencesencoding the PKSRPs (i.e., the “coding region”, indicated in Table 1),as well as 5′ untranslated sequences and 3′ untranslated sequences. Itis to be understood that SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ IDNO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25 and SEQ ID NO:26comprise both coding regions and 5′ and 3′ untranslated regions.Alternatively, the nucleic acid molecules of the present invention cancomprise only the coding region of any of the sequences in SEQ ID NO:14,SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19,SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24,SEQ ID NO:25 or SEQ ID NO:26 or can contain whole genomic fragmentsisolated from genomic DNA. A coding region of these sequences isindicated as “ORF position”. The present invention also includes PKSRPcoding nucleic acids that encode PKSRPs as described herein. Preferredis a PKSRP coding nucleic acid that encodes a PKSRP selected from thegroup consisting of, PK-6 (SEQ ID NO:27), PK-7 (SEQ ID NO:28), PK-8 (SEQID NO:29), PK-9 (SEQ ID NO:30), CK-1 (SEQ ID NO:31), CK-2 (SEQ IDNO:32), CK-3 (SEQ ID NO:33), MPK-2 (SEQ ID NO:34), MPK-3 (SEQ ID NO:35),MPK-4 (SEQ ID NO:36), MPK-5 (SEQ ID NO:37), CPK-1 (SEQ ID NO:38) andCPK-2 (SEQ ID NO:39).

Moreover, the nucleic acid molecule of the invention can comprise only aportion of the coding region of one of the sequences in SEQ ID NO:14,SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19,SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24,SEQ ID NO:25 and SEQ ID NO:26, for example, a fragment which can be usedas a probe or primer or a fragment encoding a biologically activeportion of a PKSRP. The nucleotide sequences determined from the cloningof the PKSRP genes from P. patens allow for the generation of probes andprimers designed for use in identifying and/or cloning PKSRP homologs inother cell types and organisms, as well as PKSRP homologs from othermosses and related species.

Portions of proteins encoded by the PKSRP nucleic acid molecules of theinvention are preferably biologically active portions of one of thePKSRPs described herein. As used herein, the term “biologically activeportion of” a PKSRP is intended to include a portion, e.g., adomain/motif, of a PKSRP that participates in a stress toleranceresponse in a plant, has an activity as set forth in Table 1, orparticipates in the transcription of a protein involved in a stresstolerance response in a plant. To determine whether a PKSRP, or abiologically active portion thereof, can participate in transcription ofa protein involved in a stress tolerance response in a plant, or whetherrepression of a PKSRP results in increased stress tolerance in a plant,a stress analysis of a plant comprising the PKSRP may be performed. Suchanalysis methods are well known to those skilled in the art, as detailedin Example 7. More specifically, nucleic acid fragments encodingbiologically active portions of a PKSRP can be prepared by isolating aportion of one of the sequences in SEQ ID NO:27, SEQ ID NO:28, SEQ IDNO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ IDNO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38 and SEQ IDNO:39, expressing the encoded portion of the PKSRP or peptide (e.g., byrecombinant expression in vitro) and assessing the activity of theencoded portion of the PKSRP or peptide.

Biologically active portions of a PKSRP are encompassed by the presentinvention and include peptides comprising amino acid sequences derivedfrom the amino acid sequence of a PKSRP, e.g., an amino acid sequence ofSEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31,SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36,SEQ ID NO:37, SEQ ID NO:38 or SEQ ID NO:39, or the amino acid sequenceof a protein homologous to a PKSRP, which include fewer amino acids thana full length PKSRP or the full length protein which is homologous to aPKSRP, and exhibit at least one activity of a PKSRP. Typically,biologically active portions (e.g., peptides which are, for example, 5,10, 15, 20, 30, 35, 36, 37, 38, 39, 40, 50, 100 or more amino acids inlength) comprise a domain or motif with at least one activity of aPKSRP. Moreover, other biologically active portions in which otherregions of the protein are deleted, can be prepared by recombinanttechniques and evaluated for one or more of the activities describedherein. Preferably, the biologically active portions of a PKSRP includeone or more selected domains/motifs or portions thereof havingbiological activity.

The invention also provides PKSRP chimeric or fusion proteins. As usedherein, a PKSRP “chimeric protein” or “fusion protein” comprises a PKSRPpolypeptide operatively linked to a non-PKSRP polypeptide. A PKSRPpolypeptide refers to a polypeptide having an amino acid sequencecorresponding to a PKSRP, whereas a non-PKSRP polypeptide refers to apolypeptide having an amino acid sequence corresponding to a proteinwhich is not substantially homologous to the PKSRP, e.g., a protein thatis different from the PKSRP and is derived from the same or a differentorganism. Within the fusion protein, the term “operatively linked” isintended to indicate that the PKSRP polypeptide and the non-PKSRPpolypeptide are fused to each other so that both sequences fulfill theproposed function attributed to the sequence used. The non-PKSRPpolypeptide can be fused to the N-terminus or C-terminus of the PKSRPpolypeptide. For example, in one embodiment, the fusion protein is aGST-PKSRP fusion protein in which the PKSRP sequences are fused to theC-terminus of the GST sequences. Such fusion proteins can facilitate thepurification of recombinant PKSRPs. In another embodiment, the fusionprotein is a PKSRP containing a heterologous signal sequence at itsN-terminus. In certain host cells (e.g., mammalian host cells),expression and/or secretion of a PKSRP can be increased through use of aheterologous signal sequence.

Preferably, a PKSRP chimeric or fusion protein of the invention isproduced by standard recombinant DNA techniques. For example, DNAfragments coding for the different polypeptide sequences are ligatedtogether in-frame in accordance with conventional techniques, forexample by employing blunt-ended or stagger-ended termini for ligation,restriction enzyme digestion to provide for appropriate termini,filling-in of cohesive ends as appropriate, alkaline phosphatasetreatment to avoid undesirable joining and enzymatic ligation. Inanother embodiment, the fusion gene can be synthesized by conventionaltechniques including automated DNA synthesizers. Alternatively, PCRamplification of gene fragments can be carried out using anchor primerswhich give rise to complementary overhangs between two consecutive genefragments which can subsequently be annealed and re-amplified togenerate a chimeric gene sequence (see, for example, Current Protocolsin Molecular Biology, Eds. Ausubel et al. John Wiley & Sons: 1992).Moreover, many expression vectors are commercially available thatalready encode a fusion moiety (e.g., a GST polypeptide). A PKSRPencoding nucleic acid can be cloned into such an expression vector suchthat the fusion moiety is linked in-frame to the PKSRP.

In addition to fragments and fusion proteins of the PKSRPs describedherein, the present invention includes homologs and analogs of naturallyoccurring PKSRPs and PKSRP encoding nucleic acids in a plant. “Homologs”are defined herein as two nucleic acids or proteins that have similar,or “homologous”, nucleotide or amino acid sequences, respectively.Homologs include allelic variants, orthologs, paralogs, agonists andantagonists of PKSRPs as defined hereafter. The term “homolog” furtherencompasses nucleic acid molecules that differ from one of thenucleotide sequences shown in SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16,SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21,SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25 and SEQ ID NO:26(and portions thereof) due to degeneracy of the genetic code and thusencode the same PKSRP as that encoded by the nucleotide sequences shownin SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18,SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23,SEQ ID NO:24, SEQ ID NO:25 or SEQ ID NO:26. As used herein a “naturallyoccurring” PKSRP refers to a PKSRP amino acid sequence that occurs innature. Preferably, a naturally occurring PKSRP comprises an amino acidsequence selected from the group consisting of SEQ ID NO:27, SEQ IDNO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ IDNO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ IDNO:38 and SEQ ID NO:39.

An agonist of the PKSRP can retain substantially the same, or a subset,of the biological activities of the PKSRP. An antagonist of the PKSRPcan inhibit one or more of the activities of the naturally occurringform of the PKSRP. For example, the PKSRP antagonist can competitivelybind to a downstream or upstream member of the cell membrane componentmetabolic cascade that includes the PKSRP, or bind to a PKSRP thatmediates transport of compounds across such membranes, therebypreventing translocation from taking place.

Nucleic acid molecules corresponding to natural allelic variants andanalogs, orthologs and paralogs of a PKSRP cDNA can be isolated based ontheir identity to the Physcomitrella patens PKSRP nucleic acidsdescribed herein using PKSRP cDNAs, or a portion thereof, as ahybridization probe according to standard hybridization techniques understringent hybridization conditions. In an alternative embodiment,homologs of the PKSRP can be identified by screening combinatoriallibraries of mutants, e.g., truncation mutants, of the PKSRP for PKSRPagonist or antagonist activity. In one embodiment, a variegated libraryof PKSRP variants is generated by combinatorial mutagenesis at thenucleic acid level and is encoded by a variegated gene library. Avariegated library of PKSRP variants can be produced by, for example,enzymatically ligating a mixture of synthetic oligonucleotides into genesequences such that a degenerate set of potential PKSRP sequences isexpressible as individual polypeptides, or alternatively, as a set oflarger fusion proteins (e.g., for phage display) containing the set ofPKSRP sequences therein. There are a variety of methods that can be usedto produce libraries of potential PKSRP homologs from a degenerateoligonucleotide sequence. Chemical synthesis of a degenerate genesequence can be performed in an automatic DNA synthesizer, and thesynthetic gene is then ligated into an appropriate expression vector.Use of a degenerate set of genes allows for the provision, in onemixture, of all of the sequences encoding the desired set of potentialPKSRP sequences. Methods for synthesizing degenerate oligonucleotidesare known in the art (see, e.g., Narang, S. A., 1983 Tetrahedron 39:3;Itakura et al., 1984 Annu. Rev. Biochem. 53:323; Itakura et al., 1984Science 198:1056; Ike et al., 1983 Nucleic Acid Res. 11:477).

In addition, libraries of fragments of the PKSRP coding regions can beused to generate a variegated population of PKSRP fragments forscreening and subsequent selection of homologs of a PKSRP. In oneembodiment, a library of coding sequence fragments can be generated bytreating a double stranded PCR fragment of a PKSRP coding sequence witha nuclease under conditions wherein nicking occurs only about once permolecule, denaturing the double stranded DNA, renaturing the DNA to formdouble stranded DNA, which can include sense/antisense pairs fromdifferent nicked products, removing single stranded portions fromreformed duplexes by treatment with S1 nuclease, and ligating theresulting fragment library into an expression vector. By this method, anexpression library can be derived which encodes N-terminal, C-terminaland internal fragments of various sizes of the PKSRP.

Several techniques are known in the art for screening gene products ofcombinatorial libraries made by point mutations or truncation, and forscreening cDNA libraries for gene products having a selected property.Such techniques are adaptable for rapid screening of the gene librariesgenerated by the combinatorial mutagenesis of PKSRP homologs. The mostwidely used techniques, which are amenable to high through-put analysis,for screening large gene libraries typically include cloning the genelibrary into replicable expression vectors, transforming appropriatecells with the resulting library of vectors, and expressing thecombinatorial genes under conditions in which detection of a desiredactivity facilitates isolation of the vector encoding the gene whoseproduct was detected. Recursive ensemble mutagenesis (REM), a newtechnique that enhances the frequency of functional mutants in thelibraries, can be used in combination with the screening assays toidentify PKSRP homologs (Arkin and Yourvan, 1992 PNAS 89:7811-7815;Delgrave et al., 1993 Protein Engineering 6(3):327-331). In anotherembodiment, cell based assays can be exploited to analyze a variegatedPKSRP library, using methods well known in the art. The presentinvention further provides a method of identifying a novel PKSRP,comprising (a) raising a specific antibody response to a PKSRP, or afragment thereof, as described herein; (b) screening putative PKSRPmaterial with the antibody, wherein specific binding of the antibody tothe material indicates the presence of a potentially novel PKSRP; and(c) analyzing the bound material in comparison to known PKSRP, todetermine its novelty.

To determine the percent homology of two amino acid sequences (e.g., oneof the sequences of SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ IDNO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ IDNO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38 and SEQ ID NO:39 and amutant form thereof), the sequences are aligned for optimal comparisonpurposes (e.g., gaps can be introduced in the sequence of one protein ornucleic acid for optimal alignment with the other protein or nucleicacid). The amino acid residues at corresponding amino acid positions ornucleotide positions are then compared. When a position in one sequence(e.g., one of the sequences of SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29,SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34,SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38 and SEQ ID NO:39)is occupied by the same amino acid residue as the corresponding positionin the other sequence (e.g., a mutant form of the sequence selected fromthe polypeptide of SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ IDNO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ IDNO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38 and SEQ ID NO:39), thenthe molecules are homologous at that position (i.e., as used hereinamino acid or nucleic acid “homology” is equivalent to amino acid ornucleic acid “identity”). The same type of comparison can be madebetween two nucleic acid sequences.

The percent homology between the two sequences is a function of thenumber of identical positions shared by the sequences (i.e., %homology=numbers of identical positions/total numbers of positions×100).Preferably, the amino acid sequences included in the present inventionare at least about 50-60%, preferably at least about 60-70%, and morepreferably at least about 70-80%, 80-90%, 90-95%, and most preferably atleast about 96%, 97%, 98%, 99% or more homologous to an entire aminoacid sequence shown in SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ IDNO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ IDNO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38 or SEQ ID NO:39. In yetanother embodiment, at least about 50-60%, preferably at least about60-70%, and more preferably at least about 70-80%, 80-90%, 90-95%, andmost preferably at least about 96%, 97%, 98%, 99% or more homologous toan entire amino acid sequence encoded by a nucleic acid sequence shownin SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18,SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23,SEQ ID NO:24, SEQ ID NO:25 or SEQ ID NO:26. In other embodiments, thepreferable length of sequence comparison for proteins is at least 15amino acid residues, more preferably at least 25 amino acid residues,and most preferably at least 35 amino acid residues.

In another preferred embodiment, an isolated nucleic acid molecule ofthe invention comprises a nucleotide sequence which is at least about50-60%, preferably at least about 60-70%, more preferably at least about70-80%, 80-90%, or 90-95%, and even more preferably at least about 95%,96%, 97%, 98%, 99% or more homologous to a nucleotide sequence shown inSEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18,SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23,SEQ ID NO:24, SEQ ID NO:25 or SEQ ID NO:26, or a portion thereof. Thepreferable length of sequence comparison for nucleic acids is at least75 nucleotides, more preferably at least 100 nucleotides and mostpreferably the entire length of the coding region.

It is also preferable that the homologous nucleic acid molecule of theinvention encodes a protein or portion thereof which includes an aminoacid sequence which is sufficiently homologous to an amino acid sequenceof SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31,SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36,SEQ ID NO:37, SEQ ID NO:38 or SEQ ID NO:39 such that the protein orportion thereof maintains the same or a similar function as the aminoacid sequence to which it is compared. Functions of the PKSRP amino acidsequences of the present invention include the ability to participate ina stress tolerance response in a plant, or more particularly, toparticipate in the transcription of a protein involved in a stresstolerance response in a Physcomitrella patens plant. Examples of suchactivities are described in Table 1.

In addition to the above described methods, a determination of thepercent homology between two sequences can be accomplished using amathematical algorithm. A preferred, non-limiting example of amathematical algorithm utilized for the comparison of two sequences isthe algorithm of Karlin and Altschul (1990 Proc. Natl. Acad. Sci. USA90:5873-5877). Such an algorithm is incorporated into the NBLAST andXBLAST programs of Altschul, et al. (1990 J. Mol. Biol. 215:403-410).

BLAST nucleic acid searches can be performed with the NBLAST program,score=100, wordlength=12 to obtain nucleic acid sequences homologous tothe PKSRP nucleic acid molecules of the invention. Additionally, BLASTprotein searches can be performed with the XBLAST program, score=50,wordlength=3 to obtain amino acid sequences homologous to PKSRPs of thepresent invention. To obtain gapped alignments for comparison purposes,Gapped BLAST can be utilized as described in Altschul et al. (1997Nucleic Acids Res. 25:3389-3402). When utilizing BLAST and Gapped BLASTprograms, the default parameters of the respective programs (e.g.,XBLAST and NBLAST) can be used. Another preferred non-limiting exampleof a mathematical algorithm utilized for the comparison of sequences isthe algorithm of Myers and Miller (CABIOS 1989). Such an algorithm isincorporated into the ALIGN program (version 2.0) that is part of theGCG sequence alignment software package. When utilizing the ALIGNprogram for comparing amino acid sequences, a PAM120 weight residuetable, a gap length penalty of 12 and a gap penalty of 4 can be used toobtain amino acid sequences homologous to the PKSRPs of the presentinvention. To obtain gapped alignments for comparison purposes, GappedBLAST can be utilized as described in Altschul et al. (1997 NucleicAcids Res. 25:3389-3402). When utilizing BLAST and Gapped BLASTprograms, the default parameters of the respective programs (e.g.,XBLAST and NBLAST) can be used. Another preferred non-limiting exampleof a mathematical algorithm utilized for the comparison of sequences isthe algorithm of Myers and Miller (CABIOS 1989). Such an algorithm isincorporated into the ALIGN program (version 2.0) that is part of theGCG sequence alignment software package. When utilizing the ALIGNprogram for comparing amino acid sequences, a PAM120 weight residuetable, a gap length penalty of 12 and a gap penalty of 4 can be used.

Finally, homology between nucleic acid sequences can also be determinedusing hybridization techniques known to those of skill in the art.Accordingly, an isolated nucleic acid molecule of the inventioncomprises a nucleotide sequence which hybridizes, e.g., hybridizes understringent conditions, to one of the nucleotide sequences shown in SEQ IDNO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ IDNO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ IDNO:24, SEQ ID NO:25 and SEQ ID NO:26, or a portion thereof. Moreparticularly, an isolated nucleic acid molecule of the invention is atleast 15 nucleotides in length and hybridizes under stringent conditionsto the nucleic acid molecule comprising a nucleotide sequence of SEQ IDNO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ IDNO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ IDNO:24, SEQ ID NO:25 or SEQ ID NO:26. In other embodiments, the nucleicacid is at least 30, 50, 100, 250 or more nucleotides in length.

As used herein, the term “hybridizes under stringent conditions” isintended to describe conditions for hybridization and washing underwhich nucleotide sequences at least 60% homologous to each othertypically remain hybridized to each other. Preferably, the conditionsare such that sequences at least about 65%, more preferably at leastabout 70%, and even more preferably at least about 75% or morehomologous to each other typically remain hybridized to each other. Suchstringent conditions are known to those skilled in the art and can befound in Current Protocols in Molecular Biology, 6.3.1-6.3.6, John Wiley& Sons, N.Y. (1989). A preferred, non-limiting example of stringenthybridization conditions are hybridization in 6× sodium chloride/sodiumcitrate (SSC) at about 45° C., followed by one or more washes in0.2×SSC, 0.1% SDS at 50-65° C. Preferably, an isolated nucleic acidmolecule of the invention that hybridizes under stringent conditions toa sequence of SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17,SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22,SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25 or SEQ ID NO:26 corresponds toa naturally occurring nucleic acid molecule. As used herein, a“naturally occurring” nucleic acid molecule refers to an RNA or DNAmolecule having a nucleotide sequence that occurs in nature (e.g.,encodes a natural protein). In one embodiment, the nucleic acid encodesa naturally occurring Physcomitrella patens PKSRP.

Using the above-described methods, and others known to those of skill inthe art, one of ordinary skill in the art can isolate homologs of thePKSRPs comprising amino acid sequences shown in SEQ ID NO:27, SEQ IDNO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ IDNO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ IDNO:38 or SEQ ID NO:39. One subset of these homologs are allelicvariants. As used herein, the term “allelic variant” refers to anucleotide sequence containing polymorphisms that lead to changes in theamino acid sequences of a PKSRP and that exist within a naturalpopulation (e.g., a plant species or variety). Such natural allelicvariations can typically result in 1-5% variance in a PKSRP nucleicacid. Allelic variants can be identified by sequencing the nucleic acidsequence of interest in a number of different plants, which can bereadily carried out by using hybridization probes to identify the samePKSRP genetic locus in those plants. Any and all such nucleic acidvariations and resulting amino acid polymorphisms or variations in aPKSRP that are the result of natural allelic variation and that do notalter the functional activity of a PKSRP, are intended to be within thescope of the invention.

Moreover, nucleic acid molecules encoding PKSRPs from the same or otherspecies such as PKSRP analogs, orthologs and paralogs, are intended tobe within the scope of the present invention. As used herein, the term“analogs” refers to two nucleic acids that have the same or similarfunction, but that have evolved separately in unrelated organisms. Asused herein, the term “orthologs” refers to two nucleic acids fromdifferent species, but that have evolved from a common ancestral gene byspeciation. Normally, orthologs encode proteins having the same orsimilar functions. As also used herein, the term “paralogs” refers totwo nucleic acids that are related by duplication within a genome.Paralogs usually have different functions, but these functions may berelated (Tatusov, R. L. et al. 1997 Science 278(5338):631-637). Analogs,orthologs and paralogs of a naturally occurring PKSRP can differ fromthe naturally occurring PKSRP by post-translational modifications, byamino acid sequence differences, or by both. Post-translationalmodifications include in vivo and in vitro chemical derivatization ofpolypeptides, e.g., acetylation, carboxylation, phosphorylation, orglycosylation, and such modifications may occur during polypeptidesynthesis or processing or following treatment with isolated modifyingenzymes. In particular, orthologs of the invention will generallyexhibit at least 80-85%, more preferably 90%, and most preferably 95%,96%, 97%, 98% or even 99% identity or homology with all or part of anaturally occurring PKSRP amino acid sequence and will exhibit afunction similar to a PKSRP. Orthologs of the present invention are alsopreferably capable of participating in the stress response in plants. Inone embodiment, the PKSRP orthologs maintain the ability to participatein the metabolism of compounds necessary for the construction ofcellular membranes in Physcomitrella patens, or in the transport ofmolecules across these membranes.

In addition to naturally-occurring variants of a PKSRP sequence that mayexist in the population, the skilled artisan will further appreciatethat changes can be introduced by mutation into a nucleotide sequence ofSEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18,SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23,SEQ ID NO:24, SEQ ID NO:25 or SEQ ID NO:26, thereby leading to changesin the amino acid sequence of the encoded PKSRP, without altering thefunctional ability of the PKSRP. For example, nucleotide substitutionsleading to amino acid substitutions at “non-essential” amino acidresidues can be made in a sequence of SEQ ID NO: 14, SEQ ID NO:15, SEQID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ IDNO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25 or SEQ IDNO:26. A “non-essential” amino acid residue is a residue that can bealtered from the wild-type sequence of one of the PKSRPs withoutaltering the activity of said PKSRP, whereas an “essential” amino acidresidue is required for PKSRP activity. Other amino acid residues,however, (e.g., those that are not conserved or only semi-conserved inthe domain having PKSRP activity) may not be essential for activity andthus are likely to be amenable to alteration without altering PKSRPactivity.

Accordingly, another aspect of the invention pertains to nucleic acidmolecules encoding PKSRPs that contain changes in amino acid residuesthat are not essential for PKSRP activity. Such PKSRPs differ in aminoacid sequence from a sequence contained in SEQ ID NO:27, SEQ ID NO:28,SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33,SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38 orSEQ ID NO:39, yet retain at least one of the PKSRP activities describedherein. In one embodiment, the isolated nucleic acid molecule comprisesa nucleotide sequence encoding a protein, wherein the protein comprisesan amino acid sequence at least about 50% homologous to an amino acidsequence of SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ IDNO:36, SEQ ID NO:37, SEQ ID NO:38 and SEQ ID NO:39. Preferably, theprotein encoded by the nucleic acid molecule is at least about 50-60%homologous to one of the sequences of SEQ ID NO:27, SEQ ID NO:28, SEQ IDNO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ IDNO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38 and SEQ IDNO:39, more preferably at least about 60-70% homologous to one of thesequences of SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ IDNO:36, SEQ ID NO:37, SEQ ID NO:38 and SEQ ID NO:39, even more preferablyat least about 70-80%, 80-90%, 90-95% homologous to one of the sequencesof SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31,SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36,SEQ ID NO:37, SEQ ID NO:38 and SEQ ID NO:39, and most preferably atleast about 96%, 97%, 98%, or 99% homologous to one of the sequences ofSEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31,SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36,SEQ ID NO:37, SEQ ID NO:38 and SEQ ID NO:39. The preferred PKSRPhomologs of the present invention are preferably capable ofparticipating in the a stress tolerance response in a plant, or moreparticularly, participating in the transcription of a protein involvedin a stress tolerance response in a Physcomitrella patens plant, or haveone or more activities set forth in Table 1.

An isolated nucleic acid molecule encoding a PKSRP homologous to aprotein sequence of SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ IDNO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ IDNO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38 or SEQ ID NO:39 can becreated by introducing one or more nucleotide substitutions, additionsor deletions into a nucleotide sequence of SEQ ID NO:14, SEQ ID NO:15,SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20,SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25 orSEQ ID NO:26 such that one or more amino acid substitutions, additionsor deletions are introduced into the encoded protein. Mutations can beintroduced into one of the sequences of SEQ ID NO:14, SEQ ID NO:15, SEQID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ IDNO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25 and SEQ IDNO:26 by standard techniques, such as site-directed mutagenesis andPCR-mediated mutagenesis. Preferably, conservative amino acidsubstitutions are made at one or more predicted non-essential amino acidresidues. A “conservative amino acid substitution” is one in which theamino acid residue is replaced with an amino acid residue having asimilar side chain.

Families of amino acid residues having similar side chains have beendefined in the art. These families include amino acids with basic sidechains (e.g., lysine, arginine, histidine), acidic side chains (e.g.,aspartic acid, glutamic acid), uncharged polar side chains (e.g.,glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine),nonpolar side chains (e.g., alanine, valine, leucine, isoleucine,proline, phenylalanine, methionine, tryptophan), beta-branched sidechains (e.g., threonine, valine, isoleucine) and aromatic side chains(e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, apredicted nonessential amino acid residue in a PKSRP is preferablyreplaced with another amino acid residue from the same side chainfamily. Alternatively, in another embodiment, mutations can beintroduced randomly along all or part of a PKSRP coding sequence, suchas by saturation mutagenesis, and the resultant mutants can be screenedfor a PKSRP activity described herein to identify mutants that retainPKSRP activity. Following mutagenesis of one of the sequences of SEQ IDNO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ IDNO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ IDNO:24, SEQ ID NO:25 and SEQ ID NO:26, the encoded protein can beexpressed recombinantly and the activity of the protein can bedetermined by analyzing the stress tolerance of a plant expressing theprotein as described in Example 7.

In addition to the nucleic acid molecules encoding the PKSRPs describedabove, another aspect of the invention pertains to isolated nucleic acidmolecules that are antisense thereto. An “antisense” nucleic acidcomprises a nucleotide sequence that is complementary to a “sense”nucleic acid encoding a protein, e.g., complementary to the codingstrand of a double-stranded cDNA molecule or complementary to an mRNAsequence. Accordingly, an antisense nucleic acid can hydrogen bond to asense nucleic acid. The antisense nucleic acid can be complementary toan entire PKSRP coding strand, or to only a portion thereof. In oneembodiment, an antisense nucleic acid molecule is antisense to a “codingregion” of the coding strand of a nucleotide sequence encoding a PKSRP.The term “coding region” refers to the region of the nucleotide sequencecomprising codons that are translated into amino acid residues (e.g.,the entire coding region of , , , comprises nucleotides 1 to . . . ). Inanother embodiment, the antisense nucleic acid molecule is antisense toa “noncoding region” of the coding strand of a nucleotide sequenceencoding a PKSRP. The term “noncoding region” refers to 5′ and 3′sequences that flank the coding region that are not translated intoamino acids (i.e., also referred to as 5′ and 3′ untranslated regions).

In a preferred embodiment, an isolated nucleic acid molecule of theinvention comprises a nucleic acid molecule which is a complement of oneof the nucleotide sequences shown in SEQ ID NO:14, SEQ ID NO:15, SEQ IDNO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ IDNO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25 and SEQ IDNO:26, or a portion thereof. A nucleic acid molecule that iscomplementary to one of the nucleotide sequences shown in SEQ ID NO:14,SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19,SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24,SEQ ID NO:25 and SEQ ID NO:26 is one which is sufficiently complementaryto one of the nucleotide sequences shown in SEQ ID NO:14, SEQ ID NO:15,SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20,SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25 andSEQ ID NO:26 such that it can hybridize to one of the nucleotidesequences shown in SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ IDNO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ IDNO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25 and SEQ ID NO:26,thereby forming a stable duplex.

Given the coding strand sequences encoding the PKSRPs disclosed herein(e.g., the sequences set forth in SEQ ID NO:14, SEQ ID NO:15, SEQ IDNO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ IDNO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25 and SEQ IDNO:26), antisense nucleic acids of the invention can be designedaccording to the rules of Watson and Crick base pairing. The antisensenucleic acid molecule can be complementary to the entire coding regionof PKSRP mRNA, but more preferably is an oligonucleotide which isantisense to only a portion of the coding or noncoding region of PKSRPmRNA. For example, the antisense oligonucleotide can be complementary tothe region surrounding the translation start site of PKSRP mRNA. Anantisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25,30, 35, 40, 45 or 50 nucleotides in length.

An antisense nucleic acid of the invention can be constructed usingchemical synthesis and enzymatic ligation reactions using proceduresknown in the art. For example, an antisense nucleic acid (e.g., anantisense oligonucleotide) can be chemically synthesized using naturallyoccurring nucleotides or variously modified nucleotides designed toincrease the biological stability of the molecules or to increase thephysical stability of the duplex formed between the antisense and sensenucleic acids, e.g., phosphorothioate derivatives and acridinesubstituted nucleotides can be used. Examples of modified nucleotideswhich can be used to generate the antisense nucleic acid include5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil,hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxylmethyl)uracil, 5-carboxymethylaminomethyl-2-thiouridine,5-carboxymethylaminomethyluracil, dihydrouracil,beta-D-galactosylqueosine, inosine, N6-isopentenyladenine,1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine,2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine,7-methylguanine, 5-methylaminomethyluracil,5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine,5′-methoxycarboxymethyluracil, 5-methoxyuracil,2-methylthio-N-6-isopentenyladenine, uracil-5-oxyacetic acid (v),wybutoxosine, pseudouracil, queosine, 2-thiocytosine,5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil,uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v),5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w,and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can beproduced biologically using an expression vector into which a nucleicacid has been subcloned in an antisense orientation (i.e., RNAtranscribed from the inserted nucleic acid will be of an antisenseorientation to a target nucleic acid of interest, described further inthe following subsection).

The antisense nucleic acid molecules of the invention are typicallyadministered to a cell or generated in situ such that they hybridizewith or bind to cellular mRNA and/or genomic DNA encoding a PKSRP tothereby inhibit expression of the protein, e.g., by inhibitingtranscription and/or translation. The hybridization can be byconventional nucleotide complementarity to form a stable duplex, or, forexample, in the case of an antisense nucleic acid molecule which bindsto DNA duplexes, through specific interactions in the major groove ofthe double helix. The antisense molecule can be modified such that itspecifically binds to a receptor or an antigen expressed on a selectedcell surface, e.g., by linking the antisense nucleic acid molecule to apeptide or an antibody which binds to a cell surface receptor orantigen. The antisense nucleic acid molecule can also be delivered tocells using the vectors described herein. To achieve sufficientintracellular concentrations of the antisense molecules, vectorconstructs in which the antisense nucleic acid molecule is placed underthe control of a strong prokaryotic, viral, or eukaryotic (includingplant) promoter are preferred.

In yet another embodiment, the antisense nucleic acid molecule of theinvention is an α-anomeric nucleic acid molecule. An α-anomeric nucleicacid molecule forms specific double-stranded hybrids with complementaryRNA in which, contrary to the usual β-units, the strands run parallel toeach other (Gaultier et al., 1987 Nucleic Acids. Res. 15:6625-6641). Theantisense nucleic acid molecule can also comprise a2′-o-methylribonucleotide (Inoue et al., 1987 Nucleic Acids Res.15:6131-6148) or a chimeric RNA-DNA analogue (Inoue et al., 1987 FEBSLett. 215:327-330).

In still another embodiment, an antisense nucleic acid of the inventionis a ribozyme. Ribozymes are catalytic RNA molecules with ribonucleaseactivity which are capable of cleaving a single-stranded nucleic acid,such as an mRNA, to which they have a complementary region. Thus,ribozymes (e.g., hammerhead ribozymes described in Haselhoff andGerlach, 1988 Nature 334:585-591) can be used to catalytically cleavePKSRP mRNA transcripts to thereby inhibit translation of PKSRP mRNA. Aribozyme having specificity for a PKSRP-encoding nucleic acid can bedesigned based upon the nucleotide sequence of a PKSRP cDNA, asdisclosed herein (i.e., SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ IDNO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ IDNO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25 or SEQ ID NO:26) or onthe basis of a heterologous sequence to be isolated according to methodstaught in this invention. For example, a derivative of a TetrahymenaL-19 IVS RNA can be constructed in which the nucleotide sequence of theactive site is complementary to the nucleotide sequence to be cleaved ina PKSRP-encoding mRNA. See, e.g., Cech et al. U.S. Pat. No. 4,987,071and Cech et al. U.S. Pat. No. 5,116,742. Alternatively, PKSRP mRNA canbe used to select a catalytic RNA having a specific ribonucleaseactivity from a pool of RNA molecules. See, e.g., Bartel, D. andSzostak, J. W., 1993 Science 261:1411-1418.

Alternatively, PKSRP gene expression can be inhibited by targetingnucleotide sequences complementary to the regulatory region of a PKSRPnucleotide sequence (e.g., a PKSRP promoter and/or enhancer) to formtriple helical structures that prevent transcription of a PKSRP gene intarget cells. See generally, Helene, C., 1991 Anticancer Drug Des.6(6):569-84; Helene, C. et al., 1992 Ann. N.Y. Acad. Sci. 660:27-36; andMaher, L. J., 1992 Bioassays 14(12):807-15.

In addition to the PKSRP nucleic acids and proteins described above, thepresent invention encompasses these nucleic acids and proteins attachedto a moiety. These moieties include, but are not limited to, detectionmoieties, hybridization moieties, purification moieties, deliverymoieties, reaction moieties, binding moieties, and the like. A typicalgroup of nucleic acids having moieties attached are probes and primers.The probes and primers typically comprise a substantially isolatedoligonucleotide. The oligonucleotide typically comprises a region ofnucleotide sequence that hybridizes under stringent conditions to atleast about 12, preferably about 25, more preferably about 40, 50 or 75consecutive nucleotides of a sense strand of one of the sequences setforth in SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ IDNO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ IDNO:23, SEQ ID NO:24, SEQ ID NO:25 and SEQ ID NO:26, an anti-sensesequence of one of the sequences set forth in SEQ ID NO:14, SEQ IDNO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ IDNO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ IDNO:25 and SEQ ID NO:26, or naturally occurring mutants thereof. Primersbased on a nucleotide sequence of SEQ ID NO:14, SEQ ID NO:15, SEQ IDNO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ IDNO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25 or SEQ IDNO:26 can be used in PCR reactions to clone PKSRP homologs. Probes basedon the PKSRP nucleotide sequences can be used to detect transcripts orgenomic sequences encoding the same or homologous proteins. In preferredembodiments, the probe further comprises a label group attached thereto,e.g. the label group can be a radioisotope, a fluorescent compound, anenzyme, or an enzyme co-factor. Such probes can be used as a part of agenomic marker test kit for identifying cells which express a PKSRP,such as by measuring a level of a PKSRP-encoding nucleic acid, in asample of cells, e.g., detecting PKSRP mRNA levels or determiningwhether a genomic PKSRP gene has been mutated or deleted.

In particular, a useful method to ascertain the level of transcriptionof the gene (an indicator of the amount of mRNA available fortranslation to the gene product) is to perform a Northern blot (forreference see, for example, Ausubel et al., 1988 Current Protocols inMolecular Biology, Wiley: New York). This information at least partiallydemonstrates the degree of transcription of the transformed gene. Totalcellular RNA can be prepared from cells, tissues or organs by severalmethods, all well-known in the art, such as that described in Bormann,E. R. et al., 1992 Mol. Microbiol. 6:317-326. To assess the presence orrelative quantity of protein translated from this mRNA, standardtechniques, such as a Western blot, may be employed. These techniquesare well known to one of ordinary skill in the art. (See, for example,Ausubel et al., 1988 Current Protocols in Molecular Biology, Wiley: NewYork).

The invention further provides an isolated recombinant expression vectorcomprising a PKSRP nucleic acid as described above, wherein expressionof the vector in a host cell results in increased tolerance toenvironmental stress as compared to a wild type variety of the hostcell. As used herein, the term “vector” refers to a nucleic acidmolecule capable of transporting another nucleic acid to which it hasbeen linked. One type of vector is a “plasmid”, which refers to acircular double stranded DNA loop into which additional DNA segments canbe ligated. Another type of vector is a viral vector, wherein additionalDNA segments can be ligated into the viral genome. Certain vectors arecapable of autonomous replication in a host cell into which they areintroduced (e.g., bacterial vectors having a bacterial origin ofreplication and episomal mammalian vectors). Other vectors (e.g.,non-episomal mammalian vectors) are integrated into the genome of a hostcell upon introduction into the host cell, and thereby are replicatedalong with the host genome. Moreover, certain vectors are capable ofdirecting the expression of genes to which they are operatively linked.Such vectors are referred to herein as “expression vectors”. In general,expression vectors of utility in recombinant DNA techniques are often inthe form of plasmids. In the present specification, “plasmid” and“vector” can be used interchangeably as the plasmid is the most commonlyused form of vector. However, the invention is intended to include suchother forms of expression vectors, such as viral vectors (e.g.,replication defective retroviruses, adenoviruses and adeno-associatedviruses), which serve equivalent functions.

The recombinant expression vectors of the invention comprise a nucleicacid of the invention in a form suitable for expression of the nucleicacid in a host cell, which means that the recombinant expression vectorsinclude one or more regulatory sequences, selected on the basis of thehost cells to be used for expression, which is operatively linked to thenucleic acid sequence to be expressed. Within a recombinant expressionvector, “operably linked” is intended to mean that the nucleotidesequence of interest is linked to the regulatory sequence(s) in a mannerwhich allows for expression of the nucleotide sequence (e.g., in an invitro transcription/translation system or in a host cell when the vectoris introduced into the host cell). The term “regulatory sequence” isintended to include promoters, enhancers and other expression controlelements (e.g., polyadenylation signals). Such regulatory sequences aredescribed, for example, in Goeddel, Gene Expression Technology: Methodsin Enzymology 185, Academic Press, San Diego, Calif. (1990) or see:Gruber and Crosby, in: Methods in Plant Molecular Biology andBiotechnology, eds. Glick and Thompson, Chapter 7, 89-108, CRC Press:Boca Raton, Fla., including the references therein. Regulatory sequencesinclude those that direct constitutive expression of a nucleotidesequence in many types of host cells and those that direct expression ofthe nucleotide sequence only in certain host cells or under certainconditions. It will be appreciated by those skilled in the art that thedesign of the expression vector can depend on such factors as the choiceof the host cell to be transformed, the level of expression of proteindesired, etc. The expression vectors of the invention can be introducedinto host cells to thereby produce proteins or peptides, includingfusion proteins or peptides, encoded by nucleic acids as describedherein (e.g., PKSRPs, mutant forms of PKSRPs, fusion proteins, etc.).

The recombinant expression vectors of the invention can be designed forexpression of PKSRPs in prokaryotic or eukaryotic cells. For example,PKSRP genes can be expressed in bacterial cells such as C. glutamicum,insect cells (using baculovirus expression vectors), yeast and otherfungal cells (see Romanos, M. A. et al., 1992 Foreign gene expression inyeast: a review, Yeast 8:423-488; van den Hondel, C. A. M. J. J. et al.,1991 Heterologous gene expression in filamentous fungi, in: More GeneManipulations in Fungi, J. W. Bennet & L. L. Lasure, eds., p. 396-428:Academic Press: San Diego; and van den Hondel, C. A. M. J. J. & Punt, P.J., 1991 Gene transfer systems and vector development for filamentousfungi, in: Applied Molecular Genetics of Fungi, Peberdy, J. F. et al.,eds., p. 1-28, Cambridge University Press: Cambridge), algae (Falciatoreet al., 1999 Marine Biotechnology 1(3):239-251), ciliates of the types:Holotrichia, Peritrichia, Spirotrichia, Suctoria, Tetrahymena,Paramecium, Colpidium, Glaucoma, Platyophrya, Potomacus,Pseudocohnilembus, Euplotes, Engelmaniella, and Stylonychia, especiallyof the genus Stylonychia lemnae with vectors following a transformationmethod as described in WO 98/01572 and multicellular plant cells (seeSchmidt, R. and Willmitzer, L., 1988 High efficiency Agrobacteriumtumefaciens-mediated transformation of Arabidopsis thaliana leaf andcotyledon explants, Plant Cell Rep. 583-586); Plant Molecular Biologyand Biotechnology, C Press, Boca Raton, Fla., chapter 6/7, S.71-119(1993); F. F. White, B. Jenes et al., Techniques for Gene Transfer, in:Transgenic Plants, Vol. 1, Engineering and Utilization, eds. Kung und R.Wu, 128-43, Academic Press: 1993; Potrykus, 1991 Annu. Rev. PlantPhysiol. Plant Molec. Biol. 42:205-225 and references cited therein) ormammalian cells. Suitable host cells are discussed further in Goeddel,Gene Expression Technology. Methods in Enzymology 185, Academic Press:San Diego, Calif. (1990). Alternatively, the recombinant expressionvector can be transcribed and translated in vitro, for example using T7promoter regulatory sequences and T7 polymerase.

Expression of proteins in prokaryotes is most often carried out withvectors containing constitutive or inducible promoters directing theexpression of either fusion or non-fusion proteins. Fusion vectors add anumber of amino acids to a protein encoded therein, usually to the aminoterminus of the recombinant protein but also to the C-terminus or fusedwithin suitable regions in the proteins. Such fusion vectors typicallyserve three purposes: 1) to increase expression of a recombinantprotein; 2) to increase the solubility of a recombinant protein; and 3)to aid in the purification of a recombinant protein by acting as aligand in affinity purification. Often, in fusion expression vectors, aproteolytic cleavage site is introduced at the junction of the fusionmoiety and the recombinant protein to enable separation of therecombinant protein from the fusion moiety subsequent to purification ofthe fusion protein. Such enzymes, and their cognate recognitionsequences, include Factor Xa, thrombin and enterokinase.

Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc;Smith, D. B. and Johnson, K. S., 1988 Gene 67:31-40), pMAL (New EnglandBiolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) whichfuse glutathione S-transferase (GST), maltose E binding protein, orprotein A, respectively, to the target recombinant protein. In oneembodiment, the coding sequence of the PKSRP is cloned into a pGEXexpression vector to create a vector encoding a fusion proteincomprising, from the N-terminus to the C-terminus, GST-thrombin cleavagesite-X protein. The fusion protein can be purified by affinitychromatography using glutathione-agarose resin. Recombinant PKSRPunfused to GST can be recovered by cleavage of the fusion protein withthrombin.

Examples of suitable inducible non-fusion E. coli expression vectorsinclude pTrc (Amann et al., 1988 Gene 69:301-315) and pET 11d (Studieret al., Gene Expression Technology: Methods in Enzymology 185, AcademicPress, San Diego, Calif. (1990) 60-89). Target gene expression from thepTrc vector relies on host RNA polymerase transcription from a hybridtrp-lac fusion promoter. Target gene expression from the pET 11d vectorrelies on transcription from a T7 gn10-lac fusion promoter mediated by aco-expressed viral RNA polymerase (T7 gn1). This viral polymerase issupplied by host strains BL21(DE3) or HMS174(DE3) from a resident λprophage harboring a T7 gn1 gene under the transcriptional control ofthe lacUV 5 promoter.

One strategy to maximize recombinant protein expression is to expressthe protein in a host bacteria with an impaired capacity toproteolytically cleave the recombinant protein (Gottesman, S., GeneExpression Technology. Methods in Enzymology 185, Academic Press, SanDiego, Calif. (1990) 119-128). Another strategy is to alter the sequenceof the nucleic acid to be inserted into an expression vector so that theindividual codons for each amino acid are those preferentially utilizedin the bacterium chosen for expression, such as C. glutamicum (Wada etal., 1992 Nucleic Acids Res. 20:2111-2118). Such alteration of nucleicacid sequences of the invention can be carried out by standard DNAsynthesis techniques.

In another embodiment, the PKSRP expression vector is a yeast expressionvector. Examples of vectors for expression in yeast S. cerevisiaeinclude pYepSec1 (Baldari, et al., 1987 Embo J. 6:229-234), pMFa (Kurjanand Herskowitz, 1982 Cell 30:933-943), pJRY88 (Schultz et al., 1987 Gene54:113-123), and pYES2 (Invitrogen Corporation, San Diego, Calif.).Vectors and methods for the construction of vectors appropriate for usein other fungi, such as the filamentous fungi, include those detailedin: van den Hondel, C. A. M. J. J. & Punt, P. J. (1991) “Gene transfersystems and vector development for filamentous fungi, in: AppliedMolecular Genetics of Fungi, J. F. Peberdy, et al., eds., p. 1-28,Cambridge University Press: Cambridge.

Alternatively, the PKSRPs of the invention can be expressed in insectcells using baculovirus expression vectors. Baculovirus vectorsavailable for expression of proteins in cultured insect cells (e.g., Sf9 cells) include the pAc series (Smith et al., 1983 Mol. Cell. Biol.3:2156-2165) and the pVL series (Lucklow and Summers, 1989 Virology170:31-39).

In yet another embodiment, a PKSRP nucleic acid of the invention isexpressed in mammalian cells using a mammalian expression vector.Examples of mammalian expression vectors include pCDM8 (Seed, B., 1987Nature 329:840) and pMT2PC (Kaufman et al., 1987 EMBO J. 6:187-195).When used in mammalian cells, the expression vector's control functionsare often provided by viral regulatory elements. For example, commonlyused promoters are derived from polyoma, Adenovirus 2, cytomegalovirusand Simian Virus 40. For other suitable expression systems for bothprokaryotic and eukaryotic cells see chapters 16 and 17 of Sambrook, J.,Fritsh, E. F., and Maniatis, T. Molecular Cloning. A Laboratory Manual.2^(nd), ed., Cold Spring Harbor Laboratory, Cold Spring HarborLaboratory Press, Cold Spring Harbor, N.Y., 1989.

In another embodiment, the recombinant mammalian expression vector iscapable of directing expression of the nucleic acid preferentially in aparticular cell type (e.g., tissue-specific regulatory elements are usedto express the nucleic acid). Tissue-specific regulatory elements areknown in the art. Non-limiting examples of suitable tissue-specificpromoters include the albumin promoter (liver-specific; Pinkert et al.,1987 Genes Dev. 1:268-277), lymphoid-specific promoters (Calame andEaton, 1988 Adv. Immunol. 43:235-275), in particular promoters of T cellreceptors (Winoto and Baltimore, 1989 EMBO J. 8:729-733) andimmunoglobulins (Banerji et al., 1983 Cell 33:729-740; Queen andBaltimore, 1983 Cell 33:741-748), neuron-specific promoters (e.g., theneurofilament promoter; Byrne and Ruddle, 1989 PNAS 86:5473-5477),pancreas-specific promoters (Edlund et al., 1985 Science 230:912-916),and mammary gland-specific promoters (e.g., milk whey promoter; U.S.Pat. No. 4,873,316 and European Application Publication No. 264,166).Developmentally-regulated promoters are also encompassed, for example,the murine hox promoters (Kessel and Gruss, 1990 Science 249:374-379)and the fetoprotein promoter (Campes and Tilghman, 1989 Genes Dev.3:537-546).

In another embodiment, the PKSRPs of the invention may be expressed inunicellular plant cells (such as algae) (see Falciatore et al., 1999Marine Biotechnology 1(3):239-251 and references therein) and plantcells from higher plants (e.g., the spermatophytes, such as cropplants). Examples of plant expression vectors include those detailed in:Becker, D., Kemper, E., Schell, J. and Masterson, R., 1992 New plantbinary vectors with selectable markers located proximal to the leftborder, Plant Mol. Biol. 20: 1195-1197; and Bevan, M. W., 1984 BinaryAgrobacterium vectors for plant transformation, Nucl. Acid. Res.12:8711-8721; Vectors for Gene Transfer in Higher Plants; in: TransgenicPlants, Vol. 1, Engineering and Utilization, eds.: Kung and R. Wu,Academic Press, 1993, S. 15-38.

A plant expression cassette preferably contains regulatory sequencescapable of driving gene expression in plant cells and operably linked sothat each sequence can fulfill its function, for example, termination oftranscription by polyadenylation signals. Preferred polyadenylationsignals are those originating from Agrobacterium tumefaciens t-DNA suchas the gene 3 known as octopine synthase of the Ti-plasmid pTiACH5(Gielen et al., 1984 EMBO J. 3:835) or functional equivalents thereofbut also all other terminators functionally active in plants aresuitable.

As plant gene expression is very often not limited on transcriptionallevels, a plant expression cassette preferably contains other operablylinked sequences like translational enhancers such as theoverdrive-sequence containing the 5′-untranslated leader sequence fromtobacco mosaic virus enhancing the protein per RNA ratio (Gallie et al.,1987 Nucl. Acids Research 15:8693-8711).

Plant gene expression has to be operably linked to an appropriatepromoter conferring gene expression in a timely, cell or tissue specificmanner. Preferred are promoters driving constitutive expression (Benfeyet al., 1989 EMBO J. 8:2195-2202) like those derived from plant viruseslike the 35S CAMV (Franck et al., 1980 Cell 21:285-294), the 19S CaMV(see also U.S. Pat. No. 5,352,605 and PCT Application No. WO 8402913) orplant promoters like those from Rubisco small subunit described in U.S.Pat. No. 4,962,028.

Other preferred sequences for use in plant gene expression cassettes aretargeting-sequences necessary to direct the gene product in itsappropriate cell compartment (for review see Kermode, 1996 Crit. Rev.Plant Sci. 15(4):285-423 and references cited therein) such as thevacuole, the nucleus, all types of plastids like amyloplasts,chloroplasts, chromoplasts, the extracellular space, mitochondria, theendoplasmic reticulum, oil bodies, peroxisomes and other compartments ofplant cells.

Plant gene expression can also be facilitated via an inducible promoter(for review see Gatz, 1997 Annu. Rev. Plant Physiol. Plant Mol. Biol.48:89-108). Chemically inducible promoters are especially suitable ifgene expression is wanted to occur in a time specific manner. Examplesof such promoters are a salicylic acid inducible promoter (PCTApplication No. WO 95/19443), a tetracycline inducible promoter (Gatz etal., 1992 Plant J. 2:397-404) and an ethanol inducible promoter (PCTApplication No. WO 93/21334).

Also, suitable promoters responding to biotic or abiotic stressconditions are those such as the pathogen inducible PRP1-gene promoter(Ward et al., 1993 Plant. Mol. Biol. 22:361-366), the heat induciblehsp80-promoter from tomato (U.S. Pat. No. 5,187,267), cold induciblealpha-amylase promoter from potato (PCT Application No. WO 96/12814) orthe wound-inducible pinII-promoter (European Patent No. 375091). Forother examples of drought, cold, and salt-inducible promoters, such asthe RD29A promoter, see Yamaguchi-Shinozalei et al. (1993 Mol. Gen.Genet. 236:331-340).

Especially preferred are those promoters that confer gene expression inspecific tissues and organs, such as guard cells and the root haircells. Suitable promoters include the napin-gene promoter from rapeseed(U.S. Pat. No. 5,608,152), the USP-promoter from Vicia faba (Baeumleinet al., 1991 Mol Gen Genet. 225(3):459-67), the oleosin-promoter fromArabidopsis (PCT Application No. WO 98/45461), the phaseolin-promoterfrom Phaseolus vulgaris (U.S. Pat. No. 5,504,200), the Bce4-promoterfrom Brassica (PCT Application No. WO 91/13980) or the legumin B4promoter (LeB4; Baeumlein et al., 1992 Plant Journal, 2(2):233-9) aswell as promoters conferring seed specific expression in monocot plantslike maize, barley, wheat, rye, rice, etc. Suitable promoters to noteare the lpt2 or lpt1-gene promoter from barley (PCT Application No. WO95/15389 and PCT Application No. WO 95/23230) or those described in PCTApplication No. WO 99/16890 (promoters from the barley hordein-gene,rice glutelin gene, rice oryzin gene, rice prolamin gene, wheat gliadingene, wheat glutelin gene, maize zein gene, oat glutelin gene, Sorghumkasirin-gene and rye secalin gene).

Also especially suited are promoters that confer plastid-specific geneexpression since plastids are the compartment where lipid biosynthesisoccurs. Suitable promoters are the viral RNA-polymerase promoterdescribed in PCT Application No. WO 95/16783 and PCT Application No. WO97/06250 and the clpP-promoter from Arabidopsis described in PCTApplication No. WO 99/46394.

The invention further provides a recombinant expression vectorcomprising a PKSRP DNA molecule of the invention cloned into theexpression vector in an antisense orientation. That is, the DNA moleculeis operatively linked to a regulatory sequence in a manner that allowsfor expression (by transcription of the DNA molecule) of an RNA moleculethat is antisense to a PKSRP mRNA. Regulatory sequences operativelylinked to a nucleic acid molecule cloned in the antisense orientationcan be chosen which direct the continuous expression of the antisenseRNA molecule in a variety of cell types. For instance, viral promotersand/or enhancers, or regulatory sequences can be chosen which directconstitutive, tissue specific or cell type specific expression ofantisense RNA. The antisense expression vector can be in the form of arecombinant plasmid, phagemid or attenuated virus wherein antisensenucleic acids are produced under the control of a high efficiencyregulatory region. The activity of the regulatory region can bedetermined by the cell type into which the vector is introduced. For adiscussion of the regulation of gene expression using antisense genessee Weintraub, H. et al., Antisense RNA as a molecular tool for geneticanalysis, Reviews—Trends in Genetics, Vol. 1(1) 1986 and Mol et al.,1990 FEBS Letters 268:427-430.

Another aspect of the invention pertains to host cells into which arecombinant expression vector of the invention has been introduced. Theterms “host cell” and “recombinant host cell” are used interchangeablyherein. It is understood that such terms refer not only to theparticular subject cell but they also apply to the progeny or potentialprogeny of such a cell. Because certain modifications may occur insucceeding generations due to either mutation or environmentalinfluences, such progeny may not, in fact, be identical to the parentcell, but are still included within the scope of the term as usedherein.

A host cell can be any prokaryotic or eukaryotic cell. For example, aPKSRP can be expressed in bacterial cells such as C. glutamicum, insectcells, fungal cells or mammalian cells (such as Chinese hamster ovarycells (CHO) or COS cells), algae, ciliates, plant cells, fungi or othermicroorganisms like C. glutamicum. Other suitable host cells are knownto those skilled in the art.

Vector DNA can be introduced into prokaryotic or eukaryotic cells viaconventional transformation or transfection techniques. As used herein,the terms “transformation”, “transfection”, “conjugation” and“transduction” are intended to refer to a variety of art-recognizedtechniques for introducing foreign nucleic acid (e.g., DNA) into a hostcell, including calcium phosphate or calcium chloride co-precipitation,DEAE-dextran-mediated transfection, lipofection, natural competence,chemical-mediated transfer and electroporation. Suitable methods fortransforming or transfecting host cells including plant cells can befound in Sambrook, et al. (Molecular Cloning: A Laboratory Manual.2^(nd), ed., Cold Spring Harbor Laboratory, Cold Spring HarborLaboratory Press, Cold Spring Harbor, N.Y., 1989) and other laboratorymanuals such as Methods in Molecular Biology, 1995, Vol. 44,Agrobacterium protocols, ed: Gartland and Davey, Humana Press, Totowa,N.J. As biotic and abiotic stress tolerance is a general trait wished tobe inherited into a wide variety of plants like maize, wheat, rye, oat,triticale, rice, barley, soybean, peanut, cotton, rapeseed and canola,manihot, pepper, sunflower and tagetes, solanaceous plants like potato,tobacco, eggplant, and tomato, Vicia species, pea, alfalfa, bushy plants(coffee, cacao, tea), Salix species, trees (oil palm, coconut),perennial grasses and forage crops, these crop plants are also preferredtarget plants for a genetic engineering as one further embodiment of thepresent invention.

In particular, the invention provides a method of producing a transgenicplant with a PKSRP coding nucleic acid, wherein expression of thenucleic acid(s) in the plant results in increased tolerance toenvironmental stress as compared to a wild type variety of the plantcomprising: (a) transforming a plant cell with an expression vectorcomprising a PKSRP nucleic acid, and (b) generating from the plant cella transgenic plant with a increased tolerance to environmental stress ascompared to a wild type variety of the plant. The invention alsoprovides a method of increasing expression of a gene of interest withina host cell as compared to a wild type variety of the host cell, whereinthe gene of interest is transcribed in response to a PKSRP, comprising:(a) transforming the host cell with an expression vector comprising aPKSRP coding nucleic acid, and (b) expressing the PKSRP within the hostcell, thereby increasing the expression of the gene transcribed inresponse to the PKSRP, as compared to a wild type variety of the hostcell.

For such plant transformation, binary vectors such as pBinAR can be used(Hofgen and Willmitzer, 1990 Plant Science 66:221-230). Construction ofthe binary vectors can be performed by ligation of the cDNA in sense orantisense orientation into the T-DNA. 5-prime to the cDNA a plantpromoter activates transcription of the cDNA. A polyadenylation sequenceis located 3-prime to the cDNA. Tissue-specific expression can beachieved by using a tissue specific promoter. For example, seed-specificexpression can be achieved by cloning the napin or LeB4 or USP promoter5-prime to the cDNA. Also, any other seed specific promoter element canbe used. For constitutive expression within the whole plant, the CaMV35S promoter can be used. The expressed protein can be targeted to acellular compartment using a signal peptide, for example for plastids,mitochondria or endoplasmic reticulum (Kermode, 1996 Crit. Rev. PlantSci. 4(15):285-423). The signal peptide is cloned 5-prime in frame tothe cDNA to archive subcellular localization of the fusion protein.Additionally, promoters that are responsive to abiotic stresses can beused with, such as the Arabidopsis promoter RD29A, the nucleic acidsequences disclosed herein. One skilled in the art will recognize thatthe promoter used should be operatively linked to the nucleic acid suchthat the promoter causes transcription of the nucleic acid which resultsin the synthesis of an mRNA which encodes a polypeptide. Alternatively,the RNA can be an antisense RNA for use in affecting subsequentexpression of the same or another gene or genes.

Alternate methods of transfection include the direct transfer of DNAinto developing flowers via electroporation or Agrobacterium mediatedgene transfer. Agrobacterium mediated plant transformation can beperformed using for example the GV3101(pMP90) (Koncz and Schell, 1986Mol. Gen. Genet. 204:383-396) or LBA4404 (Clontech) Agrobacteriumtumefaciens strain. Transformation can be performed by standardtransformation and regeneration techniques (Deblaere et al., 1994 Nucl.Acids. Res. 13:4777-4788; Gelvin, Stanton B. and Schilperoort, Robert A,Plant Molecular Biology Manual, 2^(nd) Ed.—Dordrecht: Kluwer AcademicPubl., 1995.—in Sect., Ringbuc Zentrale Signatur: BT11-P ISBN0-7923-2731-4; Glick, Bernard R.; Thompson, John E., Methods in PlantMolecular Biology and Biotechnology, Boca Raton: CRC Press, 1993.—360S., ISBN 0-8493-5164-2). For example, rapeseed can be transformed viacotyledon or hypocotyl transformation (Moloney et al., 1989 Plant cellReport 8:238-242; De Block et al., 1989 Plant Physiol. 91:694-701). Useof antibiotica for Agrobacterium and plant selection depends on thebinary vector and the Agrobacterium strain used for transformation.Rapeseed selection is normally performed using kanamycin as selectableplant marker. Agrobacterium mediated gene transfer to flax can beperformed using, for example, a technique described by Mlynarova et al.,1994 Plant Cell Report 13:282-285. Additionally, transformation ofsoybean can be performed using for example a technique described inEuropean Patent No. 0424 047, U.S. Pat. No. 5,322,783, European PatentNo. 0397 687, U.S. Pat. No. 5,376,543 or U.S. Pat. No. 5,169,770.Transformation of maize can be achieved by particle bombardment,polyethylene glycol mediated DNA uptake or via the silicon carbide fibertechnique. (See, for example, Freeling and Walbot “The maize handbook”Springer Verlag: New York (1993) ISBN 3-540-97826-7). A specific exampleof maize transformation is found in U.S. Pat. No. 5,990,387 and aspecific example of wheat transformation can be found in PCT ApplicationNo. WO 93/07256.

For stable transfection of mammalian cells, it is known that, dependingupon the expression vector and transfection technique used, only a smallfraction of cells may integrate the foreign DNA into their genome. Inorder to identify and select these integrants, a gene that encodes aselectable marker (e.g., resistance to antibiotics) is generallyintroduced into the host cells along with the gene of interest.Preferred selectable markers include those which confer resistance todrugs, such as G418, hygromycin and methotrexate or in plants thatconfer resistance towards a herbicide such as glyphosate or glufosinate.Nucleic acid molecules encoding a selectable marker can be introducedinto a host cell on the same vector as that encoding a PKSRP or can beintroduced on a separate vector. Cells stably transfected with theintroduced nucleic acid molecule can be identified by, for example, drugselection (e.g., cells that have incorporated the selectable marker genewill survive, while the other cells die).

To create a homologous recombinant microorganism, a vector is preparedwhich contains at least a portion of a PKSRP gene into which a deletion,addition or substitution has been introduced to thereby alter, e.g.,functionally disrupt, the PKSRP gene. Preferably, the PKSRP gene is aPhyscomitrella patens PKSRP gene, but it can be a homolog from a relatedplant or even from a mammalian, yeast, or insect source. In a preferredembodiment, the vector is designed such that, upon homologousrecombination, the endogenous PKSRP gene is functionally disrupted(i.e., no longer encodes a functional protein; also referred to as aknock-out vector). Alternatively, the vector can be designed such that,upon homologous recombination, the endogenous PKSRP gene is mutated orotherwise altered but still encodes a functional protein (e.g., theupstream regulatory region can be altered to thereby alter theexpression of the endogenous PKSRP). To create a point mutation viahomologous recombination, DNA-RNA hybrids can be used in a techniqueknown as chimeraplasty (Cole-Strauss et al., 1999 Nucleic Acids Research27(5):1323-1330 and Kmiec, 1999 Gene therapy American Scientist.87(3):240-247). Homologous recombination procedures in Physcomitrellapatens are also well known in the art and are contemplated for useherein.

Whereas in the homologous recombination vector, the altered portion ofthe PKSRP gene is flanked at its 5′ and 3′ ends by an additional nucleicacid molecule of the PKSRP gene to allow for homologous recombination tooccur between the exogenous PKSRP gene carried by the vector and anendogenous PKSRP gene, in a microorganism or plant. The additionalflanking PKSRP nucleic acid molecule is of sufficient length forsuccessful homologous recombination with the endogenous gene. Typically,several hundreds of base pairs up to kilobases of flanking DNA (both atthe 5′ and 3′ ends) are included in the vector (see e.g., Thomas, K. R.,and Capecchi, M. R., 1987 Cell 51:503 for a description of homologousrecombination vectors or Strepp et al., 1998 PNAS, 95 (8):4368-4373 forcDNA based recombination in Physcomitrella patens). The vector isintroduced into a microorganism or plant cell (e.g., via polyethyleneglycol mediated DNA), and cells in which the introduced PKSRP gene hashomologously recombined with the endogenous PKSRP gene are selectedusing art-known techniques.

In another embodiment, recombinant microorganisms can be produced thatcontain selected systems which allow for regulated expression of theintroduced gene. For example, inclusion of a PKSRP gene on a vectorplacing it under control of the lac operon permits expression of thePKSRP gene only in the presence of IPTG. Such regulatory systems arewell known in the art.

A host cell of the invention, such as a prokaryotic or eukaryotic hostcell in culture, can be used to produce (i.e., express) a PKSRP.Accordingly, the invention further provides methods for producing PKSRPsusing the host cells of the invention. In one embodiment, the methodcomprises culturing the host cell of invention (into which a recombinantexpression vector encoding a PKSRP has been introduced, or into whichgenome has been introduced a gene encoding a wild-type or altered PKSRP)in a suitable medium until PKSRP is produced. In another embodiment, themethod further comprises isolating PKSRPs from the medium or the hostcell.

Another aspect of the invention pertains to isolated PKSRPs, andbiologically active portions thereof. An “isolated” or “purified”protein or biologically active portion thereof is free of some of thecellular material when produced by recombinant DNA techniques, orchemical precursors or other chemicals when chemically synthesized. Thelanguage “substantially free of cellular material” includes preparationsof PKSRP in which the protein is separated from some of the cellularcomponents of the cells in which it is naturally or recombinantlyproduced. In one embodiment, the language “substantially free ofcellular material” includes preparations of a PKSRP having less thanabout 30% (by dry weight) of non-PKSRP material (also referred to hereinas a “contaminating protein”), more preferably less than about 20% ofnon-PKSRP material, still more preferably less than about 10% ofnon-PKSRP material, and most preferably less than about 5% non-PKSRPmaterial.

When the PKSRP or biologically active portion thereof is recombinantlyproduced, it is also preferably substantially free of culture medium,i.e., culture medium represents less than about 20%, more preferablyless than about 10%, and most preferably less than about 5% of thevolume of the protein preparation. The language “substantially free ofchemical precursors or other chemicals” includes preparations of PKSRPin which the protein is separated from chemical precursors or otherchemicals that are involved in the synthesis of the protein. In oneembodiment, the language “substantially free of chemical precursors orother chemicals” includes preparations of a PKSRP having less than about30% (by dry weight) of chemical precursors or non-PKSRP chemicals, morepreferably less than about 20% chemical precursors or non-PKSRPchemicals, still more preferably less than about 10% chemical precursorsor non-PKSRP chemicals, and most preferably less than about 5% chemicalprecursors or non-PKSRP chemicals. In preferred embodiments, isolatedproteins, or biologically active portions thereof, lack contaminatingproteins from the same organism from which the PKSRP is derived.Typically, such proteins are produced by recombinant expression of, forexample, a Physcomitrella patens PKSRP in plants other thanPhyscomitrella patens or microorganisms such as C. glutamicum, ciliates,algae or fungi.

The nucleic acid molecules, proteins, protein homologs, fusion proteins,primers, vectors, and host cells described herein can be used in one ormore of the following methods: identification of Physcomitrella patensand related organisms; mapping of genomes of organisms related toPhyscomitrella patens; identification and localization of Physcomitrellapatens sequences of interest; evolutionary studies; determination ofPKSRP regions required for function; modulation of a PKSRP activity;modulation of the metabolism of one or more cell functions; modulationof the transmembrane transport of one or more compounds; and modulationof stress resistance.

The moss Physcomitrella patens represents one member of the mosses. Itis related to other mosses such as Ceratodon purpureus which is capableof growth in the absence of light. Mosses like Ceratodon andPhyscomitrella share a high degree of homology on the DNA sequence andpolypeptide level allowing the use of heterologous screening of DNAmolecules with probes evolving from other mosses or organisms, thusenabling the derivation of a consensus sequence suitable forheterologous screening or functional annotation and prediction of genefunctions in third species. The ability to identify such functions cantherefore have significant relevance, e.g., prediction of substratespecificity of enzymes. Further, these nucleic acid molecules may serveas reference points for the mapping of moss genomes, or of genomes ofrelated organisms.

The PKSRP nucleic acid molecules of the invention have a variety ofuses. Most importantly, the nucleic acid and amino acid sequences of thepresent invention can be used to transform plants, thereby inducingtolerance to stresses such as drought, high salinity and cold. Thepresent invention therefore provides a transgenic plant transformed by aPKSRP nucleic acid (coding or antisense), wherein expression of thenucleic acid sequence in the plant results in increased tolerance toenvironmental stress as compared to a wild type variety of the plant.The transgenic plant can be a monocot or a dicot. The invention furtherprovides that the transgenic plant can be selected from maize, wheat,rye, oat, triticale, rice, barley, soybean, peanut, cotton, rapeseed,canola, manihot, pepper, sunflower, tagetes, solanaceous plants, potato,tobacco, eggplant, tomato, Vicia species, pea, alfalfa, coffee, cacao,tea, Salix species, oil palm, coconut, perennial grass and forage crops,for example.

In particular, the present invention describes using the expression ofPK-6, PK-7, PK-8, PK-9, CK-1, CK-2, CK-3, MPK-2, MPK-3, MPK-4, MPK-5,CPK-1 and CPK-2 of Physcomitrella patens to engineer drought-tolerant,salt-tolerant and/or cold-tolerant plants. This strategy has herein beendemonstrated for Arabidopsis thaliana, Rapeseed/Canola, soybeans, cornand wheat but its application is not restricted to these plants.Accordingly, the invention provides a transgenic plant containing aPKSRP selected from PK-6 (SEQ ID NO:27), PK-7 (SEQ ID NO:28), PK-8 (SEQID NO:29), PK-9 (SEQ ID NO:30), CK-1 (SEQ ID NO:31), CK-2 (SEQ IDNO:32), CK-3 (SEQ ID NO:33), MPK-2 (SEQ ID NO:34), MPK-3 (SEQ ID NO:35),MPK-4 (SEQ ID NO:36), MPK-5 (SEQ ID NO:37), CPK-1 (SEQ ID NO:38) andCPK-2 (SEQ ID NO:39), wherein the environmental stress is drought,increased salt or decreased or increased temperature. In preferredembodiments, the environmental stress is drought or decreasedtemperature.

The present invention also provides methods of modifying stresstolerance of a plant comprising, modifying the expression of a PKSRP inthe plant. The invention provides that this method can be performed suchthat the stress tolerance is either increased or decreased. Inparticular, the present invention provides methods of producing atransgenic plant having an increased tolerance to environmental stressas compared to a wild type variety of the plant comprising increasingexpression of a PKSRP in a plant.

The methods of increasing expression of PKSRPs can be used wherein theplant is either transgenic or not transgenic. In cases when the plant istransgenic, the plant can be transformed with a vector containing any ofthe above described PKSRP coding nucleic acids, or the plant can betransformed with a promoter that directs expression of native PKSRP inthe plant, for example. The invention provides that such a promoter canbe tissue specific. Furthermore, such a promoter can be developmentallyregulated. Alternatively, non-transgenic plants can have native PKSRPexpression modified by inducing a native promoter.

The expression of PK-6 (SEQ ID NO:14), PK-7 (SEQ ID NO:15), PK-8 (SEQ IDNO:16), PK-9 (SEQ ID NO:17), CK-1 (SEQ ID NO:18), CK-2 (SEQ ID NO:19),CK-3 (SEQ ID NO:20), MPK-2 (SEQ ID NO:21), MPK-3 (SEQ ID NO:22), MPK-4(SEQ ID NO:23), MPK-5 (SEQ ID NO:24), CPK-1 (SEQ ID NO:25) and CPK-2(SEQ ID NO:26) in target plants can be accomplished by, but is notlimited to, one of the following examples: (a) constitutive promoter,(b) stress-inducible promoter, (c) chemical-induced promoter, and (d)engineered promoter over-expression with for example zinc-finger derivedtranscription factors (Greisman and Pabo, 1997 Science 275:657). Thelater case involves identification of the PK-6 (SEQ ID NO:27), PK-7 (SEQID NO:28), PK-8 (SEQ ID NO:29), PK-9 (SEQ ID NO:30), CK-1 (SEQ IDNO:31), CK-2 (SEQ ID NO:32), CK-3 (SEQ ID NO:33), MPK-2 (SEQ ID NO:34),MPK-3 (SEQ ID NO:35), MPK-4 (SEQ ID NO:36), MPK-5 (SEQ ID NO:37), CPK-1(SEQ ID NO:38) or CPK-2 (SEQ ID NO:39) homologs in the target plant aswell as from its promoter. Zinc-finger-containing recombinanttranscription factors are engineered to specifically interact with thePK-6 (SEQ ID NO:27), PK-7 (SEQ ID NO:28), PK-8 (SEQ ID NO:29), PK-9 (SEQID NO:30), CK-1 (SEQ ID NO:31), CK-2 (SEQ ID NO:32), CK-3 (SEQ IDNO:33), MPK-2 (SEQ ID NO:34), MPK-3 (SEQ ID NO:35), MPK-4 (SEQ IDNO:36), MPK-5 (SEQ ID NO:37), CPK-1 (SEQ ID NO:38) or CPK-2 (SEQ IDNO:39) homolog and transcription of the corresponding gene is activated.

In addition to introducing the PKSRP nucleic acid sequences intotransgenic plants, these sequences can also be used to identify anorganism as being Physcomitrella patens or a close relative thereof.Also, they may be used to identify the presence of Physcomitrella patensor a relative thereof in a mixed population of microorganisms. Theinvention provides the nucleic acid sequences of a number ofPhyscomitrella patens genes; by probing the extracted genomic DNA of aculture of a unique or mixed population of microorganisms understringent conditions with a probe spanning a region of a Physcomitrellapatens gene which is unique to this organism, one can ascertain whetherthis organism is present.

Further, the nucleic acid and protein molecules of the invention mayserve as markers for specific regions of the genome. This has utilitynot only in the mapping of the genome, but also in functional studies ofPhyscomitrella patens proteins. For example, to identify the region ofthe genome to which a particular Physcomitrella patens DNA-bindingprotein binds, the Physcomitrella patens genome could be digested, andthe fragments incubated with the DNA-binding protein. Those fragmentsthat bind the protein may be additionally probed with the nucleic acidmolecules of the invention, preferably with readily detectable labels.Binding of such a nucleic acid molecule to the genome fragment enablesthe localization of the fragment to the genome map of Physcomitrellapatens, and, when performed multiple times with different enzymes,facilitates a rapid determination of the nucleic acid sequence to whichthe protein binds. Further, the nucleic acid molecules of the inventionmay be sufficiently homologous to the sequences of related species suchthat these nucleic acid molecules may serve as markers for theconstruction of a genomic map in related mosses.

The PKSRP nucleic acid molecules of the invention are also useful forevolutionary and protein structural studies. The metabolic and transportprocesses in which the molecules of the invention participate areutilized by a wide variety of prokaryotic and eukaryotic cells; bycomparing the sequences of the nucleic acid molecules of the presentinvention to those encoding similar enzymes from other organisms, theevolutionary relatedness of the organisms can be assessed. Similarly,such a comparison permits an assessment of which regions of the sequenceare conserved and which are not, which may aid in determining thoseregions of the protein that are essential for the functioning of theenzyme. This type of determination is of value for protein engineeringstudies and may give an indication of what the protein can tolerate interms of mutagenesis without losing function.

Manipulation of the PKSRP nucleic acid molecules of the invention mayresult in the production of PKSRPs having functional differences fromthe wild-type PKSRPs. These proteins may be improved in efficiency oractivity, may be present in greater numbers in the cell than is usual,or may be decreased in efficiency or activity.

There are a number of mechanisms by which the alteration of a PKSRP ofthe invention may directly affect stress response and/or stresstolerance. In the case of plants expressing PKSRPs, increased transportcan lead to improved salt and/or solute partitioning within the planttissue and organs. By either increasing the number or the activity oftransporter molecules which export ionic molecules from the cell, it maybe possible to affect the salt tolerance of the cell.

The effect of the genetic modification in plants, C. glutamicum, fungi,algae, or ciliates on stress tolerance can be assessed by growing themodified microorganism or plant under less than suitable conditions andthen analyzing the growth characteristics and/or metabolism of theplant. Such analysis techniques are well known to one skilled in theart, and include dry weight, wet weight, protein synthesis, carbohydratesynthesis, lipid synthesis, evapotranspiration rates, general plantand/or crop yield, flowering, reproduction, seed setting, root growth,respiration rates, photosynthesis rates, etc. (Applications of HPLC inBiochemistry in: Laboratory Techniques in Biochemistry and MolecularBiology, vol. 17; Rehm et al., 1993 Biotechnology, vol. 3, Chapter III:Product recovery and purification, page 469-714, VCH: Weinheim; Belter,P. A. et al., 1988 Bioseparations: downstream processing forbiotechnology, John Wiley and Sons; Kennedy, J. F. and Cabral, J. M. S.,1992 Recovery processes for biological materials, John Wiley and Sons;Shaeiwitz, J. A. and Henry, J. D., 1988 Biochemical separations, in:Ulmann's Encyclopedia of Industrial Chemistry, vol. B3, Chapter 11, page1-27, VCH: Weinheim; and Dechow, F. J. (1989) Separation andpurification techniques in biotechnology, Noyes Publications).

For example, yeast expression vectors comprising the nucleic acidsdisclosed herein, or fragments thereof, can be constructed andtransformed into Saccharomyces cerevisiae using standard protocols. Theresulting transgenic cells can then be assayed for fail or alteration oftheir tolerance to drought, salt, and temperature stress. Similarly,plant expression vectors comprising the nucleic acids disclosed herein,or fragments thereof, can be constructed and transformed into anappropriate plant cell such as Arabidopsis, soy, rape, maize, wheat,Medicago truncatula, etc., using standard protocols. The resultingtransgenic cells and/or plants derived there from can then be assayedfor fail or alteration of their tolerance to drought, salt, andtemperature stress.

The engineering of one or more PKSRP genes of the invention may alsoresult in PKSRPs having altered activities which indirectly impact thestress response and/or stress tolerance of algae, plants, ciliates orfungi or other microorganisms like C. glutamicum. For example, thenormal biochemical processes of metabolism result in the production of avariety of products (e.g., hydrogen peroxide and other reactive oxygenspecies) which may actively interfere with these same metabolicprocesses (for example, peroxynitrite is known to nitrate tyrosine sidechains, thereby inactivating some enzymes having tyrosine in the activesite (Groves, J. T., 1999 Curr. Opin. Chem. Biol. 3(2):226-235). Whilethese products are typically excreted, cells can be genetically alteredto transport more products than is typical for a wild-type cell. Byoptimizing the activity of one or more PKSRPs of the invention which areinvolved in the export of specific molecules, such as salt molecules, itmay be possible to improve the stress tolerance of the cell.

Additionally, the sequences disclosed herein, or fragments thereof, canbe used to generate knockout mutations in the genomes of variousorganisms, such as bacteria, mammalian cells, yeast cells, and plantcells (Girke, T., 1998 The Plant Journal 15:39-48). The resultantknockout cells can then be evaluated for their ability or capacity totolerate various stress conditions, their response to various stressconditions, and the effect on the phenotype and/or genotype of themutation. For other methods of gene inactivation see U.S. Pat. No.6,004,804 “Non-Chimeric Mutational Vectors” and Puttaraju et al., 1999Spliceosome-mediated RNA trans-splicing as a tool for gene therapyNature Biotechnology 17:246-252.

The aforementioned mutagenesis strategies for PKSRPs resulting inincreased stress resistance are not meant to be limiting; variations onthese strategies will be readily apparent to one skilled in the art.Using such strategies, and incorporating the mechanisms disclosedherein, the nucleic acid and protein molecules of the invention may beutilized to generate algae, ciliates, plants, fungi or othermicroorganisms like C. glutamicum expressing mutated PKSRP nucleic acidand protein molecules such that the stress tolerance is improved.

The present invention also provides antibodies that specifically bind toa PKSRP, or a portion thereof, as encoded by a nucleic acid describedherein. Antibodies can be made by many well-known methods (See, e.g.Harlow and Lane, “Antibodies; A Laboratory Manual” Cold Spring HarborLaboratory, Cold Spring Harbor, N.Y., (1988)). Briefly, purified antigencan be injected into an animal in an amount and in intervals sufficientto elicit an immune response. Antibodies can either be purifieddirectly, or spleen cells can be obtained from the animal. The cells canthen fused with an immortal cell line and screened for antibodysecretion. The antibodies can be used to screen nucleic acid clonelibraries for cells secreting the antigen. Those positive clones canthen be sequenced. (See, for example, Kelly et al., 1992 Bio/Technology10:163-167; Bebbington et al., 1992 Bio/Technology 10:169-175).

The phrases “selectively binds” and “specifically binds” with thepolypeptide refer to a binding reaction that is determinative of thepresence of the protein in a heterogeneous population of proteins andother biologics. Thus, under designated immunoassay conditions, thespecified antibodies bound to a particular protein do not bind in asignificant amount to other proteins present in the sample. Selectivebinding of an antibody under such conditions may require an antibodythat is selected for its specificity for a particular protein. A varietyof immunoassay formats may be used to select antibodies that selectivelybind with a particular protein. For example, solid-phase ELISAimmunoassays are routinely used to select antibodies selectivelyimmunoreactive with a protein. See Harlow and Lane “Antibodies, ALaboratory Manual” Cold Spring Harbor Publications, New York, (1988),for a description of immunoassay formats and conditions that could beused to determine selective binding.

In some instances, it is desirable to prepare monoclonal antibodies fromvarious hosts. A description of techniques for preparing such monoclonalantibodies may be found in Stites et al., editors, “Basic and ClinicalImmunology,” (Lange Medical Publications, Los Altos, Calif., FourthEdition) and references cited therein, and in Harlow and Lane(“Antibodies, A Laboratory Manual” Cold Spring Harbor Publications, NewYork, 1988).

Throughout this application, various publications are referenced. Thedisclosures of all of these publications and those references citedwithin those publications in their entireties are hereby incorporated byreference into this application in order to more fully describe thestate of the art to which this invention pertains.

It should also be understood that the foregoing relates to preferredembodiments of the present invention and that numerous changes may bemade therein without departing from the scope of the invention. Theinvention is further illustrated by the following examples, which arenot to be construed in any way as imposing limitations upon the scopethereof. On the contrary, it is to be clearly understood that resort maybe had to various other embodiments, modifications, and equivalentsthereof, which, after reading the description herein, may suggestthemselves to those skilled in the art without departing from the spiritof the present invention and/or the scope of the appended claims.

EXAMPLES Example 1

Growth of Physcomitrella patens Cultures

For this study, plants of the species Physcomitrella patens (Hedw.)B.S.G. from the collection of the genetic studies section of theUniversity of Hamburg were used. They originate from the strain 16/14collected by H.L.K. Whitehouse in Gransden Wood, Huntingdonshire(England), which was subcultured from a spore by Engel (1968, Am. J.Bot. 55, 438-446). Proliferation of the plants was carried out by meansof spores and by means of regeneration of the gametophytes. Theprotonema developed from the haploid spore as a chloroplast-richchloronema and chloroplast-low caulonema, on which buds formed afterapproximately 12 days. These grew to give gametophores bearingantheridia and archegonia. After fertilization, the diploid sporophytewith a short seta and the spore capsule resulted, in which themeiospores matured.

Culturing was carried out in a climatic chamber at an air temperature of25° C. and light intensity of 55 micromol s⁻¹ m⁻² (white light; PhilipsTL 65W/25 fluorescent tube) and a light/dark change of 16/8 hours. Themoss was either modified in liquid culture using Knop medium accordingto Reski and Abel (1985, Planta 165:354-358) or cultured on Knop solidmedium using 1% oxoid agar (Unipath, Basingstoke, England). Theprotonemas used for RNA and DNA isolation were cultured in aeratedliquid cultures. The protonemas were comminuted every 9 days andtransferred to fresh culture medium.

Example 2

Total DNA Isolation from Plants

The details for the isolation of total DNA relate to the working up ofone gram fresh weight of plant material. The materials used include thefollowing buffers: CTAB buffer: 2% (w/v)N-cethyl-N,N,N-trimethylammonium bromide (CTAB); 100 mM Tris HCl pH 8.0;1.4 M NaCl; 20 mM EDTA; N-Laurylsarcosine buffer: 10% (w/v)N-laurylsarcosine; 100 mM Tris HCl pH 8.0; 20 mM EDTA.

The plant material was triturated under liquid nitrogen in a mortar togive a fine powder and transferred to 2 ml Eppendorf vessels. The frozenplant material was then covered with a layer of 1 ml of decompositionbuffer (1 ml CTAB buffer, 100 μl of N-laurylsarcosine buffer, 20 μl ofβ-mercaptoethanol and 10 μl of proteinase K solution, 10 mg/ml) andincubated at 60° C. for one hour with continuous shaking. The homogenateobtained was distributed into two Eppendorf vessels (2 ml) and extractedtwice by shaking with the same volume of chloroform/isoamyl alcohol(24:1). For phase separation, centrifugation was carried out at 8000×gand room temperature for 15 minutes in each case. The DNA was thenprecipitated at −70° C. for 30 minutes using ice-cold isopropanol. Theprecipitated DNA was sedimented at 4° C. and 10,000 g for 30 minutes andresuspended in 180 μl of TE buffer (Sambrook et al., 1989, Cold SpringHarbor Laboratory Press: ISBN 0-87969-309-6). For further purification,the DNA was treated with NaCl (1.2 M final concentration) andprecipitated again at −70° C. for 30 minutes using twice the volume ofabsolute ethanol. After a washing step with 70% ethanol, the DNA wasdried and subsequently taken up in 50 μl of H₂O+RNAse (50 mg/ml finalconcentration). The DNA was dissolved overnight at 4° C. and the RNAsedigestion was subsequently carried out at 37° C. for 1 hour. Storage ofthe DNA took place at 4° C.

Example 3

Isolation of Total RNA and poly-(A)+ RNA and cDNA Library Constructionfrom Physcomitrella patens

For the investigation of transcripts, both total RNA and poly-(A)+ RNAwere isolated. The total RNA was obtained from wild-type 9 day oldprotonemata following the GTC-method (Reski et al. 1994, Mol. Gen.Genet., 244:352-359). The Poly(A)+ RNA was isolated using Dyna Beads^(R)(Dynal, Oslo, Norway) following the instructions of the manufacturersprotocol. After determination of the concentration of the RNA or of thepoly(A)+ RNA, the RNA was precipitated by addition of 1/10 volumes of 3M sodium acetate pH 4.6 and 2 volumes of ethanol and stored at −70° C.

For cDNA library construction, first strand synthesis was achieved usingMurine Leukemia Virus reverse transcriptase (Roche, Mannheim, Germany)and oligo-d(T)-primers, second strand synthesis by incubation with DNApolymerase I, Klenow enzyme and RNAseH digestion at 12° C. (2 hours),16° C. (1 hour) and 22° C. (1 hour). The reaction was stopped byincubation at 65° C. (10 minutes) and subsequently transferred to ice.Double stranded DNA molecules were blunted by T4-DNA-polymerase (Roche,Mannheim) at 37° C. (30 minutes). Nucleotides were removed byphenol/chloroform extraction and Sephadex G50 spin columns. EcoRIadapters (Pharmacia, Freiburg, Germany) were ligated to the cDNA ends byT4-DNA-ligase (Roche, 12° C., overnight) and phosphorylated byincubation with polynucleotide kinase (Roche, 37° C., 30 minutes). Thismixture was subjected to separation on a low melting agarose gel. DNAmolecules larger than 300 base pairs were eluted from the gel, phenolextracted, concentrated on Elutip-D-columns (Schleicher and Schuell,Dassel, Germany) and were ligated to vector arms and packed into lambdaZAPII phages or lambda ZAP-Express phages using the Gigapack Gold Kit(Stratagene, Amsterdam, Netherlands) using material and following theinstructions of the manufacturer.

Example 4

Sequencing and Function Annotation of Physcomitrella patens ESTs

cDNA libraries as described in Example 3 were used for DNA sequencingaccording to standard methods, and in particular, by the chaintermination method using the ABI PRISM Big Dye Terminator CycleSequencing Ready Reaction Kit (Perkin-Elmer, Weiterstadt, Germany).Random Sequencing was carried out subsequent to preparative plasmidrecovery from cDNA libraries via in vivo mass excision,retransformation, and subsequent plating of DH10B on agar plates(material and protocol details from Stratagene, Amsterdam, Netherlands.Plasmid DNA was prepared from overnight grown E. coli cultures grown inLuria-Broth medium containing ampicillin (see Sambrook et al. 1989 ColdSpring Harbor Laboratory Press: ISBN 0-87969-309-6) on a Qiagene DNApreparation robot (Qiagen, Hilden) according to the manufacturer'sprotocols. Sequencing primers with the following nucleotide sequenceswere used: 5′-CAGGAAACAGCTATGACC-3′ SEQ ID NO:405′-CTAAAGGGAACAAAAGCTG-3′ SEQ ID NO:41 5′-TGTAAAACGACGGCCAGT-3′ SEQ IDNO:42

Sequences were processed and annotated using the software packageEST-MAX commercially provided by Bio-Max (Munich, Germany). The programincorporates practically all bioinformatics methods important forfunctional and structural characterization of protein sequences. Forreference the website at pedant.mips.biochem.mpgde. The most importantalgorithms incorporated in EST-MAX are: FASTA: Very sensitive sequencedatabase searches with estimates of statistical significance; Pearson W.R. (1990) Rapid and sensitive sequence comparison with FASTP and FASTA.Methods Enzymol. 183:63-98; BLAST: Very sensitive sequence databasesearches with estimates of statistical significance. Altschul S. F.,Gish W., Miller W., Myers E. W., and Lipman D. J. Basic local alignmentsearch tool. Journal of Molecular Biology 215:403-10; PREDATOR:High-accuracy secondary structure prediction from single and multiplesequences. Frishman, D. and Argos, P. (1997) 75% accuracy in proteinsecondary structure prediction. Proteins, 27:329-335; CLUSTAL W:Multiple sequence alignment. Thompson, J. D., Higgins, D. G. and Gibson,T. J. (1994) CLUSTAL W: improving the sensitivity of progressivemultiple sequence alignment through sequence weighting,positions-specific gap penalties and weight matrix choice. Nucleic AcidsResearch, 22:4673-4680; TMAP: Transmembrane region prediction frommultiply aligned sequences. Persson, B. and Argos, P. (1994) Predictionof transmembrane segments in proteins utilizing multiple sequencealignments. J. Mol. Biol. 237:182-192; ALOM2: Transmembrane regionprediction from single sequences. Klein, P., Kanehisa, M., and DeLisi,C. Prediction of protein function from sequence properties: Adiscriminate analysis of a database. Biochim. Biophys. Acta 787:221-226(1984). Version 2 by Dr. K. Nakai; PROSEARCH: Detection of PROSITEprotein sequence patterns. Kolakowski L. F. Jr., Leunissen J. A. M.,Smith J. E. (1992) ProSearch: fast searching of protein sequences withregular expression patterns related to protein structure and function.Biotechniques 13, 919-921; BLIMPS: Similarity searches against adatabase of ungapped blocks. J. C. Wallace and Henikoff S., (1992);PATMAT: A searching and extraction program for sequence, pattern andblock queries and databases, CABIOS 8:249-254. Written by Bill Alford.

Example 5

Identification of Physcomitrella patens ORFs Corresponding to PK-6,PK-7, PK-8, PK-9, CK-1, CK-2, CK-3, MPK-2, MPK-3, MPK-4, MPK-5, CPK-1and CPK-2

The Physcomitrella patens partial cDNAs (ESTs) shown in Table 1 belowwere identified in the Physcomitrella patens EST sequencing programusing the program EST-MAX through BLAST analysis. The SequenceIdentification Numbers corresponding to these ESTs are as follows: PK-6(SEQ ID NO:1), PK-7 (SEQ ID NO:2), PK-8 (SEQ ID NO:3), PK-9 (SEQ IDNO:4), CK-1 (SEQ ID NO:5), CK-2 (SEQ ID NO:6), CK-3 (SEQ ID NO:7), MPK-2(SEQ ID NO:8), MPK-3 (SEQ ID NO:9), MPK-4 (SEQ ID NO:10), MPK-5 (SEQ IDNO:11), CPK-1 (SEQ ID NO:12) and CPK-2 (SEQ ID NO:13). TABLE 1Functional ORF Name categories Function Sequence code position PpPK-6Protein Kinase serine/threonine protein c_pp004044242r  1-474 kinaselike protein PpPK-7 Protein Kinase cdc2-like protein kinases_pp001031042f  1-267 cdc2MsF PpPK-8 Protein Kinase protein kinasehomolog c_pp004044100r  1-581 F13C5.120 PpPK-9 Protein Kinase proteinkinase; similar to c_pp004071077r 709-137 human PKX1 PpCK-1 ProteinKinase receptor protein kinase c_pp001062017r 1160-1   PpCK-2 ProteinKinase kasein kinase c_pp004038371r 1909-1421 PpCK-3 Protein Kinasecasein kinase II catalytic c_pp004076164r  2-877 subunit PpMPK-2 ProteinKinase mitogen-activated protein c_pp004041329r 952-293 kinase 6 PpMPK-3Protein Kinase big MAP kinase 1c c_pp004061263r 221-550 PpMPK-4 ProteinKinase protein kinase MEK1 (EC c_pp001064077r 1153-596  2.7.1.—) PpMPK-5Protein Kinase protein kinase MEK1 c_pp004064129r 114-233 PpCPK-1Protein Kinase protein kinase c_pp004014376r 1084-173  PpCPK-2 ProteinKinase calcium-dependent protein c_pp004038141r  422-1213 kinase PpPK-6Protein Kinase cdc2-like protein kinase s_pp001031042f  1-267 cdc2MsF

TABLE 2 Degree of Amino Acid Identity and Similarity of PpPK-6 and OtherHomologous Proteins GCG Gap program was used: gap penalty: 10; gapextension penalty: 0.1; score matrix: blosum62) Swiss-Prot # O81106Q9LUL4 Q9ZQZ2 Q9MAS2 Q9LK66 Protein LEUCINE- SERILNE/THREONINE PUTATIVEPUTATIVE PROTEIN name RICH PROTEIN LRR LRR KINASE- REPEAT KINASE-RECEPTOR- RECEPTOR LIKE TRANSMEMBRANE LIKE LINKED PROTEIN PROTEINPROTEIN PROTEIN PROTEIN KINASE KINASE 2 KINASE Species Zea maysArabidopsis Arabidopsis Arabidopsis Arabidopsis (Maize) thalianathaliana thaliana thaliana (Mouse-ear (Mouse-ear (Mouse-ear (Mouse-earcress) cress) cress) cress) Identity % 42% 42% 38% 37% 37% Similarity %54% 52% 50% 49% 48%

TABLE 3 Degree of Amino Acid Identity and Similarity of PpPK-7 and OtherHomologous Proteins GCG Gap program was used: gap penalty: 10; gapextension penalty: 0.1; score matrix: blosum62) Swiss-Prot # P25859O49120 Q38774 P93321 Q9ZVI4 Protein CELL CYCLIN- CELL CDC2 PUTATIVE nameDIVISION DEPENDENT DIVISION KINASE SERINE/THREONINE CONTROL KINASE 1CONTROL HOMOLOG PROTEIN PROTEIN 2 PROTEIN 2 CDC2MSD KINASE HOMOLOG BHOMOLOG C Species Arabidopsis Dunaliella Antirrhinum MedicagoArabidopsis thaliana tertiolecta majus sativa thaliana (Mouse-ear(Garden (Alfalfa) (Mouse-ear cress) snapdragon) cress) Identity % 70%68% 70% 69% 69% Similarity % 79% 76% 81% 79% 77%

TABLE 4 Degree of Amino Acid Identity and Similarity of PpPK-8 and OtherHomologous Proteins GCG Gap program was used: gap penalty: 10; gapextension penalty: 0.1; score matrix: blosum62) Swiss-Prot # O82754Q9M085 Q02779 Q05609 Q39886 Protein PUTATIVE PROTEIN MITOGEN-SERINE/THREONINE- PROTEIN name SERINE/THREONINE KINASE- ACTIVATEDPROTEIN KINASE KINASE LIKE PROTEIN KINASE CTR1 PROTEIN KINASE KINASEKINASE 10 Species Arabidopsis Arabidopsis Homo sapiens ArabidopsisGlycine thaliana thaliana (Human) thaliana max (Mouse-ear (Mouse-ear(Mouse-ear (Soybean) cress) cress) cress) Identity % 25% 26% 27% 27% 26%Similarity % 42% 40% 38% 40% 40%

TABLE 5 Degree of Amino Acid Identity and Similarity of PpPK-9 and OtherHomologous Proteins GCG Gap program was used: gap penalty: 10; gapextension penalty: 0.1; score matrix: blosum62) Swiss-Prot # Q9SL77P34099 Q9TXB8 P40376 Q9SXP9 Protein PUTATIVE CAMP- SERINE/ CAMP- CAMP-name CAMP- DEPENDENT THREONINE DEPENDENT DEPENDENT DEPENDENT PROTEINPROTEIN PROTEIN PROTEIN PROTEIN KINASE KINASE KINASE KINASE KINASECATALYTIC CATALYTIC CATALYTIC SUBUNIT SUBUNIT SUBUNIT SpeciesArabidopsis Dictyostelium Dictyostelium Schizosaccharomyces Euglenathaliana discoideum pombe gracilis (Mouse-ear (Slime mold) (Fissionyeast) cress) Identity % 45% 33% 32% 33% 28% Similarity % 60% 48% 48%50% 40%

TABLE 6 Degree of Amino Acid Identity and Similarity of PpCK-1 and OtherHomologous Proteins GCG Gap program was used: gap penalty: 10; gapextension penalty: 0.1; score matrix: blosum62) Swiss-Prot # Q9SZI1Q9ZUP4 P42158 Q9LW62 Q39050 Protein COL-0 PUTATIVE CASEIN CASEIN CASEINname CASEIN CASEIN KINASE I, KINASE KINASE I KINASE I- KINASE I DELTALIKE ISOFORM PROTEIN LIKE Species Arabidopsis Arabidopsis ArabidopsisArabidopsis Arabidopsis thaliana thaliana thaliana thaliana thaliana(Mouse-ear (Mouse-ear (Mouse-ear (Mouse-ear (Mouse-ear cress) cress)cress) cress) cress) Identity % 49% 48% 48% 46% 40% Similarity % 62% 61%61% 58% 52%

TABLE 7 Degree of Amino Acid Identity and Similarity of PpCK-2 and OtherHomologous Proteins GCG Gap program was used: gap penalty: 10; gapextension penalty: 0.1; score matrix: blosum62) Swiss-Prot # Q9SZI1P42158 Q9ZWB3 Q9ZUP4 Q9LSX4 Protein COL-0 CASEIN ADK1 PUTATIVE CASEINname CASEIN KINASE I CASEIN KINASE I KINASE I- KINASE I LIKE PROTEINSpecies Arabidopsis Arabidopsis Arabidopsis Arabidopsis Arabidopsisthaliana thaliana thaliana thaliana thaliana (Mouse-ear (Mouse-ear(Mouse-ear (Mouse-ear (Mouse-ear cress) cress) cress) cress) cress)Identity % 64% 59% 60% 58% 57% Similarity % 73% 66% 72% 67% 69%

TABLE 8 Degree of Amino Acid Identity and Similarity of PpCK-3 and OtherHomologous Proteins GCG Gap program was used: gap penalty: 10; gapextension penalty: 0.1; score matrix: blosum62) Swiss-Prot # O64816Q9ZR52 P28523 Q9SN18 Q08466 Protein PUTATIVE CASEIN CASEIN CASEIN CASEINname CASEIN KINASE II KINASE II, KINASE II, KINASE II, KINASE II ALPHAALPHA ALPHA ALPHA CATALYTIC SUBUNIT CHAIN CHAIN 2 CHAIN 2 SUBUNIT (CKII) Species Arabidopsis Zea mays Zea mays Arabidopsis Arabidopsisthaliana (Maize) (Maize) thaliana thaliana (Mouse-ear (Mouse-ear(Mouse-ear cress) cress) cress) Identity % 87% 89% 89% 88% 88%Similarity % 93% 94% 93% 93% 93%

TABLE 9 Degree of Amino Acid Identity and Similarity of PpMPK-2 andOther Homologous Proteins GCG Gap program was used: gap penalty: 10; gapextension penalty: 0.1; score matrix: blosum62) Swiss-Prot # Q9M136Q40531 Q39024 Q40353 Q07176 Protein MAP MITOGEN- MITOGEN- MITOGEN-MITOGEN- name KINASE 4 ACTIVATED ACTIVATED ACTIVATED ACTIVATED PROTEINPROTEIN PROTEIN PROTEIN KINASE KINASE KINASE KINASE HOMOLOG HOMOLOG 4HOMOLOG HOMOLOG NTF6 MMK2 MMK1 Species Arabidopsis Nicotiana ArabidopsisMedicago Medicago thaliana tabacum thaliana sativa sativa (Mouse-ear(Common (Mouse-ear (Alfalfa) (Alfalfa) cress) tobacco) cress) Identity %70% 69% 69% 68% 66% Similarity % 80% 78% 80% 79% 76%

TABLE 10 Degree of Amino Acid Identity and Similarity of PpMPK-3 andOther Homologous Proteins GCG Gap program was used: gap penalty: 10; gapextension penalty: 0.1; score matrix: blosum62) Swiss-Prot # Q9SUX2P13983 Q41192 O70495 Q9RLD9 Protein EXTENSIN- EXTENSIN NAPRP3 PLENTY-FERULOYL- name LIKE OF- COA PROTEIN PROLINES- SYNTHETASE 101 SpeciesArabidopsis Nicotiana Nicotiana Mus Pseudomonas thaliana tabacum alatamusculus sp. (Mouse-ear (Common (Winged (Mouse) cress) tobacco) tobacco)(Persian tobacco) Identity % 12% 15% 22% 18% 11% Similarity % 21% 22%30% 26% 20%

TABLE 11 Degree of Amino Acid Identity and Similarity of PpMZPK-4 andOther Homologous Proteins GCG Gap program was used: gap penalty: 10; gapextension penalty: 0.1; score matrix: blosum62) Swiss-Prot # O49975O48616 Q9M6Q9 O80395 Q9S7U9 Protein PROTEIN MAP KINASE MAP KINASE MAPKINASE MAP2K name KINASE KINASE KINASE KINASE 2 BETA ZMMEK1 PROTEINSpecies Zea mays Lycopersicon Nicotiana Arabidopsis Arabidopsis (Maize)esculentum tabacum thaliana thaliana (Tomato) (Common (Mouse-ear(Mouse-ear tobacco) cress) cress) Identity % 59% 54% 53% 50% 50%

TABLE 12 Degree of Amino Acid Identity and Similarity of PpMPK-5 andOther Homologous Proteins GCG Gap program was used: gap penalty: 10; gapextension penalty: 0.1; score matrix: blosum62) Swiss-Prot # O49975O48616 Q9M6Q9 O80395 Q9S7U9 Protein PROTEIN MAP MAP MAP MAP2K BETA nameKINASE KINASE KINASE KINASE PROTEIN ZMMEK1 KINASE KINASE KINASE 2Species Zea mays Lycopersicon Nicotiana Arabidopsis Arabidopsis (Maize)esculentum tabacum thaliana thaliana (Tomato) (Common (Mouse-ear cress)(Mouse-ear cress) tobacco) Identity % 59% 54% 53% 50% 50% Similarity %72% 66% 66% 62% 62%

TABLE 13 Degree of Amino Acid Identity and Similarity of PpCPK-1 andOther Homologous Proteins GCG Gap program was used: gap penalty: 10; gapextension penalty: 0.1; score matrix: blosum62) Swiss-Prot # Q9SCS2O04290 P53681 P93520 Q41792 Protein CDPK- CDPK- CDPK- CALCIUM/CAL CDPK-name RELATED RELATED RELATED MODULIN- RELATED PROTEIN PROTEIN PROTEINDEPENDENT PROTEIN KINASE KINASE KINASE PROTEIN KINASE KINASE HOMOLOGSpecies Arabidopsis Arabidopsis Daucus Zea mays Zea mays thalianathaliana carota (Maize) (Maize) (Mouse-ear (Mouse-ear (Carrot) cress)cress) Identity % 64% 64% 63% 63% 63% Similarity % 76% 76% 75% 73% 74%

TABLE 14 Degree of Amino Acid Identity and Similarity of PpCPK-2 andOther Homologous Proteins GCG Gap program was used: gap penalty: 10; gapextension penalty: 0.1; score matrix: blosum62) Swiss-Prot # Q9S7Z4Q42479 Q41790 O81390 Q9ZPM0 Protein CALCIUM- CALCIUM- CALCIUM- CALCIUM-CA2+- name DEPENDENT DEPENDENT DEPENDENT DEPENDENT DEPENDENT PROTEINPROTEIN PROTEIN PROTEIN PROTEIN KINASE KINASE KINASE KINASE KINASESpecies Marchantia Arabidopsis Zea mays Nicotiana Mesembryant polymorphathaliana (Maize) tabacum hemum (Liverwort) (Mouse-ear (Commoncrystallinum cress) tobacco) (Common ice plant) Identity % 66% 62% 59%59% 59% Similarity % 75% 73% 70% 68% 70%

Example 6

Cloning of the Full-Length Physcomitrella patens cDNA Encoding for PK-6,PK-7, PK-8, PK-9, CK-1, CK-2, CK-3, MPK-2, MPK-3, MPK-4, MPK-5, CPK-1and CPK-2

To isolate the clones encoding PK-6 (SEQ ID NO:14), PK-7 (SEQ ID NO:15),PK-8 (SEQ ID NO:16), PK-9 (SEQ ID NO:17), CK-1 (SEQ ID NO:18), CK-2 (SEQID NO:19), CK-3 (SEQ ID NO:20), MPK-2 (SEQ ID NO:21), MPK-3 (SEQ IDNO:22), MPK-4 (SEQ ID NO:23), MPK-5 (SEQ ID NO:24), CPK-1 (SEQ ID NO:25)and CPK-2 (SEQ ID NO:26) from Physcomitrella patens, cDNA libraries werecreated with SMART RACE cDNA Amplification kit (Clontech Laboratories)following manufacturer's instructions. Total RNA isolated as describedin Example 3 was used as the template. The cultures were treated priorto RNA isolation as follows: Salt Stress: 2, 6, 12, 24, 48 hours with1-M NaCl-supplemented medium; Cold Stress: 4° C. for the same timepoints as for salt; Drought Stress: cultures were incubated on dryfilter paper for the same time points as for salt.

5′ RACE Protocol

The EST sequences PK-6 (SEQ ID NO:1), PK-7 (SEQ ID NO:2), PK-8 (SEQ IDNO:3), PK-9 (SEQ ID NO:4), CK-1 (SEQ ID NO:5), CK-2 (SEQ ID NO:6), CK-3(SEQ ID NO:7), MPK-2 (SEQ ID NO:8), MPK-3 (SEQ ID NO:9), MPK-4 (SEQ IDNO:10), MPK-5 (SEQ ID NO:11), CPK-1 (SEQ ID NO:12) and CPK-2 (SEQ IDNO:13) identified from the database search as described in Example 4were used to design oligos for RACE (see Table 15). The extendedsequences for these genes were obtained by performing RapidAmplification of cDNA Ends polymerase chain reaction (RACE PCR) usingthe Advantage 2 PCR kit (Clontech Laboratories) and the SMART RACE cDNAamplification kit (Clontech Laboratories) using a Biometra T3Thermocycler following the manufacturer's instructions. The sequencesobtained from the RACE reactions corresponded to full-length codingregions of CC-2 and CC-3 and were used to design oligos for full-lengthcloning of the respective genes (see below full-length amplification).

Full-Length Amplification

Full-length clones corresponding PK-6 (SEQ ID NO:14), PK-7 (SEQ IDNO:15), PK-8 (SEQ ID NO:16), PK-9 (SEQ ID NO:17), CK-1 (SEQ ID NO:18),CK-2 (SEQ ID NO:19), CK-3 (SEQ ID NO:20), MPK-2 (SEQ ID NO:21), MPK-3(SEQ ID NO:22), MPK-4 (SEQ ID NO:23), MPK-5 (SEQ ID NO:24), CPK-1 (SEQID NO:25) and CPK-2 (SEQ ID NO:26) were obtained by performingpolymerase chain reaction (PCR) with gene-specific primers (see Table15) and the original EST as the template. The conditions for thereaction were standard conditions with PWO DNA polymerase (Roche). PCRwas performed according to standard conditions and to manufacturer'sprotocols (Sambrook et al., 1989 Molecular Cloning, A Laboratory Manual.2nd Edition. Cold Spring Harbor Laboratory Press. Cold Spring Harbor,N.Y., Biometra T3 Thermocycler). The parameters for the reaction were:five minutes at 94° C. followed by five cycles of one minute at 94° C.,one minute at 50° C. and 1.5 minutes at 72° C. This was followed bytwenty five cycles of one minute at 94° C., one minute at 65° C. and 1.5minutes at 72° C.

The amplified fragments were extracted from agarose gel with a QIAquickGel Extraction Kit (Qiagen) and ligated into the TOPO pCR 2.1 vector(Invitrogen) following manufacturer's instructions. Recombinant vectorswere transformed into Top 10 cells (Invitrogen) using standardconditions (Sambrook et al. 1989. Molecular Cloning, A LaboratoryManual. 2nd Edition. Cold Spring Harbor Laboratory Press. Cold SpringHarbor, N.Y.). Transformed cells were selected for on LB agar containing100 μg/ml carbenicillin, 0.8 mg X-gal(5-bromo-4-chloro-3-indolyl-β-D-galactoside) and 0.8 mg IPTG(isopropylthio-β-D-galactoside) grown overnight at 37° C. White colonieswere selected and used to inoculate 3 ml of liquid LB containing 100μg/ml ampicillin and grown overnight at 37° C. Plasmid DNA was extractedusing the QIAprep Spin Miniprep Kit (Qiagen) following manufacturer'sinstructions. Analyses of subsequent clones and restriction mapping wasperformed according to standard molecular biology techniques (Sambrooket al., 1989 Molecular Cloning, A Laboratory Manual. 2nd Edition. ColdSpring Harbor Laboratory Press. Cold Spring Harbor, N.Y.). TABLE 15Scheme and primers used for cloning of full-length clones Final productIsolation Gene Sites Method Primers Race Primers RT-PCR PpPK-6 XmaI/HpaI5′ RACE and RC782: RC858: RT-PCR for (SEQ ID NO:43) (SEQ ID NO:46)Full-length CCACGGTCTTCGG ATCCCGGGTGAGT clone CTGCTGGTCGTG ATCACTTACGGTGRC783: GCGA (SEQ ID NO:44) RC859: GCAGCACAGCAC (SEQ ID NO:47)CACCAGCGGCTAT GCGTTAACTCGAC . . . CAAGGTCACTATT NVT: CCAAGCA (SEQ IDNO:45) GCGCCCAGTGAG TAGCTCCAGCATT PpPK-7 XmaI/HpaI 5′ RACE and RC250:RC590: RT-PCR for (SEQ ID NO:48) (SEQ ID NO:49) Full-lengthCGGTGCCCACCTC ATCCCGGGAGTGG clone GTTCCTGTGGTT GTGGTTGGACTGT AAGGARC591: (SEQ ID NO:50) GCGTTAACCTTCG TCTTGGACAGGTA GAGGTTAC PpPK-8XmaI/HpaI 5′ RACE and (SEQ ID NO:51) RC1016: RT-PCR for GACTCAGCCCCGT(SEQ ID NO:52) Full-length AATCCTTCAACA ATCCCGGGCAACG cloneAGAAGCATTCGAG ATGGC RC1021: (SEQ ID NO:53) GCGTTAACGAGCA TCACGATACTCGGTGATTTC PpPK-9 XmaI/SacI 5′ RACE and RC263: RC831: RT-PCR for (SEQ IDNO:54) (SEQ ID NO:55) Full-length CGACGGCTAATA ATCCCGGGCTGTG cloneCCACGTTGGCGAC ATGTCGGTGTGGT CA GCTCTGC RC832: (SEQ ID NO:56)GCGAGCTCGCACC ACTGAATGATGGA GACTCAGG PpCK-1 XmaI/HpaI 5′ RACE and NVT:RC614: RT-PCR for (SEQ ID NO:57) (SEQ ID NO:58) Full-length CGACCGCAGCCCATCCCGGGCTCAC clone ATGAGGAAGTTAT GTAGTGCACTGAA CTCTGTC RC615: (SEQ IDNO:59) GCGTTAACATGCC CATCTTCTCATACT CAGACC PpCK-2 XmaI/HpaI 5′ RACE andNVT: RC1012: RT-PCR for (SEQ ID NO:60) (SEQ ID NO:61) Full-lengthCTCGCCTACCAAG ATCCCGGGTTGTC clone CCCCATTAGAAA GAGGACGGAGAG AGAAGAGRC1015: (SEQ ID NO:62) GCGTTAACCTTAG GAATCGTATGGCA GAGAGCT PpCK-3HpaI/SacI 5′ RACE and NVT: RC640: RT-PCR for (SEQ ID NO:63) (SEQ IDNO:64) Full-length GCTTCACAATGTT GCGTTAACGGGAG clone GGGCCCTCCACAGAAGGTCGGGGGA AGAGACG RC641: (SEQ ID NO:65) GCGAGCTCAGCGC TTCGCACAACTGAGAAACCT PpMPK-2 XmaI/HpaI 5′ RACE and NVT: RC664: RT-PCR for (SEQ IDNO:66) (SEQ ID NO:67) Full-length ACGAGAAGGTTG ATCCCGGGCGAGC cloneGTGGGCTTCAAGT CATGGCGCCACTT GCTT RC665: (SEQ ID NO:68) GCGTTAACGCCGAGCAACAATGTCTG CTGGATG PpMPK-3 XmaI/HpaI 5′ RACE and RC268: RC662: RT-PCRfor (SEQ ID NO:69) (SEQ ID NO:70) Full-length CCCGGTAAGCCATATCCCGGGCTTGT clone CGGAGTGTGGAA ATTGGCTCGGATA ATTT RC663: (SEQ IDNO:71) GCGTTAACGGCAA TATCTGCACAGCC GTTCACT PpMPK-4 XmaI/SacI 5′ RACE andNVT: RC1001: RT-PCR for (SEQ ID NO:72) (SEQ ID NO:73) Full-lengthGTGTCTCGCTGGG ATCCCGGGCGGTC clone CCAAGGAATGAA GAGTCGTATTAGG TGTTGTTTCRC1005: (SEQ ID NO:74) GAGCTCCGGTAGG TCCGACCTCTTCA ATTG PpMPK-5XmaI/SacI 5′ RACE and RC266: RC572: RT-PCR for (SEQ ID NO:75) (SEQ IDNO:76) Full-length GACGACGCGAAG ATCCCGGGAGAGG clone CCCGGTGTGGTTGCTGATCTGATGCT A ACAGT RC573: (SEQ ID NO:77) ATGAGCTCTGGCG GATTGGCGAGGTAGTTCGAC PpCPK-1 XmaI/HpaI 5′ RACE and RC526: RC817: RT-PCR for (SEQ IDNO:78) (SEQ ID NO:82) Full-length CGGCGCAACGTA ATCCCGGGTGTAG cloneGTATGCGCTTCCA GCGGGCGAGGTTC . . . GATGC RC723N: RC818: (SEQ ID NO:79)(SEQ ID NO:83) CGCGGTGAACAA GCGTTAACGACAA CACCTTGCAGGTG CCGGAGTAGAACG ACGCAGTCCA RC767: (SEQ ID NO:80) GCTCGGGTCAGCC CTCAACACCGCA . . . NVT:(SEQ ID NO:81) GTTAAAGCTTGTG CAGCAGTCATGC PpCPK-2 XmaI/HpaI 5′ RACE andNVT: RC703: RT-PCR for (SEQ ID NO:84) (SEQ ID NO:85) Full-lengthAGAAGCGAGGAA ATCCCGGGCGAAC clone TGGGCAGGGACG TGCGATCTGAGAT A TCCAACRC704: (SEQ ID NO:86) GCGTTAACGAGAT CCAACCGAAGCCA TCCTACGA

Example 7

Engineering Stress-Tolerant Arabidopsis Plants by Over-Expressing theGenes PK-6, PK-7, PK-8, PK-9, CK-1, CK-2, CK-3, MPK-2, MPK-3, MPK-4,MPK-5, CPK-1 and CPK-2

Binary Vector Construction: Kanamycin

The plasmid construct pACGH101 was digested with PstI (Roche) and FseI(NEB) according to manufacturers' instructions. The fragment waspurified by agarose gel and extracted via the Qiaex II DNA Extractionkit (Qiagen). This resulted in a vector fragment with the ArabidopsisActin2 promoter with internal intron and the OCS3 terminator. Primersfor PCR amplification of the NPTII gene were designed as follows:5′NPT-Pst: GCG-CTG-CAG-ATT-TCA-TTT-GGA-GAG-GAC- (SEQ ID NO:87) ACG3′NPT-Fse: CGC-GGC-CGG-CCT-CAG-AAG-AAC-TCG-TCA- (SEQ ID NO:88)AGA-AGG-CG.

The 0.9 kilobase NPTII gene was amplified via PCR from pCambia 2301plasmid DNA [94oC 60 sec, {94oC 60 sec, 61oC (−0.1oC per cycle) 60 sec,72oC 2 min}×25 cycles, 72oC 10 min on Biometra T-Gradient machine], andpurified via the Qiaquick PCR Extraction kit (Qiagen) as permanufacturer's instructions. The PCR DNA was then subcloned into thepCR-BluntII TOPO vector (Invitrogen) pursuant to the manufacturer'sinstructions (NPT-Topo construct). These ligations were transformed intoTop10 cells (Invitrogen) and grown on LB plates with 50 ug/ml kanamycinsulfate overnight at 37oC. Colonies were then used to inoculate 2 ml LBmedia with 50 ug/ml kanamycin sulfate and grown overnight at 37oC.Plasmid DNA was recovered using the Qiaprep Spin Miniprep kit (Qiagen)and sequenced in both the 5′ and 3′ directions using standardconditions. Subsequent analysis of the sequence data using VectorNTIsoftware revealed no PCR errors present in the NPTII gene sequence.

The NPT-Topo construct was then digested with PstI (Roche) and FseI(NEB) according to manufacturers' instructions. The 0.9 kilobasefragment was purified on agarose gel and extracted by Qiaex II DNAExtraction kit (Qiagen). The Pst/Fse insert fragment from NPT-Topo andthe Pst/Fse vector fragment from pACGH101 were then ligated togetherusing T4 DNA Ligase (Roche) following manufacturer's instructions. Theligation was then transformed into Top10 cells (Invitrogen) understandard conditions, creating pBPSsc019 construct. Colonies wereselected on LB plates with 50 ug/ml kanamycin sulfate and grownovernight at 37° C. These colonies were then used to inoculate 2 ml LBmedia with 50 ug/ml kanamycin sulfate and grown overnight at 37° C.Plasmid DNA was recovered using the Qiaprep Spin Miniprep kit (Qiagen)following the manufacturer's instructions.

The pBPSSC019 construct was digested with KpnI and BsaI (Roche)according to manufacturer's instructions. The fragment was purified viaagarose gel and then extracted via the Qiaex II DNA Extraction kit(Qiagen) as per its instructions, resulting in a 3 kilobase Act-NPTcassette, which included the Arabidopsis Actin2 promoter with internalintron, the NPTII gene and the OCS3 terminator.

The pBPSJH001 vector was digested with SpeI and ApaI (Roche) andblunt-end filled with Klenow enzyme and 0.1 mM dNTPs (Roche) accordingto manufacture's instructions. This produced a 10.1 kilobase vectorfragment minus the Gentamycin cassette, which was recircularized byself-ligating with T4 DNA Ligase (Roche), and transformed into Top10cells (Invitrogen) via standard conditions. Transformed cells wereselected for on LB agar containing 50 μg/ml kanmycin sulfate and grownovernight at 37° C. Colonies were then used to inoculate 2 ml of liquidLB containing 50 μg/ml kanamycin sulfate and grown overnight at 37° C.Plasmid DNA was extracted using the QIAprep Spin Miniprep Kit (Qiagen)following manufacture's instructions. The recircularized plasmid wasthen digested with KpnI (Roche) and extracted from agarose gel via theQiaex II DNA Extraction kit (Qiagen) as per manufacturer's instructions.

The Act-NPT Kpn-cut insert and the Kpn-cut pBPSJH001 recircularizedvector were then ligated together using T4 DNA Ligase (Roche) andtransformed into Top10 cells (Invitrogen) as per manufacturers'instructions. The resulting construct, pBPSsc022, now contained theSuper Promoter, the GUS gene, the NOS terminator, and the Act-NPTcassette. Transformed cells were selected for on LB agar containing 50μg/ml kanmycin sulfate and grown overnight at 37° C. Colonies were thenused to inoculate 2 ml of liquid LB containing 50 μg/ml kanamycinsulfate and grown overnight at 37° C. Plasmid DNA was extracted usingthe QIAprep Spin Miniprep Kit (Qiagen) following manufacturer'sinstructions. After confirmation of ligation success via restrictiondigests, pBPSsc022 plasmid DNA was further propigated and recoveredusing the Plasmid Midiprep Kit (Qiagen) following the manufacturer'sinstructions.

Subcloning of PK-6, PK-7, PK-8, PK-9, CK-1, CK-2, CK-3, MPK-2, MPK-3.MPK-4, MPK-5, CPK-1 and CPK-2 into the Binary Vector

The fragments containing the different Physcomitrella patens proteinkinases were subcloned from the recombinant PCR2.1 TOPO vectors bydouble digestion with restriction enzymes (see Table 16) according tomanufacturer's instructions. The subsequence fragment was excised fromagarose gel with a QIAquick Gel Extraction Kit (QLAgen) according tomanufacture's instructions and ligated into the binary vectors pGMSG,cleaved with XmaI and Ecl136II and dephosphorylated prior to ligation.The resulting recombinant pGMSG contained the correspondingtranscription factor in the sense orientation under the constitutivesuper promoter. TABLE 16 Listed are the names of the various constructsof the Physcomitrella patens transcription factors used for planttransformation Enzymes used to Enzymes used generate gene to restrictBinary Vector Gene fragment pBPSJH001 Construct PpPK-6 XmaI/HpalXmaI/SacI pBPSJyw022 PpPK-7 XmaI/HpaI XmaI/Ecl136 pBPSJyw012 PpPK-8XmaI/HpaI XmaI/Ecl136 pBPSJYW030 PpPK-9 XmaI/SacI XmaI/SacI PBPSERG010PpCK-1 XmaI/HpaI XmaI/Ecl136 pBPSSY012 PpCK-2 XmaI/HpaI XmaI/Ecl136pBPSJyw034 PpCK-3 HpaI/SacI SmaI/SacI pBPSSY011 PpMPK-2 XmaI/HpaIXmaI/Ecl136 pBPSSY016 PpMPK-3 XmaI/HpaI XmaI/Ecl136 pBPSJyw014 PpMPK-4XmaI/SacI XmaI/SacI pBPSJyw025 PpMPK-5 XmaI/SacI XmaI/SacI PBPSERG009PpCPK-1 XmaI/HpaI XmaI/Ecl136 PBPSERG019 PpCPK-2 XmaI/HpaI XmaI/Ecl136pBPSJyw008Agrobacterium Transformation

The recombinant vectors were transformed into Agrobacterium tumefaciensC58C1 and PMP90 according to standard conditions (Hoefgen andWillmitzer, 1990).

Plant Transformation

Arabidopsis thaliana ecotype C24 were grown and transformed according tostandard conditions (Bechtold 1993, Acad. Sci. Paris. 316:1194-1199;Bent et al. 1994, Science 265:1856-1860).

Screening of Transformed Plants

T1 seeds were sterilized according to standard protocols (Xiong et al.1999, Plant Molecular Biology Reporter 17: 159-170). Seeds were platedon 12 Murashige and Skoog media (MS) (Sigma-Aldrich) pH 5.7 with KOH,0.6% agar and supplemented with 1% sucrose, 0.5 g/L2-[N-Morpholino]ethansulfonic acid (MES) (Sigma-Aldrich), 50 μg/mlkanamycin (Sigma-Aldrich), 500 μg/ml carbenicillan (Sigma-Aldrich) and 2μg/ml benomyl (Sigma-Aldrich). Seeds on plates were vernalized for fourdays at 4° C. The seeds were germinated in a climatic chamber at an airtemperature of 22° C. and light intensity of 40 micromol s⁻¹ m⁻² (whitelight; Philips TL 65W/25 fluorescent tube) and 16 hours light and 8hours dark day length cycle. Transformed seedlings were selected after14 days and transferred to ½ MS media pH 5.7 with KOH 0.6% agar platessupplemented with 0.6% agar, 1% sucrose, 0.5 g/L MES (Sigma-Aldrich),and 2 μg/ml benomyl (Sigma-Aldrich) and allowed to recover forfive-seven days.

Drought Tolerance Screening

T1 seedlings were transferred to dry, sterile filter paper in a petridish and allowed to desiccate for two hours at 80% RH (relativehumidity) in a Percieval Growth Cabinet MLR-350H, micromole s⁻¹ m⁻²(white light; Philips TL 65W/25 fluorescent tube). The RH was thendecreased to 60% and the seedlings were desiccated further for eighthours. Seedlings were then removed and placed on ½ MS 0.6% agar platessupplemented with 2 μg/ml benomyl (Sigma-Aldrich) and 0.5 g/L MES(Sigma-Aldrich) and scored after five days.

Under drought stress conditions, PpPK-6 over-expressing Arabidopsisthaliana plants showed a 95% (20 survivors from 21 stressed plants)survival rate to the stress screening; PpPK-8, 40% (2 survivors from 5stressed plants), PpPK-9, 78% (38 survivors from 49 stressed plants),PpCK-1, 50% (5 survivors from 10 stressed plants), PpCK-2, 52% (16survivors from 31 stressed plants), PpCK-3, 60% (3 survivors from 5stressed plants), PpMPK-2, 100% (52 survivors from 52 stressed plants),PpMPK-3, 98% (44 survivors from 45 stressed plants), PpMPK-4, 92% (11survivors from 12 stressed plants), PpMPK-5, 100% (9 survivors from 9stressed plants), PpCPK-1, 60% (12 survivors from 20 stressed plants),PpCPK-2, 89% (17 survivors from 19 stressed plants), whereas theuntransformed control only showed an 11% survival rate (1 survivor from9 stressed plants). It is noteworthy that the analyses of thesetransgenic lines were performed with T1 plants, and therefore, theresults will be better when a homozygous, strong expresser is found.TABLE 17 Summary of the drought stress tests Drought Stress Test Numberof Total number Percentage of Gene Name survivors of plants survivorsPpPK-6 20 21 95% PpPK-8 2 5 40% PpPK-9 38 49 78% PpCK-1 5 10 50% PpCK-216 31 52% PpCK-3 3 5 60% PpMPK-2 52 52 100% PpMPK-3 44 45 98% PpMPK-4 1112 92% PpMPK-5 9 9 100%

Freezing Tolerance Screening

Seedlings were moved to petri dishes containing 12 MS 0.6% agarsupplemented with 2% sucrose and 2 μg/ml benomyl. After four days, theseedlings were incubated at 4° C. for 1 hour and then covered withshaved ice. The seedlings were then placed in an EnvironmentalSpecialist ES2000 Environmental Chamber and incubated for 3.5 hoursbeginning at −1.0° C. decreasing 1° C./hour. The seedlings were thenincubated at −5.0° C. for 24 hours and then allowed to thaw at 5° C. for12 hours. The water was poured off and the seedlings were scored after 5days.

Under freezing stress conditions, PpPK-7 over-expressing Arabidopsisthaliana plants showed a 73% (8 survivors from 11 stressed plants)survival rate to the stress screening; PpPK-9, 100% (45 survivors from45 stressed plants), PpCK-1, 100% (14 survivors from 14 stressedplants), PpMPK-2, 68% (36 survivors from 53 stressed plants), PpMPK-3,92% (24 survivors from 26 stressed plants), PpCPK-2, 64% (7 survivorsfrom 11 stressed plants), whereas the untransformed control only showeda 2% survival rate (1 survivor from 48 stressed plants). It isnoteworthy that the analyses of these transgenic lines were performedwith T1 plants, and therefore, the results will be better when ahomozygous, strong expresser is found. TABLE 18 Summary of the freezingstress tests Freezing Stress Test Number of Total number Percentage ofGene Name survivors of plants survivors PpPK-7 8 11 73% PpPK-9 45 45100% PpCK-1 14 14 100% PpMPK-2 36 53 68% PpMPK-3 24 26 92% PpCPK-2 7 1164% Control 1 48 2%

Salt Tolerance Screening

Seedlings were transferred to filter paper soaked in ½ MS and placed on½ MS 0.6% agar supplemented with 2 μg/ml benomyl the night before thesalt tolerance screening. For the salt tolerance screening, the filterpaper with the seedlings was moved to stacks of sterile filter paper,soaked in 50 mM NaCl, in a petri dish. After two hours, the filter paperwith the seedlings was moved to stacks of sterile filter paper, soakedwith 200 mM NaCl, in a petri dish. After two hours, the filter paperwith the seedlings was moved to stacks of sterile filter paper, soakedin 600 mM NaCl, in a petri dish. After 10 hours, the seedlings weremoved to petri dishes containing ½ MS 0.6% agar supplemented with 2μg/ml benomyl. The seedlings were scored after 5 days.

The transgenic plants are screened for their improved salt tolerancedemonstrating that transgene expression confers salt tolerance.

Example 8

Detection of the PK-6, PK-7, PK-8, PK-9, CK-1, CK-2, CK-3, MPK-2, MPK-3,MPK-4, MPK-5, CPK-1 and CPK-2 Transgenes in the Transgenic ArabidopsisLines

One leaf from a wild type and a transgenic Arabidopsis plant washomogenized in 250 μl Hexadecyltrimethyl ammonium bromide (CTAB) buffer(2% CTAB, 1.4 M NaCl, 8 mM EDTA and 20 mM Tris pH 8.0) and 1 μlβ-mercaptoethanol. The samples were incubated at 60-65° C. for 30minutes and 250 μl of Chloroform was then added to each sample. Thesamples were vortexed for 3 minutes and centrifuged for 5 minutes at18,000×g. The supernatant was taken from each sample and 150 μlisopropanol was added. The samples were incubated at room temperaturefor 15 minutes, and centrifuged for 10 minutes at 18,000×g. Each pelletwas washed with 70% ethanol, dried, and resuspended in 20 μl TE. 4 μl ofabove suspension was used in a 20 μl PCR reaction using Taq DNApolymerase (Roche Molecular Biochemicals) according to themanufacturer's instructions.

Binary vector plasmid with each gene cloned in was used as positivecontrol, and the wild-type C24 genomic DNA was used as negative controlin the PCR reactions. 10 μl PCR reaction was analyzed on 0.8%agarose-ethidium bromide gel. GCTGACACGCCAAGCCTCGCTAGTC (SEQ ID NO:89)GCGTTAACTCGACCAAGGTCACTATTCCAAGCA (SEQ ID NO:90)

The PCR program was as following: 30 cycles of 1 minute at 94° C., 1minute at 62° C. and 4 minutes at 72° C., followed by 10 minutes at 72°C. A 2.8 kb fragment was produced from the positive control and thetransgenic plants.

PpPk-7: The primers used in the reactions are: GCTGACACGCCAAGCCTCGCTAGTC(SEQ ID NO:89) GCGTTAACCTTCGTCTTGGACAGGTAGAGGTTAC (SEQ ID NO:91)

The primers were used in the first round of reactions with the followingprogram: 30 cycles of 1 minute at 94° C., 1 minute at 62° C. and 4minutes at 72° C., followed by 10 minutes at 72° C. A 1.1 kb fragmentwas generated from the positive control and the T1 transgenic plants.

PpPK-8: The primers used in the reactions were:GCTGACACGCCAAGCCTCGCTAGTC (SEQ ID NO:89)GCGTTAACGAGCATCACGATACTCGGTGATTTC (SEQ ID NO:92)

The PCR program was as following: 30 cycles of 1 minute at 94° C., 1minute at 62° C. and 4 minutes at 72° C., followed by 10 minutes at 72°C. A 1.6 kb fragment was produced from the positive control and thetransgenic plants.

PpPK-9: The primers used in the reactions are: GCTGACACGCCAAGCCTCGCTAGTC(SEQ ID NO:89) GCGAGCTCGCACCACTGAATGATGGAGACTCAGG (SEQ ID NO:93)

The PCR program was as following: 30 cycles of 1 minute at 94° C., 1minute at 62° C. and 4 minutes at 72° C., followed by 10 minutes at 72°C. A 1.4 kb fragment was produced from the positive control and thetransgenic plants.

PpCK-1: The primers used in the reactions are: GCTGACACGCCAAGCCTCGCTAGTC(SEQ ID NO:89) GCGTTAACATGCCCATCTTCTCATACTCAGACC (SEQ ID NO:94)

The PCR program was as following: 30 cycles of 1 minute at 94° C., 1minute at 62° C. and 4 minutes at 72° C., followed by 10 minutes at 72°C. A 1.7 kb fragment was produced from the positive control and thetransgenic plants.

PpCK-2: The primers used in the reactions are: GCTGACACGCCAAGCCTCGCTAGTC(SEQ ID NO:89) GCGTTAACCTTAGGAATCGTATGGCAGAGAGCT (SEQ ID NO:95)

The PCR program was as following: 30 cycles of 1 minute at 94° C., 1minute at 62° C. and 4 minutes at 72° C., followed by 10 minutes at 72°C. A 1.9 kb fragment was produced from the positive control and thetransgenic plants.

PpCK-3: The primers used in the reactions are: GCTGACACGCCAAGCCTCGCTAGTC(SEQ ID NO:89) GCGAGCTCAGCGCTTCGCACAACTGAGAAACCT (SEQ ID NO:96)

The PCR program was as following: 30 cycles of 1 minute at 94° C., 1minute at 62° C. and 4 minutes at 72° C., followed by 10 minutes at 72°C. A 1.2 kb fragment was produced from the positive control and thetransgenic plants.

PpMPK-2: The primers used in the reactions are: (SEQ ID NO:89)GCTGACACGCCAAGCCTCGCTAGTC (SEQ ID NO:97)GCGTTAACGGCAATATCTGCACAGCCGTTCACT

The PCR program was as following: 30 cycles of 1 minute at 94° C., 1minute at 62° C. and 4 minutes at 72° C., followed by 10 minutes at 72°C. A 1.7 kb fragment was produced from the positive control and thetransgenic plants.

PpMPK-3: The primers used in the reactions are: (SEQ ID NO:89)GCTGACACGCCAAGCCTCGCTAGTC (SEQ ID NO:98)GCGTTAACGGCAATATCTGCACAGCCGTTCACT

The PCR program was as following: 30 cycles of 1 minute at 94° C., 1minute at 62° C. and 4 minutes at 72° C., followed by 10 minutes at 72°C. A 2.2 kb fragment was produced from the positive control and thetransgenic plants.

PpMPK-4: The primers used in the reactions are: (SEQ ID NO:89)GCTGACACGCCAAGCCTCGCTAGTC (SEQ ID NO:99) GAGCTCCGGTAGGTCCGACCTCTTCAATTG

The PCR program was as following: 30 cycles of 1 minute at 94° C., 1minute at 62° C. and 4 minutes at 72° C., followed by 10 minutes at 72°C. A 1.7 kb fragment was produced from the positive control and thetransgenic plants.

PpMPK-5: The primers used in the reactions are: (SEQ ID NO:89)GCTGACACGCCAAGCCTCGCTAGTC (SEQ ID NO:100)ATGAGCTCTGGCGGATTGGCGAGGTAGTTCGAC

The PCR program was as following: 30 cycles of 1 minute at 94° C., 1minute at 62° C. and 4 minutes at 72° C., followed by 10 minutes at 72°C. A 1.4 kb fragment was produced from the positive control and thetransgenic plants.

PpCPK-1: The primers used in the reactions are: (SEQ ID NO:89)GCTGACACGCCAAGCCTCGCTAGTC (SEQ ID NO:101)GCGTTAACGACAACCGGAGTAGAACGGCAGTCCA

The PCR program was as following: 30 cycles of 1 minute at 94° C., 1minute at 62° C. and 4 minutes at 72° C., followed by 10 minutes at 72°C. A 2.3 kb fragment was produced from the positive control and thetransgenic plants.

PpCPK-2: The primers used in the reactions are: (SEQ ID NO:89)GCTGACACGCCAAGCCTCGCTAGTC (SEQ ID NO:102)GCGTTAACGAGATCCAACCGAAGCCATCCTACGA

The PCR program was as following: 30 cycles of 1 minute at 94° C., 1minute at 62° C. and 4 minutes at 72° C., followed by 10 minutes at 72°C. A 2.2 kb fragment was produced from the positive control and thetransgenic plants.

The transgenes were successfully amplified from the T1 transgenic lines,but not from the wild type C24. This result indicates that the T1transgenic plants contain at least one copy of the transgenes. There wasno indication of existence of either identical or very similar genes inthe untransformed Arabidopsis thaliana control which could be amplifiedby this method.

Example 9

Detection of the PK-6, PK-7, PK-8, PK-9, CK-1, CK-2, CK-3, MPK-2, MPK-3,MPK-4, MPK-5, CPK-1 and CPK-2 Transgene mRNA in Transgenic ArabidopsisLines

Transgene expression was detected using RT-PCR. Total RNA was isolatedfrom stress-treated plants using a procedure adapted from (Verwoerd etal., 1989 NAR 17:2362). Leaf samples (50-100 mg) were collected andground to a fine powder in liquid nitrogen. Ground tissue wasresuspended in 500 μl of a 80° C., 1:1 mixture, of phenol to extractionbuffer (100 mM LiCl, 100 mM Tris pH8, 10 mM EDTA, 1% SDS), followed bybrief vortexing to mix. After the addition of 250 μl of chloroform, eachsample was vortexed briefly. Samples were then centrifuged for 5 minutesat 12,000×g. The upper aqueous phase was removed to a fresh eppendorftube. RNA was precipitated by adding 1/10^(th) volume 3M sodium acetateand 2 volumes 95% ethanol. Samples were mixed by inversion and placed onice for 30 minutes. RNA was pelleted by centrifugation at 12,000×g for10 minutes. The supernatant was removed and pellets briefly air-dried.RNA sample pellets were resuspended in 10 μl DEPC treated water. Toremove contaminating DNA from the samples, each was treated withRNase-free DNase (Roche) according to the manufacturer'srecommendations. cDNA was synthesized from total RNA using the 1^(st)Strand cDNA synthesis kit (Boehringer Mannheim) following manufacturer'srecommendations.

PCR amplification of a gene-specific fragment from the synthesized cDNAwas performed using Taq DNA polymerase (Roche) and gene-specific primers(see Table 15 for primers) in the following reaction: 1×PCR buffer, 1.5mM MgCl₂, 0.2 μM each primer, 0.2 μM dNTPs, 1 unit polymerase, 5 μl cDNAfrom synthesis reaction. Amplification was performed under the followingconditions: Denaturation, 95° C., 1 minute; annealing, 62° C., 30seconds; extension, 72° C., 1 minute, 35 cycles; extension, 72° C., 5minutes; hold, 4° C., forever. PCR products were run on a 1% agarosegel, stained with ethidium bromide, and visualized under UV light usingthe Quantity-One gel documentation system (Bio-Rad).

Expression of the transgenes was detected in the T1 transgenic line.This result indicated that the transgenes are expressed in thetransgenic lines and strongly suggested that their gene product improvedplant stress tolerance in the transgenic line. On the other hand, noexpression of identical or very similar endogenous genes could bedetected by this method. These results are in agreement with the datafrom Example 7. This greatly supports our statement that the observedstress tolerance is due to the introduced transgene. PpPK-6 (SEQ IDNO:103) CCCAGTAATAGCAGGGTTGGAGGAA (SEQ ID NO:104)GGCTGCCTGAAGATCCGCTACAGAG PpPK-7 (SEQ ID NO:105)CGTCAGGCTACTTTGCGTGGAGCAC (SEQ ID NO:106) CGGTGCTGGCTAACACCAGGCCAGAPpPK-8 (SEQ ID NO:107) ATCCCGGGCAACGAGAAGCATTCGAGATGGC (SEQ ID NO:108)GCGTTAACGAGCATCACGATACTCGGTGATTTC PpPK-9 (SEQ ID NO:109)CGTGGCATCTCTCCCGATGTTCTTA (SEQ ID NO:110) GGCCAACTGAAGGCGTGTCATGATCPpCK-1 (SEQ ID NO:111) CTCGAGGGCTCGTTCACCGTGACCT (SEQ ID NO:112)CGGAGGTAACAGTAGTCAGGCTGCTC PpCK-2 (SEQ ID NO:113)CCGCGACCCTTCCACGCATCAGCAT (SEQ ID NO:114) CCTCCAGGAAGCCTGCGCCGAGAAGPpCK-3 (SEQ ID NO:115) GGACATTGTCCGTGATCAGCAATCGA (SEQ ID NO:116)CAGCCTCTGGAACAACCAGACGCTG PpMPK-2 (SEQ ID NO:117)GTCACCGCGAGGTACAAGCCACCAC (SEQ ID NO:118) GCAGCTCTGGAGCTCTGTACCACCTPpMPK-3 (SEQ ID NO:119) ACGGCCACGTCGAGAATCTGAGCAA (SEQ ID NO:120)CGAAGTGCTCGCAAGCAATGCCGAA PpMPK-4 (SEQ ID NO:121)ATCCCGGGCGGTCGAGTCGTATTAGGTGTTGTTTC (SEQ ID NO:122)GAGCTCCGGTAGGTCCGACCTCTTCAATTG PpMPK-5 (SEQ ID NO:123)GGGCAACTGTCAATAGCAGACCTGGA (SEQ ID NO:124) GCAAGTCCCAACGAACGTGTCTCGCTPpCPK-1 (SEQ ID NO:125) GCGAAGATGACGACTGCTATTGCGA (SEQ ID NO:126)CGTGATGACTCCAATGCTCCATACG PpCPK-2 (SEQ ID NO:127)GCCAGCATCGAGGTCAGTATCCGGTGT (SEQ ID NO:128) GTCTGTGGCCTTCAGAGGCGCATCCTC

Amplification was performed under the following conditions:Denaturation, 95° C., 1 minute; annealing, 62° C., 30 seconds;extension, 72° C., 1 minute, 35 cycles; extension, 72° C., 5 minutes;hold, 4° C., forever. PCR products were run on a 1% agarose gel, stainedwith ethidium bromide, and visualized under UV light using theQuantity-One gel documentation system (Bio-Rad).

Expression of the transgenes was detected in the T1 transgenic line.These results indicated that the transgenes are expressed in thetransgenic lines and strongly suggested that their gene product improvedplant stress tolerance in the transgenic lines. In agreement with theprevious statement, no expression of identical or very similarendogenous genes could be detected by this method. These results are inagreement with the data from Example 7.

Example 10

Engineering Stress-Tolerant Soybean Plants by Over-Expressing the PK-6,PK-7, PK-8, PK-9, CK-1, CK-2, CK-3, MPK-2, MPK-3, MPK-4, MPK-5, CPK-1and CPK-2 Gene

The constructs pBPSJyw022, pBPSJyw012, pBPSJYW030, PBPSERG010,pBPSSY012, pBPSJyw034, pBPSSY011, pBPSSY016, pBPSJyw014, pBPSJyw025,PBPSERG009, PBPSERG019 and pBPSJyw008 are used to transform soybean asdescribed below.

Seeds of soybean are surface sterilized with 70% ethanol for 4 minutesat room temperature with continuous shaking, followed by 20% (v/v)Clorox supplemented with 0.05% (v/v) Tween for 20 minutes withcontinuous shaking. Then, the seeds are rinsed 4 times with distilledwater and placed on moistened sterile filter paper in a Petri dish atroom temperature for 6 to 39 hours. The seed coats are peeled off, andcotyledons are detached from the embryo axis. The embryo axis isexamined to make sure that the meristematic region is not damaged. Theexcised embryo axes are collected in a half-open sterile Petri dish andair-dried to a moisture content less than 20% (fresh weight) in a sealedPetri dish until further use.

Agrobacterium tumefaciens culture is prepared from a single colony in LBsolid medium plus appropriate antibiotics (e.g. 100 mg/l streptomycin,50 mg/l kanamycin) followed by growth of the single colony in liquid LBmedium to an optical density at 600 nm of 0.8. Then, the bacteriaculture is pelleted at 7000 rpm for 7 minutes at room temperature, andresuspended in MS (Murashige and Skoog, 1962) medium supplemented with100 μM acetosyringone. Bacteria cultures are incubated in thispre-induction medium for 2 hours at room temperature before use. Theaxis of soybean zygotic seed embryos at approximately 15% moisturecontent are imbibed for 2 hours at room temperature with the pre-inducedAgrobacterium suspension culture. The embryos are removed from theimbibition culture and are transferred to Petri dishes containing solidMS medium supplemented with 2% sucrose and incubated for 2 days, in thedark at room temperature. Alternatively, the embryos are placed on topof moistened (liquid MS medium) sterile filter paper in a Petri dish andincubated under the same conditions described above. After this period,the embryos are transferred to either solid or liquid MS mediumsupplemented with 500 mg/L carbenicillin or 300 mg/L cefotaxime to killthe agrobacteria. The liquid medium is used to moisten the sterilefilter paper. The embryos are incubated during 4 weeks at 25° C., under150 μmol m⁻² sec⁻¹ and 12 hours photoperiod. Once the seedlings produceroots, they are transferred to sterile metromix soil. The medium of thein vitro plants is washed off before transferring the plants to soil.The plants are kept under a plastic cover for 1 week to favor theacclimatization process. Then the plants are transferred to a growthroom where they are incubated at 25° C., under 150 μmol m⁻² sec⁻¹ lightintensity and 12 hours photoperiod for about 80 days.

The transgenic plants are then screened for their improved drought, saltand/or cold tolerance according to the screening method described inExample 7 to demonstrate that transgene expression confers stresstolerance.

Example 11

Engineering Stress-Tolerant Rapeseed/Canola Plants by Over-Expressingthe PK-6, PK-7, PK-8, PK-9, CK-1, CK-2, CK-3, MPK-2, MPK-3, MPK-4,MPK-5, CPK-1 and CPK-2 Genes

The constructs pBPSJyw022, pBPSJyw012, pBPSJYW030, PBPSERG010,pBPSSY012, pBPSJyw034, pBPSSY011, pBPSSY016, pBPSJyw014, pBPSJyw025,PBPSERG009, PBPSERG019 and pBPSJyw008 are used to transformrapeseed/canola as described below.

The method of plant transformation described herein is also applicableto Brassica and other crops. Seeds of canola are surface sterilized with70% ethanol for 4 minutes at room temperature with continuous shaking,followed by 20% (v/v) Clorox supplemented with 0.05% (v/v) Tween for 20minutes, at room temperature with continuous shaking. Then, the seedsare rinsed 4 times with distilled water and placed on moistened sterilefilter paper in a Petri dish at room temperature for 18 hours. Then theseed coats are removed and the seeds are air dried overnight in ahalf-open sterile Petri dish. During this period, the seeds lose approx.85% of its water content. The seeds are then stored at room temperaturein a sealed Petri dish until further use. DNA constructs and embryoimbibition are as described in Example 10. Samples of the primarytransgenic plants (T0) are analyzed by PCR to confirm the presence ofT-DNA. These results are confirmed by Southern hybridization in whichDNA is electrophoresed on a 1% agarose gel and transferred to apositively charged nylon membrane (Roche Diagnostics). The PCR DIG ProbeSynthesis Kit (Roche Diagnostics) is used to prepare adigoxigenin-labelled probe by PCR, and used as recommended by themanufacturer.

The transgenic plants are then screened for their improved stresstolerance according to the screening method described in Example 7 todemonstrate that transgene expression confers drought tolerance.

Example 12

Engineering Stress-Tolerant Corn Plants by Over-Expressing the PK-6,PK-7, PK-8, PK-9, CK-1, CK-2, CK-3, MPK-2, MPK-3, MPK-4, MPK-5, CPK-1and CPK-2 Genes

The constructs pBPSJyw022, pBPSJyw012, pBPSJYW030, PBPSERG010,pBPSSY012, pBPSJyw034, pBPSSY011, pBPSSY016, pBPSJyw014, pBPSJyw025,PBPSERG009, PBPSERG019 and pBPSJyw008 are used to transform corn asdescribed below.

Transformation of maize (Zea Mays L.) is performed with the methoddescribed by Ishida et al. 1996. Nature Biotch 14745-50. Immatureembryos are co-cultivated with Agrobacterium tumefaciens that carry“super binary” vectors, and transgenic plants are recovered throughorganogenesis. This procedure provides a transformation efficiency ofbetween 2.5% and 20%. The transgenic plants are then screened for theirimproved drought, salt and/or cold tolerance according to the screeningmethod described in Example 7 to demonstrate that transgene expressionconfers stress tolerance.

Example 13

Engineering Stress-Tolerant Wheat Plants by Over-Expressing the PK-6,PK-7, PK-8, PK-9, CK-1, CK-2, CK-3, MPK-2, MPK-3, MPK-4, MPK-5, CPK-1and CPK-2

The constructs pBPSJyw022, pBPSJyw012, pBPSJYW030, PBPSERG010,pBPSSY012, pBPSJyw034, pBPSSY011, pBPSSY016, pBPSJyw014, pBPSJyw025,PBPSERG009, PBPSERG019 and pBPSJyw008 are used to transform wheat asdescribed below.

Transformation of wheat is performed with the method described by Ishidaet al. 1996 Nature Biotch. 14745-50. Immature embryos are co-cultivatedwith Agrobacterium tumefaciens that carry “super binary” vectors, andtransgenic plants are recovered through organogenesis. This procedureprovides a transformation efficiency between 2.5% and 20%. Thetransgenic plants are then screened for their improved stress toleranceaccording to the screening method described in Example 7 to demonstratethat transgene expression confers drought tolerance.

Example 14

Identification of Homologous and Heterologous Genes

Gene sequences can be used to identify homologous or heterologous genesfrom cDNA or genomic libraries. Homologous genes (e.g. full-length cDNAclones) can be isolated via nucleic acid hybridization using for examplecDNA libraries. Depending on the abundance of the gene of interest,100,000 up to 1,000,000 recombinant bacteriophages are plated andtransferred to nylon membranes. After denaturation with alkali, DNA isimmobilized on the membrane by e.g. UV cross linking. Hybridization iscarried out at high stringency conditions. In aqueous solutionhybridization and washing is performed at an ionic strength of 1 M NaCland a temperature of 68° C. Hybridization probes are generated by e.g.radioactive (³²P) nick transcription labeling (High Prime, Roche,Mannheim, Germany). Signals are detected by autoradiography.

Partially homologous or heterologous genes that are related but notidentical can be identified in a manner analogous to the above-describedprocedure using low stringency hybridization and washing conditions. Foraqueous hybridization, the ionic strength is normally kept at 1 M NaClwhile the temperature is progressively lowered from 68 to 42° C.

Isolation of gene sequences with homologies (or sequenceidentity/similarity) only in a distinct domain of (for example 10-20amino acids) can be carried out by using synthetic radio labeledoligonucleotide probes. Radio labeled oligonucleotides are prepared byphosphorylation of the 5-prime end of two complementary oligonucleotideswith T4 polynucleotide kinase. The complementary oligonucleotides areannealed and ligated to form concatemers. The double strandedconcatemers are than radiolabeled by, for example, nick transcription.Hybridization is normally performed at low stringency conditions usinghigh oligonucleotide concentrations.

Oligonucleotide hybridization solution:

6×SSC

0.01 M sodium phosphate

1 mM EDTA (pH 8)

0.5% SDS

100 μg/ml denatured salmon sperm DNA

0.1% nonfat dried milk

During hybridization, temperature is lowered stepwise to 5-10° C. belowthe estimated oligonucleotide Tm or down to room temperature followed bywashing steps and autoradiography. Washing is performed with lowstringency such as 3 washing steps using 4×SSC. Further details aredescribed by Sambrook, J. et al. (1989), “Molecular Cloning: ALaboratory Manual”, Cold Spring Harbor Laboratory Press or Ausubel, F.M. et al. (1994) “Current Protocols in Molecular Biology”, John Wiley &Sons.

Example 15

Identification of Homologous Genes by Screening Expression Librarieswith Antibodies

cDNA clones can be used to produce recombinant protein for example in E.coli (e.g. Qiagen QIAexpress pQE system). Recombinant proteins are thennormally affinity purified via Ni-NTA affinity chromatography (Qiagen).Recombinant proteins are then used to produce specific antibodies forexample by using standard techniques for rabbit immunization. Antibodiesare affinity purified using a Ni-NTA column saturated with therecombinant antigen as described by Gu et al., 1994 BioTechniques17:257-262. The antibody can than be used to screen expression cDNAlibraries to identify homologous or heterologous genes via animmunological screening (Sambrook, J. et al. (1989), “Molecular Cloning:A Laboratory Manual”, Cold Spring Harbor Laboratory Press or Ausubel, F.M. et al. (1994) “Current Protocols in Molecular Biology”, John Wiley &Sons).

Example 16

In Vivo Mutagenesis

In vivo mutagenesis of microorganisms can be performed by passage ofplasmid (or other vector) DNA through E. coli or other microorganisms(e.g. Bacillus spp. or yeasts such as Saccharomyces cerevisiae) whichare impaired in their capabilities to maintain the integrity of theirgenetic information. Typical mutator strains have mutations in the genesfor the DNA repair system (e.g., mutHLS, mutD, mutT, etc.; forreference, see Rupp, W. D. (1996) DNA repair mechanisms, in: Escherichiacoli and Salmonella, p. 2277-2294, ASM: Washington.) Such strains arewell known to those skilled in the art. The use of such strains isillustrated, for example, in Greener, A. and Callahan, M. (1994)Strategies 7: 32-34. Transfer of mutated DNA molecules into plants ispreferably done after selection and testing in microorganisms.Transgenic plants are generated according to various examples within theexemplification of this document.

Example 17

In Vitro Analysis of the Function of Physcomitrella Genes in TransgenicOrganisms

The determination of activities and kinetic parameters of enzymes iswell established in the art. Experiments to determine the activity ofany given altered enzyme must be tailored to the specific activity ofthe wild-type enzyme, which is well within the ability of one skilled inthe art. Overviews about enzymes in general, as well as specific detailsconcerning structure, kinetics, principles, methods, applications andexamples for the determination of many enzyme activities may be found,for example, in the following references: Dixon, M., and Webb, E. C.,(1979) Enzymes. Longmans: London; Fersht, (1985) Enzyme Structure andMechanism. Freeman: New York; Walsh, (1979) Enzymatic ReactionMechanisms. Freeman: San Francisco; Price, N. C., Stevens, L. (1982)Fundamentals of Enzymology. Oxford Univ. Press: Oxford; Boyer, P. D.,ed. (1983) The Enzymes, 3^(rd) ed. Academic Press: New York; Bisswanger,H., (1994) Enzymkinetik, 2^(nd) ed. VCH: Weinheim (ISBN 3527300325);Bergmeyer, H. U., Bergmeyer, J., Graβl, M., eds. (1983-1986) Methods ofEnzymatic Analysis, 3^(rd) ed., vol. I-XII, Verlag Chemie: Weinheim; andUllmann's Encyclopedia of Industrial Chemistry (1987) vol. A9, Enzymes.VCH: Weinheim, p. 352-363.

The activity of proteins which bind to DNA can be measured by severalwell-established methods, such as DNA band-shift assays (also called gelretardation assays). The effect of such proteins on the expression ofother molecules can be measured using reporter gene assays (such as thatdescribed in Kolmar, H. et al. (1995) EMBO J. 14: 3895-3904 andreferences cited therein). Reporter gene test systems are well known andestablished for applications in both pro- and eukaryotic cells, usingenzymes such as β-galactosidase, green fluorescent protein, and severalothers.

The determination of activity of membrane-transport proteins can beperformed according to techniques such as those described in Gennis, R.B. Pores, Channels and Transporters, in Biomembranes, MolecularStructure and Function, pp. 85-137, 199-234 and 270-322, Springer:Heidelberg (1989).

Example 18

Purification of the Desired Product from Transformed Organisms

Recovery of the desired product from plant material (i.e.,Physcomitrella patents or Arabidopsis thaliana), fungi, algae, ciliates,C. glutamicum cells, or other bacterial cells transformed with thenucleic acid sequences described herein, or the supernatant of theabove-described cultures can be performed by various methods well knownin the art. If the desired product is not secreted from the cells, canbe harvested from the culture by low-speed centrifugation, the cells canbe lysed by standard techniques, such as mechanical force orsonification. Organs of plants can be separated mechanically from othertissue or organs. Following homogenization cellular debris is removed bycentrifugation, and the supernatant fraction containing the solubleproteins is retained for further purification of the desired compound.If the product is secreted from desired cells, then the cells areremoved from the culture by low-speed centrifugation, and the supernatefraction is retained for further purification.

The supernatant fraction from either purification method is subjected tochromatography with a suitable resin, in which the desired molecule iseither retained on a chromatography resin while many of the impuritiesin the sample are not, or where the impurities are retained by the resinwhile the sample is not. Such chromatography steps may be repeated asnecessary, using the same or different chromatography resins. Oneskilled in the art would be well-versed in the selection of appropriatechromatography resins and in their most efficacious application for aparticular molecule to be purified. The purified product may beconcentrated by filtration or ultrafiltration, and stored at atemperature at which the stability of the product is maximized.

There is a wide array of purification methods known to the art and thepreceding method of purification is not meant to be limiting. Suchpurification techniques are described, for example, in Bailey, J. E. &Ollis, D. F. Biochemical Engineering Fundamentals, McGraw-Hill: New York(1986). Additionally, the identity and purity of the isolated compoundsmay be assessed by techniques standard in the art. These includehigh-performance liquid chromatography (HPLC), spectroscopic methods,staining methods, thin layer chromatography, NIRS, enzymatic assay, ormicrobiologically. Such analysis methods are reviewed in: Patek et al.,1994 Appl. Environ. Microbiol. 60:133-140; Malakhova et al., 1996Biotekhnologiya 11:27-32; and Schmidt et al., 1998 Bioprocess Engineer.19:67-70. Ulmann's Encyclopedia of Industrial Chemistry, (1996) vol.A27, VCH: Weinheim, p. 89-90, p. 521-540, p. 540-547, p. 559-566,575-581 and p. 581-587; Michal, G. (1999) Biochemical Pathways: An Atlasof Biochemistry and Molecular Biology, John Wiley and Sons; Fallon, A.et al. (1987) Applications of HPLC in Biochemistry in: LaboratoryTechniques in Biochemistry and Molecular Biology, vol. 17. APPENDIXNucleotide sequence of the partial PK-6 from Physcomitrella patens (SEQID NO:1) GCACGAGCTCAATCCTCATGTTTCGGACTGTGGACTAGCTGCCCTTGCACCATCTGGTTCTGAACGCCAGGTGTCGGCACAAATGTTGGGCTCTTTCGGTTACAGTGCCCCTGAGTACGCCATGTCTGGAACCTATACCGTGAAGAGTGACGTCTACAGCTTCGGTGTTGTAATGCTGGAGCTACTCACTGGGCGCAAGCCTTTAGACAGCTCAAGACCACGATCCGAGCAATCTTTGGTACGATGGGCCACACCTCAATTGCACGACATCGACGCCCTTGCACGAATGGTGGATCCGTCGTTGAAGGGCATCTACCCTGCTAAATCACTCTCTCGGTTTGCTGATATAGTCGCCCTTTGCGTCCAGCCGGAGCCCGAGTTCCGACCCCCGATGTCTGAAGTGGTGCAGGCACTTGTAAGGCTGATGCAGCGTGCGAGTCTGAGCAAACGCAGATCGGAGTCCGCTGTTGGGAATTGAGTCGAACGAGCCATCTGAGACTTCACCTTTGAGAGTACTGAAGCGCCCACTAGCCTAATCGTGCATCTTTGGCCATCTCGTTTCTGAGTGGAACACAAAGCTGGGTATATTCTTTGGTGGTTAAGCAACCATTTGTCCCAATTTGAACTTCCGCTGGNGAAGGTCTGTATGTTGAGAAACGATGCAAAGCGTTCGCGTGGTNTGCTTGAACTTCAAA Nucleotide sequence of thepartial PK-7 from Physcomitrella patens (SEQ ID NO:2)GCACGAGCTCAATCCTCATGTTTCGGACTGTGGACTAGCTGCCCTTGCACCATCTGGTTCTGAACGCCAGGTGTCGGCACAAATGTTGGGCTCTTTCGGTTACAGTGCCCCTGAGTACGCCATGTCTGGAACCTATACCGTGAAGAGTGACGTCTACAGCTTCGGTGTTGTAATGCTGGAGCTACTCACTGGGCGCAAGCCTTTAGACAGCTCAAGACCACGATCCGAGCAATCTTTGGTACGATGGGCCACACCTCAATTGCACGACATCGACGCCCTTGCACGAATGGTGGATCCGTCGTTGAAGGGCATCTACCCTGCTAAATCACTCTCTCGGTTTGCTGATATAGTCGCCCTTTGCGTCCAGCCGGAGCCCGAGTTCCGACCCCCGATGTCTGAAGTGGTGCAGGCACTTGTAAGGCTGATGCAGCGTGCGAGTCTGAGCAAACGCAGATCGGAGTCCGCTGTTGGGAATTGAGTCGAACGAGCCATCTGAGACTTCACCTTTGAGAGTACTGAAGCGCCCACTAGCCTAATCGTGCATCTTTGGCCATCTCGTTTCTGAGTGGAACACAAAGCTGGGTATATTCTTTGGTGGTTAAGCAACCATTTGTCCCAATTTGAACTTCCGCTGGNGAAGGTCTGTATGTTGAGAAACGATGCAAAGCGTTCGCGTGGTNTGCTTGAACTTCAAA Nucleotide sequence of thepartial PK-8 from Physcomitrella patens (SEQ ID NO:3)GCACCAGACTATGACAAGCGCACGCCCTTGCACATCGCCGCGTCCCTGGATTGTGTCCCTGTTGCTAAAGTCCTGCTTGCGGAAGGAGCAGAGTTGAATGCAAAAGACAGGTGGGGGAAATCTCCGAGAGGCGAGGCGGAGAGTGCAGGATACATGGAGATGGTAAAGCTGTTGAAGGATTACGGGGCTGAGTCACACGCAGGTGCCCCGAGGGGCCACGTTGAGAGTCTGATTCAGGTTGCCCCTCCGTTGCCTTCTAACCGCGACTGGGAGATCGCTCCGTCGGAGATTGAACTTGATACCAGCGAGCTCATCGGCAAAGGCTCCTTTGGAGAGATTCGGAAGGCGCTTTGGCGCGGCACACCCGTCGCTGTGAAGACAATCAGACCTTCTCTGTCCAACGACAGAATGGTCATCAAGGACTTCCAGCACGAGGTGCAATTGCTCGTAAAGGTTCGGCACCCAAACATTGTGCAGTTCCTCGGGGCTGTTACCCGTCAAAGACCTCTCATGTTAGTCACCGAGTTTCTGGCAGGGGGGCGATTTGCATCAGTTGCTGAGGAGCACCCTAAATTTGGCTCCTGACCGCATCGTGAAGTATGCCCTCNACATAGCTCGCGGCATGTCTTACTTCACCATCGGAGCAGCCC A Nucleotide sequenceof the partial PK-9 from Physcomitrella patens (SEQ ID NO:4)TCCAGCCCATTTGGTTGGCCACACACAGCTGTTCATGAGTCACCCGCTTCAGGNTGAACTGAAGAAACGTAACTCCGTACGGCTATTTTACCAAATTTTCAAGCTCGTTGTCCCGCCATGATCCAAATGGAAGCTCAGTTTGCAACATGAAGTACATTGAACACACCTACCGCCCACCAGTCAGAAGCCAGGCCATGACCTTGTCCTTGAATGATCTCGGGTGCTAAGAAATCAGCCATGCCACAGACTGTGAAAGTGCGCTCATCCGACATTTGCTTTGCAAACCGAAAATCAACCAGCTGAAGTCGTCCTTTCCGATCTATCATAAGAACATCGGGAGAGATGCCACGATATACAACGCCATCCTTGTGCAGAAGTTCGACGGCTAATACCACGTTGGCGACCAGAAAACGAGCTGAGTTCTCGTCTAAAGGTGACCGAAGTAGAAGTTCTAGAGGCCCAGCTAACACACAATTAAGAACGAGTGCCACATTGTCACTGTCAATAGGGGTGGCCAAGAGATGCGGCACGAATGGGGAAGGCCTCAGTTGCTTGAAAAGAGTTCTCTCCAATAGGACTTGGCCCTCCCGACCGAGTCTCTGAACTTTACGTCTCTGGTACCTTTTCATGCTTATGACGTCATCTGATTTCTTGCAGAGCACCACACCGACATCACAGCAATCGGTTGAATAGACCTGGT GCCGATTCCT Nucleotidesequence of the partial CK-1 from Physcomitrella patens (SEQ ID NO:5)TATGCCCATCTTCTCATACTCAGACCAGATCCTCTATTTCAATTACAGAAGAAAGTTGCTTGTGCAACGTATTGAAATCATCACCGTCATGGGCTTTCCGAGTAAAAATTCTTGTAATGGATAAAGTCATTTCTAGTCTGATCCATACAAGCTACCGACACAATGCTAGAAGCCTTGATTTACACACTACACACTAGAGAGTCTACAACTCTTTTCCTACACTCTGCTTAGTTGCCTCATCCTCAACTCCATAAACCCCCATTCACAATCATGTAAGACTTGAGAGAGGGAAACAGTAAGCAACCTTGTGCTATTTTAGTACCAGAGCAGAGGATGAACCACTAGTCCTCCCAACGTAAGCCCTAATTCGCCGCAACAACCTCACGACGGAACTCCGACTTGGTCAAGGGTGGACAATATGATACATTCGAAGGTCGATTTTGCAAATGGGACGAAGCAGCGGAATTCTGGCTGCGCACTGATTGCAGAGAGCCATTCTGGGGGAGTTGAGTATACACAGTCCAGTCGTACACATGGTCGAGCTGGAATTTTTTCTGAATGAAAAGATCACGGAACAAGCTTCGGAGGTACAGTAGTCAGGCTGCTCGTAAAAACCTANACTTCGCGGCGTGGTGCAAAAAGTCGGCAAATTGACTGGGATACCCATCACAAAGCTCCTCCCACAGTGGGGGTCATCTTGATTTTGTTGTGCATGTACTCGTGTTGCTTCTGGTCAGTGAGGGCGTTGCCCGCCCTTCCCTTGCCATGGCAAATTGCCTCTTAGAAAGTACATAAGAATGTAACCCAAGTGATTCTATGTCATCTCTTCTACTGTGCTCGATTCCTCTGTGCTGATTCCTACTAGCGTACCGTGCCGTCCCTGTGAAGCTCTTCCTATCTCGGTAAGGGATATGCCTTCGTGTTGCCGGGTCCATGTACTCCTTTGCCAAGCCAAAATCTATAATGAACACTTGGTTTCCTTGCCGACCGCAGCCCATGAGGAAGTTATCCGGCTTCAGGTCACGGTGAACGAGCCCTCGAGAATGCACGTATTCCACCCGGTCAATCATTTGGTAACCGAGCATAATCACGGTCTTCAACGAAAACCTTAGCCCACACACCTTAAAGAGGTGCAACAGGTTCGGCCCCAATAGGTCTAGCACCATCACATTGTAGTCTTCTGCTGCTTTTCCGAACCATCTCATGTTGGGCACTCCCTTCCCACCCCGCAATATGTTGTACAAGCGCGA CTCGTGCATTAACTCTCGTGCNucleotide sequence of the partial CK-2 from Physcomitrella patens (SEQID NO:6) TTTTTTTTTTCCAATAGATTTGCATTACATAACTCCAAGTTATGATATGTACAGGTTAGCAACAAGCTAATGGCTGCAAGCAGTGAACATACTACCAAGGGAGAGATTCTCACTCCCTAGACTTCATCCTCGTACGTTACTTGGCAAGGATTATGGTTTAGTGATAAAAAGCTTCACAAGCCGGCAAGCATGCTGGTTGCTTCTGCTGCAATCTAATGATTATTTCCTTAGGAATCGTATGGCAGAGAGCTACCACACAAAGCACTGACAATGGTTTGATGGTAACAAGATAGAGATCCATTCATTCCTAAGTATGAGAGACCTGTAGTCTTAGCACCATTGTAGGACAGAACCACCGTTTTCCCCTCAATCAGGCTGTTGCCAAATGTAGAGCAACTCTCATCAACATAACAAGAGGGTTTGATAGAAGACAGAGCCCGGCTATATAACCACAAGCCCTGCGCCTACCTTATAACGGCTTGGATCCACCTCAACAGAAAGTGATTCAACTCCCTTGATACCGGCTTTCGTAAATCCTCAAGTTGGCAGATGGCGGTTGTGGATGGCGGCTAGATATCCGCTTTGGGTCCGAAGTAACTGGAGAGCTCCTCTGCATCCCTGCTGACGACCGTAAGCTGGTGGGACCAAGCTTACTGCTCCCTGTTCGAGAGGAATCTACGACTTCTGCTGATGCCCCTGAGGGCCTGCTGCTAGATAGGACAGCTCGCCTGGAGGAAGAACCCCCCCGAGTTGCATACGAAGATGTATGCATGCGCTCTGGTTCTGACACAACAGCAAGAGCAGAATCCTTAGCAGATTCATCAAGTCCAGGACTTTTGTGCTTAGATGAGTCCAAAGCATTTGCGACCCCGGAGCCATTTGCTCCTCCAGGAAGCCTGCGCCGAGAAGGATCCATTGGTTCGGTGGGCCGCTGCAGGTCTCGGCTTCCTGTAGCCCCAGTTCCAAGTGCACCACTGGTTTGCCCTGCAGAAGCACCCAGTCGAGTTGAACTGCCACCGGAAATTTGTGACTGCTGGTACTTCAGAATTGTCCAGTCAAAAACGTAGTCAAATTGAAAACCTGTAAAACTATTTCCAGTTTAGGCAAACAGAAGTGGCACTGTAATAAACTGAAAATCATCAAACATTCACAAACTATCTGTTCGTTGATAGAGCATAGTAAAGTCTGCGCTTAGGATCAAGTCTTGATACATTACAATGCCCAAGCAAGAGTGAAACCTACAAAAGTTACAGTTTTCATACCCTCACGAATAAAGAGGTCACGGAAGATTCTTTTCAAATATGCATAGTCGGGTTTGTCATCAAAACGCAAGGACCGGCAGTAGTGGAAGTACGCTCGTGCGAATTCTGAAGGATAATTTTTACAAAGGACCTCAATGGGCGTGGACATTTGTTTTCTCACTGATCTTCTCGTACTTCTGCTTCTTGGTTCCCGCTTTCAGTCCTTGCCCATGGAAGACTGCCTCTCAGGAAGTACATGAGCACATATCCAAGAGATTCCAAATCATCTCGTCTGCTTTGCTCAATACCAAGATGAGTGTTGATGCTTGCATACCGAGCAGTCCCTGTCAGATTTTTGTTCTCCCTGTAGGGAATATGCTGATGCGTGGAAGGGTCGCGGTACTTCTTGGCAAGACCAAAATCAATAATGTAGACCTGGTTTGCTCGCCTACCAAGCCCCATTAGAAAATTATCAGGCTTGATGTCTCTATGAAGAAAGCTTTTCGCATGCACATACTCCACTCTGTTGATCAGCTGGTCAGCAAGCATGAGAACAGTCTTTAAAGAGAACTTCCGGCTGCAGAAGTTGAAAAGGTCTTCGAGACTTGGCCCCAACAGATCCAGAACCAAGACATTGTAGTCTCCTTCTATCCCGAACC ATCCTCGTGC Nucleotidesequence of the partial CK-3 from Physcomitrella patens (SEQ ID NO:7)CGGTGGGGCGCTCCCCAATATTTTATCCCCGGGGCTGCAGGGAATCCGGCGACCAGTNTTTGAAGGTGTCAACGCCGTGAATAGTGAGCGTTGCGTTATGAAGATTTTGAAGCCAGTAAAGAAAAAAAAGATCAAAAGAGAGATCAAGATTCTGCAAAACCTTTGTGGAGGGCCCAACATTGTGAAGCTTCTGGACATTGTCCGTGATCAGCAATCGAAGACACCCAGCCTAATTTTTGAGTATGTGAACAATACTGATTTCAAAGTGCTCTACCCCACTCTTACAGACTTTGATATCCGATACTACATTCATGAGCTGCTCAAGGCTTTGGACTATTGCCATTCTCAAGGGATTATGCACAGGGATGTGAAGCCACACAACGTGATGATTGACCATGAGCAGCGGAAGCTTAGGCTTATTGACTGGGGACTTGCCGAATTCTATCATCCTGGCAAAGAGTATAATGTGCGTGTTGCCTCTAGGTACTTCAAGGGTCCTGAGCTGCTGGTTGATCTTCAAGATTATGATTACTCTCTCGACATGTGGAGCTCTGGGGTGCATGTTTGCCGGCATGATATTTCGGAAGGAGCCATTCTTTTATGGGCATGACANTTCATGATCAACTTGGTGAAGATCGCTAAGGTGTTGGGAACTTGATGAATTGAATTCCTATCTAACAAATACCGCTAAGTGGACCCC ATTGGAGCACCTGGTGGGGGNucleotide sequence of the partial MPK-2 from Physcomitrella patens (SEQID NO:8) GCACGAGGAACTAACGAATTGTCATTCTATAATCCAATAGTGTAATCACACGGGGGGGAATAAGTTGCAAAACCATACAACGCCGGGATAGCGTTGTAGCCACCTAAAGAATTGAGAGTAGGCCTTACAACTTGAGATGAAGTGTGAAGTGGTACTGCACCATATCATCAGGACCTAAGCTGCAATCCAGAGCCTCCCTCCAAATGAGATCCCTGATAGGCTCCTCCGAGATAGAGGGCTCCTCGAAGCCAAACTCGAAGGGAGATACCGAGCCAGGCTCATCGTTGATGTCATGAAGTGAAGCTTAAATAAGGGTGCGCCAAGGCAGCTTCCACTGTGATTCTTTTCGCTGGATCAAAGACCAGCATCTTTTCAACAAGATCAAGAGCAGAACGATTAATGCCTCTGAACTTCTGGGTTAAGGGAATAGGCGACTGTCGAGGCAGGTGCTTGATATACCGCCTAGCATTGTCGCTTCTCAAAAACCCAAGATCCCTATCTTCAGGAGTTCCGATGAGTTCTGTAATTAGGCGGAGCTGATGCACATAGTCTCTCCCAGGGAACAACGCAGATCGGTTAAGCAACTCCATGAAGATGCACCCCACAGACCAAATGTCAATAGCTGCAGTGTATGCTGAACAATTCAGGAGCAGCTCTGGAGCTCTGTACCACCTCGTTACAACATACTCAGTCATGAAATCCGTTTCAGAGAGAGTGCGTGCCAAGCCAAAATCTGCGATTTTCAAATCGCAATTGGCATTGACGAGAAGGTTGGTGGGCTTCAAGTCCCGGTGCAAGACGTTCGCCGAATGGATGTACTTCAAGCCCCGCAAGATTTGATACAGAAAATACTGACAGTGGTCTTCTGTGAGAGCTTGATTTGAACGAATGATCTGGTGTAGGTCCGTATCCATCAACTCGTATACAATGTACACGTCGTTGAAATCTCG TGC Nucleotidesequence of the partial MPK-3 from Physcomitrella patens (SEQ ID NO:9)CGGCACCAGCCTCGCTGGAGACCGACCATCGAAGCACCTTAAGCTCGTTTTCATTCGGCATTGCTTGCGAGCACTTCGACTTCCTAGAATTTCAATAGACCTAATGGAATCGCCACTCCCTAATCTTTCCGGAGAGGCCTTATCGCCGACGGCAACTGCCGAAGACGAGATTACTCAGATGATACTAAAAAGTGCCGCAAGGTCCGAATTAGGAATGTATGTTTCGAAGAGACAGGAATTCTATCTTCGAAGAGCGCGGAGGCGGCGTAAGTTTGCGTGGAAGCCGGTTTTGCAGAGCATCTCCGAGATGAAGCCTGTCATGGAATTCCACACTCCGATGGCTTACCGGGATAGTGGGTCTCCGCCGAAGAACGCCTCTACCCCATCCTTACCTGGCCCGAAGAACATTTCACCGCCACGACAAGTGAGTGTCCCGCAAAGGAGCAGTCCTCCGCCGAAGAACGTCTCACCACCTCCCCAGCCCGGCATTTTGTAGCGCGGACTGCGATCGAAGTATTCTGCTGCATCTCAGCAAGTTCAACGAAATCGAGGGCAACGCGAAATCTCTTTTATATGGCGTAGTTTGTGTCTCCGACTGGACTCCTATCTATCCCCATCGAGATAACTGATTCGGTGGATAATTTCTCCAAATTTTGGCTAACNCAAGAANCTCAAGGGCGAAT Nucleotide sequence of the partialMPK-4 from Physcomitrella patens (SEQ ID NO:10)GCACGAGGTTGGTGTAAGTTATTGATAGTGCTGTGCAATTCACAGTTTTGCTACTCCGGTAGGTCCGACCTCTTCAATTGTCAGTTTAAAAACTCTAAAAACATTTGAGAAAAGTGTTGAAAAATCTCCGTGAGGAAATTCCTTGTCGCAAGACGTGAAAAAAAGAAGAAAGAAGATGGAAATATTGTTTTGGGTATCGAAGAAGTGTTCGATGCTGTGCAATAAGGAAAGAAAAAGTGCAGGTAACATAAAAAGCTAGCATGGTGATGATAATATAAGACCCCGATTAACACACTTATGGATTGTTTCATGAGCTGCACGTTCTCAGCGACAAATGGGGCTCATTGAGAAAACTCCACTTTCTATAAGGTTGGGAAACGAGCGTTTTTTTTTTGAAGATGTTTTTTCCGTCAATCTGATTTGATATCGTTCTCAACTTGACCACATATGACTATATAAGGAAAAGGCATTGAGAAAGTGGCGGATTGGCGAGGTAGTTCGACCATGCTTTTGGTAAAGTCCCTTGAAGTTCAGTGGTGGATCAGGCTTGTGGTAGTGACAGTCTCTGCACGCCATGCGAGGCTAACTTTAAGTTACAAAATCTTGCTCAAATGGTACTCTTCCTCGTTGTACTTTTGCAGGAACGGATGTTTAAGTAAATCAGTAGTTGATGGTCGTTCACTGGGACATTTCCGGATGCAGGATTCAATAAAAGAACAAAATTCGGGGGAGAATTTGTCAGGGGATGCGGCTGCGGGGGGTTGATTAACTATACATTCCATGAGGATGAAGAAATTTTGCCAACCCTCTTCCATTCCAGCTGGTTTGTATGGGAAGGTACCCAACGCACACTCCAAAAGAGTCAATCCTAAACTCCATAGGTCACTGTCGTATGCATACGAACGCCCCTGAAGGCGTTCTGNCGACATATATGTGCAAGTCCCAACGAACGTGTCTCGCTGGGCCAAGGAATGAACCAACACAGCACTGACACCAAAATCAGATATTTTGACCTCACCCTTGTGATTGATGAGGAGGTTGGAGGGCTTTATATCACGATGTATGATGTGCCTGACTTGGTGTAGGTATTCCAATCCCTTCAGAACTTGACTAGCAATGACGGCCAAATACGGCTCAGGTATNTGCTTTC TGGTGC Nucleotidesequence of the partial MPK-5 from Physcomitrella patens (SEQ ID NO:11)TCCCCGGGCTGAGGAATTCGGCACGAGCGGTTGATCCTCACCCTTGGGAAGGACCCTGGAATTGAGTAGCGTGCGGAAGCTGCATCGATCCGGAAGAGACGATGAGTAGGAGAGTGAGAAGGGGAGGTCTTCGCGTCGCGGTGCCGAAGCAAGAGACTCCCGTCAGCAAATTTTTGACTGCCAGTGGAACTTTCCAGGATGATGATATCAAGCTCAACCACACCGGGCTTCGCGTCGTCTCTTCAGAACCTAACCTTCCTACGCAGACGCAGTCTAGCTCCCCAGATGGGCAACTGTCAATAGCAGACCTGGAGTTAGTGCGGTTCTTAGGAAAGGGTGCGGGTGGAACCGGTGCAGCTTGGTCCGGCACAAATGGACCAATGTCAATTATGCACTGAAGGCGATACAAATGAATATCAACGAAACAGTGAGGAAGCAGATTGTTCAGGAGCTGAAAATCAACCAAGTGACGCACCAGCAGTGCCCTTATATCGTGGAATGCTTCCACTCCTTCTACCACAACGGCGTCATATCCATGATCCTAGAGTACATGGACAGGGGCTCGTTGTCCGACATTATTAAGCAACAAAAGCAGATACCTGAGCCGTATTTGGCCGTCATTGCTAGTC Nucleotide sequence of the partial CPK-1from Physcomitrella patens (SEQ ID NO:12)GCACCAGCCGAGTCGGGCATTTTTCGTGCGGTGTTGAGGGCTGACCCGAGCTTTGAAGAAGCCCCTTGGCCTTCCATCTCTCCCGAAGCCAAGGATTTCGTGAAGCGTCTCCTGAATAAGGATATGCGGAAACGCATGACTGCTGCACAAGCTTTAACTCATCCATGGATTCGAAGTAACAACGTGAAGATACCTCTGGATATCTTAGTGTACAGACTTGTGAGGAATTATCTTCGTGCATCATCCATGAGAAAGGCTGCTTTGAAGGCCCTGTCAAAGACTTTAACCGAAGACGAGACTTTTTATCTACGTACTCAATTTATGCTGCTAGAACCAAGTAACAACGGTCGTGTTACTTTTGAGAATTTCAGACAGGCACTGCTGAAAAATTCAACAGAGGCCATGAAAGAGTCACGGGTTTTTGAAATTCTGGAATCGATGGATGGTCTTCATTTCGCACCAGCCGAGTCGGGCATTTTTCGTGCGGTGTTGAGGGCTGACCCGAGCTTTGAAGAAGCCCCTTGGCCTTCCATCTCTCCCGAAGCCAAGGATTTCGTGAAGCGTCTCCTGAATAAGGATATGCGGAAACGCATGACTGCTGCACAAGCTTTAACTCATCCATGGATTCGAAGTAACAACGTGAAGATACCTCTGGATATCTTAGTGTACAGACTTGTGAGGAATTATCTTCGTGCATCATCCATGAGAAAGGCTGCTTTGAAGGCCCTGTCAAAGACTTTAACCGAAGACGAGACTTTTTATCTACGTACTCAATTTATGCTGCTAGAACCAAGTAACAACGGTCGTGTTACTTTTGAGAATTTCAGACAGGCACTGCTGAAAAATTCAACAGAGGCCATGAAAGAGTCACGGGTTTTTGAAATTCTGGAATCGATGGATGGTCTTCATTTCAAGAAAATGGACTTTTCAGAGTTCTGTGCAGCGGCCAT TAGTGTTCTCCAGTTAGAAGNucleotide sequence of the partial CPK-2 from Physcomitrella patens (SEQID NO:13) GCACGAGCTCCTGCATCTCCCCCTCCTTCTCCTCCTCATCATTCTGGAGCCCAGCGAACTGCGATCTGAGATTCCAACTTGGAAGGGCCTCGCGTAAGCACCGGAGCTCGTTTCTTACGCTTTTGCGCCTCGCGATATTTGTACATTGTTTCCTCTGGTTTTATTCGATTCCGCCTCTGAAAATGTGAACGGGCTGCAAGCTTGGTTTTGGAGCAACGTTGGAGCATTGAAGGGTTGCGCTCGTCCCTGCCCATTCCTCGCTTCTGCTCTGGCCTATGTCATGACGACGTGAAGGAGAGGATTTGAGGGTTTTGCAAGTGATATAATCCTCCCCGAGGAGATTTCTGTGAGTTGATTAACTTGGATCAGCGACATGGGGAACACTAGTTCGAGGGGATCGAGGAAGTCCACTCGGCAGGTGAATCAGGGAGTCGGGTCTCAAGACACCCGAGAGAAGAATGATAGCGTCAATCCAAAGACGAGACAGGGTGGTAGCGTTGGCGCAAACAACTATGGCGGAAAGCACAAGCAGTGGTGCTCAGGCCGGAGAACGATCCACCTCTGCGCCCGCTGCTCTGCCGAGGCCGAAGCCAGCATCGAGGTCAGTATCCGGTGTTTTGGGTAAGCCGCTGTCAGATATTCGTCAATCTTACATCCTGGGACGGGAGCTTGGCCGAGGGCAGTTCGGAGTGACTTACTTGTGTACTGACAAGATGACGAATGAGGCGTACGCGTGCAAGAGCATCGCCAAACGGAAACTGACCAGTAAGGAGGATATCGAGGATGTTAAGCGGGAGGTTCAGATTATGCATCACCTGTCGGGGACACCCAATATCGTGGTGTTAAAGGATGTGTTCGAGGACAAGCATTCCGTGCATCTTGTGATGGAGCTCTGTGCAGGTGGCGAGCTCTTCGATCGCATCATTGCCAAGGGGCATTACAGTGAGCGCGCCGCTGCCGATATGTGCAGAGTCATCGTCAATGTGGTGCACAGATGCCACTCATTAGGGGTCTTCCATCGGGATCTCAAGCCAGAGAATTTTCTGTTGGCCAGCAAGGCTGAGGATGCGCCTCTGAAGGCCACAGACTTCGGTCTGTCAACTTTCTTTAAGCCAGGAGATGTGTTCCAGGATATTGTTGGAAGTGCGTATTACGTGGCCCCTGAAGTTTTGAAGAGAAGTTATGGTCCTGAGCTGATGTTTGGAGTGCAGGCGTGATTGTGTACATTCTGCTGTGTGGTGTACCCCCCTTCTGGGCTGAAACTGAGCAGGGTATCTTTGACGCTGTGCTCAAAGGGCACATAGACTTCGAGAACGAGTCCATGGCCGAAAATCTCCAACGGGGCTAAGGATTTGGTGAGGAAAATGCTAAACCCTAACGTGAANAT Nucleotide sequence of thefull-length PK-6 from Physcomitrella patens (SEQ ID NO:14)ATCCCGGGTGAGTATCACTTACGGTGGCGAGGGATGGCCTTTGGGGTAGGAGCTGGTATATGCGGAGTCCAACAGAAGCTTGTGCAGGACTCTTGAGTTGTGCGTGCGAGGGCTGAGTGCCGGAAAGGTATTTTCCGACGAAGAGTCAATGTGGGCGTGGACAAACGTTTGAAGAGATGGGTGTGGATATGAAGGCTCCGGCTAAGCAGTCGCTGGGAGTCGGACTGCTCCTGTGCTCTGTAGTGATCCTCTCGGTGGTGAGCTCTGTGTATGGCCAAGTTCAGACAGATCCAGTGGATACTACAGGCTTAATTTCCATGTGGTATGACTTAAAACAGAGTCAATCTCTCACGGGGTGGACTCAAAATGCTTCTAACCCTTGTGGGCAGCAGTGGTACGGCGTTGTATGTGATGGCTCTTCTGTCACGGAAATCAAAATTGGAAGTCGGGGTTTGAATGGAAATTTTAATCCTTCGTACTTTCAAAACGCTTTTAAAAAGCTTCGAATTTTTGATGCTAGTAACAACAACATCGAAGGAAATATTCCTCAACAGTTTCCTACGTCTCTTACTCAAATGATATTGAACAACAATAAATTGACCGGAGGTCTCCCACAGTTTGATCAATTGGGCGCCTTGACAGTCGTAAACTTGAGCAACAACAATCTGACCGGCAACATGAACCCCAACTATTTCAATGTGATCGTGAATGTGGAAACCTTCGATGTTTCCTATAACCAACTTGAAGGCACTCTTCCCGACTCCATTCTAAACCTGGCCAAGCTTCGTTTCTTGAATTTGCAGAACAATAAATTTAATGGTAAACTTCCCGACGATTTCTCTCGGCTGAAGAATTTGCAGACTTTCAACATTGAGAACGATCAGTTCACGGGTAATTATCCATCAGGTTTACCCAGTAATAGCAGGGTTGGAGGAAATCGTCTTACATTTCCCCCACCTCCAGCCCCCGGCACACCTGCTCCCAGGACTCCTTCTCCTTCAGGAACATCGAATGGATCATCGTCGCATCTCCCTCTAGGGGCGATCATTGGAATAGCCGCTGGTGGTGCTGTGCTGCTTTTATTACTAGCACTCGGCATCTGTTTGTGTTGTCGTAAGCGGTCCAAGAAAGCATTGGGCGATCCAGAGGCCACGACCAGCAGCCGAAGACCGTGGTTCACACCTCCCCTCTCCGCAAAGAGCCAGAGTGATCCCAGCAAGAGCATAGACAAAACGACGAAACGCAACATCTTTGGCAGCAGTAAGAGTGAGAAGAAAAGTTCAAAGCACAGAGTATTTGAGCCAGCTCCTCTTGACAAAGGAGCAGCCGACGAACCAGTGGTGAAGGCGTCTCCGCCCGTCAAGGTACTGAAGGCTCCTCCTTCATTTAAGGGTATCAGCGGCCTGGGTGCTGGACATTCGAAAGCAACAATTGGCAAGGTGAACAAGAGCAATATTGCAGCCACCCCATTCTCTGTAGCGGATCTTCAGGCAGCCACAAACAGCTTCTCCCAGGATAATCTGATTGGAGAAGGGAGCATGGGTCGCGTGTATCGTGCCGAGTTTCCCAACGGCCAGGTCTTGGCCGTGAAGAAGATCGACAGCAGCGCGTCGATGGTGCAGAATGAGGATGACTTCTTGAGTGTAGTAGACAGTTTGGCTCGCCTGCAGCATGCTAATACGGCTGAGCTTGTGGGTTACTGTATTGAACATGACCAACGGCTGTTGGTGTACGAGTACGTGAGTCGTGGAACCCTGAACGAATTGCTCCATTTCTCGGGTGAAAACACCAAGGCCCTGTCCTGGAATGTCCGCATTAAGATTGCTTTGGGATCCGCGCGTGCTCTGGAGTACTTGCACGAAGTCTGTGCACCTCCCGTGGTTCACCACAACTTCAAATCTGCCAATATTCTGCTAGACGATGAGCTCAATCCTCATGTTTCGGACTGTGGACTAGCTGCCCTTGCACCATCTGGTTCTGAACGCCAGGTGTCGGCACAAATGTTGGGCTCTTTCGGTTACAGTGCCCCTGAGTACGCCATGTCTGGAACCTATACCGTGAAGAGTGACGTCTACAGCTTCGGTGTTGTAATGCTGGAGCTACTCACTGGGCGCAAGTCTTTAGACAGCTCAAGACCACGATCCGAGCAATCTTTGGTACGATGGGCCACACCTCAATTGCACGACATCGACGCCCTTGCACGAATGGTGGATCCGTCGTTGAAGGGCATCTACCCTGCTAAATCACTCTCTCGGTTTGCTGATATAGTCGCCCTTTGCGTCCAGCCGGAGCCCGAGTTCCGACCCCCGATGTCTGAAGTGGTGCAGGCACTTGTAAGGCTGATGCAGCGTGCGAGTCTGAGCAAACGCAGATCGGAGTCCGCTGTTGGAATTGAGTCGAACGAGCCATCTGAGACTTCACTTTGAGAGTACTGAAGCGCCCACTAGCCTAATCGTGCATCTTTGGCCATCTCGTTTCTGAGTGGAACACAAGCTGGGTATATTCTTTGGTGGTTAAGCAACATTTTGTCACAATTTGAACTTCAGCTGGAGAAGGGTCTGTAGTGTTGAAGAAAACGAATGCAAAGCGTTTCGGCGTGGATGTGCTTTGAGAACTTACAAAACTCATCAAGACTTTGAAGATCTTTGTATTGCATCGAATCCTTTCAATCAGTCTCGGGTAGGATCAGTTCCTCTGTATCGGATACCCTTTTCATCCTAACATGGGACCCTTTTAATCCAGAGGATGGAGTGCTTGGAATAGTGACCTTGGTCGAGTTAACGC Nucleotide sequence of thefull-length PK-7 from Physcomitrella patens (SEQ ID NO:15)ATCCCGGGAGTGGGTGGTTGGACTGTAAGGAGCTAGCGTTTTAGAGCTACAGTGCGGTTTGCTGTGTGAGTGAGTGAGTGAGTGAGTGCGTGAGTGAGGATGTCTGTTTCTGGTATGGACAACTATGAGAAGCTGGAGAAGGTAGGAGAGGGGACTTACGGAAAGGTGTATAAGGCCCGTGATAAACGCTCCGGGCAGCTGGTGGCGCTCAAGAAGACTAGGTTGGAGATGGAGGAAGAAGGCGTCCCTTCCACCGCTTTGCGCGAAGTTTCGTTGCTACAAATGCTCTCCCACAGCATGTATATCGTCAGGCTACTTTGCGTGGAGCACGTCGAGAAAGGCAGCAAGCCCATGCTCTACTTGGTCTTTGAATATATGGACACTGATCTTAAGAAGTATATTGACTTGCACGGTCGTGGTCCGAGCGGGAAGCCTCTGCCTCCCAAAGTGGTCCAGAGTTTCATGTATCAATTGTGCACAGGGCTTGCCCACTGTCATGGCCACGGAGTAATGCACAGGGATCTGAAACCCCAGAATTTGCTCGTCGACAAGCAAACCCGTCGTCTTAAGATTGCCGACCTTGGTCTCGGTCGGGCATTCACAGTGCCAATGAAGAGTTACACACACGAGATTGTTACTCTATGGTACCGAGCTCCTGAAGTTCTTCTTGGAGCGACCCACTACTCTCTACCTGTGGATATCTGGTCTGTTGGGTGCATCTTCGCTGAACTCGTCCGGAAAATGCCGCTCTTCACTGGAGACTCCGAACTTCAGCAGCTTCTTCACATCTTCAGGTTGCTTGGCACCCCGAATGAGACAATCTGGCCTGGTGTTAGCCAGCACCGTGATTGGCACGAGTTTCCTCAATGGAGACCACAAGATCTGTCCCTTGCTGTTCCCGGACTCAGCGCGGTTGGCTTAGACCTTCTCGCCAAAATGTTGGTATTCGAGCCCTCAAAGAGAATCTCTGCCAAAGCCGCCTTGAGCCATACTTATTTCGCTGATGTTGATAAGACAGCAACCTAAACACAACAGAACAATTCAAGAGAACCAGGTAACCTCTACCTGTCCAAGACGAAGGTTAACGC Nucleotide sequence of thefull-length PK-8 from Physcomitrella patens (SEQ ID NO:16)ATCCCGGGCAACGAGAAGCATTCGAGATGGCAGATGCGAAGGAGGAACTGGCGCTGCGCACGGAAATGCACTGGGCTGTGAGGAGTAACGACGTGGGGCTGTTAAGGACCATTCTGAAGAAAGACAAGCAGCTCGTGAATGCTGCGGACTATGACAAGCGCACGCCCTTGCACATCGCCGCGTCCCTGGATTGTGTCCCTGTTGCTAAAGTCCTGCTTGCGGAAGGAGCAGAGTTGAATGCAAAAGACAGGTGGGGGAAATCTCCGAGAGGCGAGGCGGAGAGTGCAGGATACATGGAGATGGTAAAGCTGTTGAAGGATTACGGGGCTGAGTCACACGCAGGTGCCCCGAGGGGCCACGTTGAGAGTCTGATTCAGGTTGCCCCTCCGTTGCCTTCTAACCGCGACTGGGAGATCGCTCCGTCGGAGATTGAACTTGATACCAGCGAGCTCATCGGCAAAGGCGCCTTTGGAGAGATTCGGAAGGCGCTTTGGCGCGGCACACCCGTCGCTGTGAAGACAATCAGACCTTCTCTGTCCAACGACAGAATGGTCATCAAGGACTTCCAGCACGAGGTGCAATTGCTCGTAAAGGTTCGGCACCCAAACATTGTGCAGTTCCTCGGGGCTGTTACCCGTCAAAGACCTCTCATGTTAGTCACCGAGTTTCTGGCAGGGGGCGATTTGCATCAGTTGCTGAGGAGCAACCCTAATTTGGCTCCTGACCGCATCGTGAAGTATGCCCTCGACATAGCTCGCGGCATGTCTTACCTTCACAATCGGAGCAAGCCCATCATCCACCGCGATCTCAAACCCCGAAACATCATAGTGGACGAAGAGCATGAGCTGAAGGTCGGCGACTTCGGACTGAGCAAGCTGATCGACGTAAAGCTTATGCATGATGTGTACAAGATGACGGGGGGGACTGGGAGTTACAGATACATGGCGCCTGAGGTCTTCGAACATCAACCCTACGACAAATCCGTCGACGTGTTTTCCTTTGGAATGATATTATATGAGATGTTTGAAGGCGTCGCTCCGTTTGAGGACAAGGATGCATACGACGCTGCCACACTAGTTGCTAGAGACGATAAGCGGCCAGAGATGAGAGCCCAAACGTATCCCCCACAAATGAAGGCATTGATCGAGGATTGCTGGTCACCGTATACCCCGAAGCGACCACCTTTCGTCGAAATCGTCAAAAAACTCGAGGTAATGTATGAGGATTGCTTATTGAGATTGCCCAAAGACCGTCGTCATCTCCGCGACATCTTGCATCTTCGACGCAATCCTGCAGACTCGTGATTGATCGGGCCAACCTTCGAGCTGATCAATCTAAGTAGTCAATGCCTTACTGTGTCAAATTCAGCCTCCGCCGACAGATTGGCTATGGTTCAAGTGATTGGATTCTCTGCTTCTCCAGAGCCAGAAACGACCCCCGTGCAATTTCTTCTCCGACGACCACATTGCGACATGAAGCACCAGACTTTGGATGTAGAAGGCATGGTCTACATGCTTTGCTGTGAGCCTTGCACGTCTCGCAGGTTGATCTCTTTAACCAGCTTCTAGCCTTTCGCAATGGCTGCATCACTTAAGAAATCACCGAGTATCGTGATGCTCGTTAACGC Nucleotide sequence of the full-length PK-9from Physcomitrella patens (SEQ ID NO:17)ATCCCGGGCTGTGATGTCGGTGTGGTGCTCTGCAAGAAATCAGATGACGTCATAAGCATGAAAAGGTACCAGAGACGTAAAGTTCAGAGACTCGGTCGGGAGGGCCAAGTCCTATTGGAGAGAACTCTTTTCAAGCAACTGAGGCCTTCCCCATTCGTGCCGCATCTCTTGGCCACCCCTATTGACAGTGACAATGTGGCACTCGTTCTTAATTGTGTGTTAGCTGGGCCTCTAGAACTTCTACTTCGGTCACCTTTAGACGAGAACTCAGCTCGTTTTCTGGTCGCCAACGTGGTATTAGCCGTCGAACTTCTGCACAAGGATGGCGTTGTATATCGTGGCATCTCTCCCGATGTTCTTATGATAGATCGGAAAGGACGACTTCAGCTGGTTGATTTTCGGTTTGCAAAGCAAATGTCGGATGAGCGCACTTTCACAGTCTGTGGCATGGCTGATTTCTTAGCACCCGAGATCATTCAAGGACAAGGTCATGGCCTGGCTTCTGACTGGTGGGCGGTAGGTGTGTTAATGTACTTCATGTTGCAAACTGAGCTTCCATTTGGATCATGGCGGGACAACGAGCTTGAAATTTTTGGTAGAATAGCCCGTCGGCAGCTTACGTTTCCTTCAAGTTTCAGCCCTGAAGCGGTTGACCTCATTGACAAGCTGCTGGTGGTGGACCCAACCAAGAGACTGGGCTGTGACAGCCATGGATCGCTTGCCATAAGGGAACATCCTTGGTTCCGAGGTATAAACTGGGACAAGCACCTCGATTGCAGTGTGGAAGTTCCTTCAGAGATCATGACACGCCTTCAGTTGGCCATAGACTTTCTTCCCGTGGATGATAGTTATCAAGTGTTTGATCTCCAACCCGATGAAGACGATCCACCATGGCTTGATGGCTGGTGATAGCTTGATGGCTCGTAGATCCCCCTTCTCCAAGCATCAATGGCACAGTACCGAATGGCTATAACAGAAGATGCACATTAAGTGCTCCATGAACAGATACCGTAGCGCTTAGGATTTTTCGGTCGTCACAAATGACGGCTCTCTTGTGAGGTTCGAATGTTGTGTCACCCGATGATCTCTACTGGCACAAACCTCCAGGCTGAATCTTAAGGCCAGCTGTTTTAGGTGAGACGTTTACCTTGGTTCGAACTCACGCTCGTGTTGTTAAGCGCGAGTCGATGATGTATGAAATGACGGTGTTCCTTGAAAGTCTTGAAAGGCAATCAATTCGCTTATGTGTGTCCCTTCCATGTGGTCATTAGGGAAGGGAACCGCTGCACTAGTCAGTAAACGAACATGGCTTCAATTGTATAGCATAGCGGTAGAGGTTTCGTACGAAATGTGGTTGCAGTCGGTGATTATAGGCGCATTTCTCTGAACATGCACGAGAATCGTGCTCCTGAGTCTCCATCATTCAGTGGTGCGAGCTCGC Nucleotide sequence of thefull-length CK-1 from Physcomitrella patens (SEQ ID NO:18)ATCCCGGGCTCACGTAGTGCACTGAACTCTGTCTGAATTTTAGGGGATGAGAGGTAGATTTGAAGAATACTGGTGTCTAATTTTCTGTTAATTTTTCACCCTTGAGGTAGCTCATGGATTTGGGAGGTGATCGCATGAGAGCTCCTCAGAGGCAGTCTCGAGAATATCAATATAGATCATTGGACGTCTTCACAGAGCAGCACGAGCAGTTGCAAAAGCAGCAGCAGCAAGATGAGTATCAGAGAACAGAATTGAAGCTCGAGACACTGCCAAAAATGTTAAGCAATGCGACCGTGTCATCTTCCCCTCGAAGCAGTCCGGATGGACGTAGACTACGTACAGTCGCGAATAAGTATGCTGTGGAAGGTATGGTTGGGAGTGGCGCATTCTGCAAGGTGTATCAGGGCTCCGATTTGACGAACCACGAGGTTGTGGGCATCAAGCTGGAGGATACGAGAACTGAGCACGCTCAGTTAATGCACGAGTCGCGCTTGTACAACATATTGCGGGGTGGGAAGGGAGTGCCCAACATGAGATGGTTCGGAAAAGAGCAAGACTACAATGTGATGGTGCTAGACCTATTGGGGCCGAACCTGTTGCACCTCTTTAAGGTGTGTGGGCTAAGGTTTTCGTTGAAGACCGTGATTATGCTCGGTTACCAAATGATTGACCGGGTGGAATACGTGCATTCTCGAGGGCTCGTTCACCGTGACCTGAAGCCGGATAACTTCCTCATGGGCTGCGGTCGGCAAGGAAACCAAGTGTTCATTATAGATTTTGGCTTGGCAAAGGAGTACATGGACCCGGCAACACGAAGGCATATCCCTTACCGAGATAGGAAGAGCTTCACAGGGACGGCACGGTACGCTAGTAGGAATCAGCACAGAGGAATCGAGCACAGTAGAAGAGATGACATAGAATCACTTGGTTACATTCTTATGTACTTTCTAAGAGGCAATTTGCCATGGCAAGGGAAGGGCGGGCAACGCCTCACTGACCAGAAGCAACACGAGTACATGCACAACAAAATCAAGATGAACACCACTGTGGAGGAGCTTTGTGATGGGTATCCCAGTCAATTTGCCGACTTTTTGCACCACGCGCGAAGTCTAGGTTTCTACGAGCAGCCTGACTACTGTTACCTCCGAAGCTTGTTCCGTGATCTTTTCATTCAGAAAAAATTCCAGCTCGACCATGTGTACGACTGGACTGTGTATACTCAACTCCCCCAGAATGGCTCTCTGCAATCAGTGCGCAGCCAGAATTCCGCTGCTTCGTCCCATTTGCAAAATCGACCTTCGAATGTATCATATTGTCCACCCTTGACCAAGTCGGAGTTCCGTCGTGAGGTTGTTGCGGCGAATTAGGGCTTACGTTGGGAGGACTAGTGGTTCATCCTCTGCTCTGGTACTAAAATAGCACAAGGTTGCTTACTGTTTCCCTCTCTCAAGTCTTACATGATTGTGAATGGGGGTTTATGGAGTTGAGGATGAGGCAACTAAGCAGAGTGTAGGAAAAGAGTTGTAGACTCTCTAGTGTGTAGTGTGTAAATCAAGGCTTCTAGCATTGTGTCGGTAGCTTGTATGGATCAGACTAGAAATGACTTTATCCATTACAAGAATTTTTACTCGGAAAGCCCATGACGGTGATGATTTCAATACGTTGCACAAGCAACTTTCTTCTGTAATTGAAATAGAGGATCTGGTCTGAGTATGAGAAGATGGGCATGTTAACGC Nucleotide sequence of thefull-length CK-2 from Physcomitrella patens (SEQ ID NO:19)ATCCCGGGTTGTCGAGGACGGAGAGAGAAGAGAGAGAGAGAGAGAGAGAGAGGTGTTGTTTAGGGGAGGCATGCGGGAGCAGGATTGGTGTTAAGTTCGTAAGGAGAAGGGAGTACATGCAAGTGCGTGCTTGTCGGATATCGGACAGCTGGATTTGTAAATAAGCGGAGAGGAGGGTCGGTAATCAGGGGCGTACATCGATGGAGCCGCGTGTGGGAAACAAGTATCGGCTGGGACGGAAAATTGGGAGCGGTTCCTTTGGGGAGATCTATCTTGGGACCAATGTTCAGACCAATGAGGAGGTCGGAATAAAGCTGGAAAGCATCAAGACGAAGCATCCACAATTGCTGTACGAGTCCAAGCTCTACCGGATACTACAAGGAGGAACTGGGATTCCCAATATCAGATGGTTCGGGATAGAAGGAGACTACAATGTCTTGGTTCTGGATCTGTTGGGGCCAAGTCTCGAAGACCTTTTCAACTTCTGCAGCCGGAAGTTCTCTTTAAAGACTGTTCTCATGCTTGCTGACCAGCTGATCAACAGAGTGGAGTATGTGCATGCGAAAAGCTTTCTTCATAGAGACATCAAGCCTGATAATTTTCTAATGGGGCTTGGTAGGCGAGCAAACCAGGTCTACATTATTGATTTTGGTCTTGCCAAGAAGTACCGCGACCCTTCCACGCATCAGCATATTCCCTACAGGGAGAACAAAAATCTGACAGGGACTGCTCGGTATGCAAGCATCAACACTCATCTTGGTATTGAGCAAAGCAGACGAGATGATTTGGAATCTCTTGGATATGTGCTCATGTACTTCCTGAGAGGCAGTCTTCCATGGCAAGGACTGAAAGCGGGAACCAAGAAGCAGAAGTACGAGAAGATCAGTGAGAAAAAAATGTCCACGCCCATTGAGGTCCTTTGTAAAAATTATCCTTCAGAATTCGCCTCGTACTTCCACTACTGCCGGTCCTTGCGTTTTGATGACAAACCCGACTATGCATATTTGAAAAGAATCTTCCGTGACCTCTTTATTCGTGAGGGTTTTCAATTTGACTACGTTTTTGACTGGACAATTCTGAAGTACCAGCAGTCACAAATTTCCGGTGGCAGTTCAACTCGACTGGGTGCTTCTGCAGGGCAAACCAGTGGTGCACTTGGAACTGGGGCTACAGGAAGCCGAGACCTGCAGCGGCCCACCGAACCAATGGATCCTTCTCGGCGCAGGCTTCCTGGAGGAGCAAATGGCTCCGGGGTCGCAAATGCTTTGGACTCATCTAAGCACAAAAGTCCTGGACTTGATGAATCTGCTAAGGATTCTGCTCTTGCTGTTGTGTCAGAACCAGAGCGCATGCATACATCTTCGTATGCAACTCGGGGGGGTTCTTCCTCCAGGCGAGCTGTCCTATCTAGCAGCAGGCCCTCAGGGGCATCAGCAGAAGTCGTAGATTCCTCTCGAACAGGGAGCAGTAAGCTTGGTCCCACCAGCTTACGGTCGTCAGCAGGGATGCAGAGGAGCTCTCCAGTTACTTCGGACCCAAAGCGGATATCTAGCCGCCATCCACAACCGCCATCTGCCAACTTGAGGATTTACGAAGCCGCTATCAAGGGAGTTGAATCACTTTCTGTTGAGGTGGATCAAAGCCGTTATAAGTAGGCCCAGGCTTGTGGTTATATAGCCGGGCTCTGTCTTCTATCAAACCCTCTTGTTATGTAGATGAGAGTTGCTCTACATTTGGCAACAGCCTGATTGAGGGGAAAACGGTGGTTCTGTCCTACAATGGTGCTAAGACTACAGGTCTCTCATACTTAGGAATGAATGGATCTCTATCTTGTTACCATCAAACCATTGTCAGTGCTTTGTGTGGTAGCTCTCTGCCATACGATTCCTAAGGTTAACGC Nucleotide sequenceof the full-length CK-3 from Physcomitrella patens (SEQ ID NO:20)GCGTTAACGGGAGGAAGGTCGGGGGAAGAGACGCTTGAGGCTGCTGAAAGGGGATTCACTCAGCGTCCCCACCCATTCGTCAATCTGGCGCAGAAGATCGGAAAATCGGTCCGACGGCCAGGTGTTATGTCCAAGGCCCGGGTTTACACAGATGTGAATGTCCAACGTCCGAAAGATTATTGGGACTACGAGGCCCTCACCGTCCAATGGGGGGACCAAGACGATTACGAGGTAGTGCGTAAGGTGGGGCGAGGGAAATACAGTGAGGTTTTTGAAGGTGTCAACGCCGTGAATAGTGAGCGTTGCGTTATGAAGATTTTGAAGCCAGTAAAGAAAAAAAAGATCAAAAGAGAGATCAAGATTCTGCAAAACCTTTGTGGAGGGCCCAACATTGTGAAGCTTCTGGACATTGTCCGTGATCAGCAATCGAAGACACCCAGCCTAATTTTTGAGTATGTGAACAATACTGATTTCAAAGTGCTCTACCCCACTCTTACAGACTTTGATATCCGATACTACATTCATGAGCTGCTCAAGGCTTTGGACTATTGCCATTCTCAAGGGATTATGCACAGGGATGTGAAGCCACACAACGTGATGATTGACCATGAGCAGCGGAAGCTTAGGCTTATTGACTGGGGACTTGCCGAATTCTATCATCCTGGCAAAGAGTATAATGTGCGTGTTGCCTCTAGGTACTTCAAGGGTCCTGAGCTGCTGGTTGATCTTCAAGATTATGATTACTCTCTCGACATGTGGAGCTTGGGGTGCATGTTTGCCGGCATGATATTTCGGAAGGAGCCATTCTTTTATGGGCATGACAATTATGATCAACTTGTGAAGATTGCTAAGGTGTTGGGAACTGATGAATTGAATTCCTATCTAAACAAATACCGCCTAGAGCTGGACCCCCATTTGGAAGCACTGGTTGGCAGGCATAGCAGGAAACCTTGGTCAAAGTTCATCAATGCTGATAATCAGCGTCTGGTTGTTCCAGAGGCTGTGGATTTTTTGGATAAGCTTCTACGCTACGATCATCAAGACAGGCTGACTGCGAAGGAAGCTATGGCACATCCCTATTTTTATCCCGTGAAGGTGTCGGAGGTTAGCAACCGTCGCAGTGCTTGATATGAATTGATATATCTCATATGGGCTTTCTTGTGATTACGTCCCACCCGGCTACCAGGTTTCTCAGTTGTG CGAAGCGCTGAGCTCGCNucleotide sequence of full-length MPK-2 from Physcomitrella patens (SEQID NO:21) ATCCCGGGCGAGCCATGGCGCCACTTGCTTCGGCGAATGGGACTGTTTGACTTCTTCGCTTCGCCCCCGCCTCGCCCTTCACCCTCCTCTGTTCTTGTCACAGCCTCCTCCTCCGTCTCTGTCTGTTGGCTGGGTAAGTTTTGGGAGTGAGGAGGACGTGGTCATGGAAGAAGAGCCCCCCTCTTTTGTAGTGGACTGTCGGTAAATTGGACCTGGAGCCTGCCGGCTCATCGCGTTTGCTTAGATTGTGGGCGGGTGCTGTTGAAATTCCTTGAACTTGCTACTGGTCGGAAACGCTCGAATTGCGACTTTGATTGAAGGTCTGGTTGTTGCTGCGGTCGGGATCTTACTCAGTCTCTTCAATAGGACCTCTGAAGCAGTATGGAGACTAGCAGTGGAACTCCAGAATTGAAAGTTATAAGTACTCCGACCTACGGAGGTCATTACGTGAAATATGTTGTGGCGGGAACTGATTTCGAAGTCACCGCGAGGTACAAGCCACCACTTCGTCCGATTGGGCGCGGAGCTTATGGAATCGTCTGTTCACTCTTTGATACCGTTACGGGTGAGGAGGTGGCGGTCAAAAAGATTGGAAACGCCTTCGACAACAGGATCGATGCGAAGCGAACACTGCGTGAAATAAAACTCCTCCGGCATATGGATCATGAAAACGTCGTTGCCATTACAGACATCATTCGTCCCCCAACTAGGGAGAATTTCAACGACGTGTACATTGTATACGAGTTGATGGATACGGACCTACACCAGATCATTCGTTCAAATCAAGCTCTCACAGAAGACCACTGTCAGTATTTTCTGTATCAAATCTTGCGGGGCTTGAAGTACATCCATTCGGCGAACGTCTTGCACCGGGACTTGAAGCCCACCAACCTTCTCGTCAATGCCAATTGCGATTTGAAAATCGCAGATTTTGGCTTGGCACGCACTCTCTCTGAAACGGATTTCATGACTGAGTATGTTGTAACGAGGTGGTACAGAGCTCCAGAGCTGCTCCTGAATTGTTCAGCATACACTGCAGCTATTGACATTTGGTCTGTGGGGTGCATCTTCATGGAGTTGCTTAACCGATCTGCGTTGTTCCCTGGGAGAGACTATGTGCATCAGCTCCGCCTAATTACAGAACTCATCGGAACTCCTGAAGATAGGGATCTTGGGTTTTTGAGAAGCGACAATGCTAGGCGGTATATCAAGCACCTGCCTCGACAGTCGCCTATTCCCTTAACCCAGAAGTTCAGAGGCATTAATCGTTCTGCTCTTGATCTTGTTGAAAAGATGCTGGTCTTTGATCCAGCGAAAAGAATCACAGTGGAAGCTGCCTTGGCGCACCCTTATTTAGCTTCACTTCATGACATCAACGATGAGCCTGCCTCGGTATCTCCCTTCGAGTTTGACTTCGAGGAGCCCCCTATCTCGGAGGAGCATATCAAGGATCTCATTTGGAGGGAGGCTCTGGATTGCAGCTTAGGTCCTGATGATATGGTGCAGTAACTTCACACTTCATCTCAAGTTGTAAGGCCTACTCTCAATTCTTTAGGTGGCTACAACGCTATCCCGGCGTTGTATGGTTTTGCAACTTATTCCCCCCCGTGTGATTACACTATTGGATTATAGAATGACAATTCGTTAGTTCTTTTCCCTGGCGCTATATCTTTGTCTGCACATTTCATCCAGCAGACATT GTTGCTCGGCGTTAACGCNucleotide sequence of full-length MPK-3 from Physcomitrella patens (SEQID NO:22) ATCCCGGGCTTGTATTGGCTCGGATAATTTATGTTGACAATTGATTTGTGAGGCTTCGTATTGAGTCAGCGAGCAGGCTGAGAGTTCGGCAGCGAAGTTACACTCGACCTGGCTGAAATTTGGAATTGAAGCGCGTGAAGCTTCATCTGTGATTTTGGAGGTTGTTTGACTGATGAGAAGAGGTCTCTGAGCTGAGAATGTTTGCAATTTAGGGGCACCACCGGTTTGTTGGAGTCCCTTGCCACTTATTACAATTGTTGGTTTACAAGCTCGACGAGTTTCAATCGAACGTAGAGTTTTAGTCGGGTCGAGGATCTATGTATCCGCTCAGCGGAGAAGAGAGCCTGATGTTGCCGAAGCGATCGTGTGGGATTTGACTAGAAAGAGGTGGACCGCATCAGAACTATTTATTCCTTGTGAGGGAAGGATCGAGGTTCCAATGGGTCTCACTCCGTTTTCTTGTGTCACGGTTCAAGGTTATGTCCGGGTGGTCTACCCCGACGGCCACGTCGAGAATCTGAGCAAATCTTGTAGCGTGCACGATCTTCTTCTGGGTAATCCAGACTACTATGTCTGCGGTAGCACCCCTTACACAATCACCAATCGTATGGCAGCGGAAGAGGTGCTCGAGTATGGGGTGACCTACTTCGTTTGCGCAACGCCAAATGCCCAACCTTTCITAGAACGTCAGCCGAAGGTAGTACATCGAGGATCCAAGATTTTGCCACGATTTTCCAAACATGGGGTCCATGTGCGGGAGTTGCGAAGCCCGACGCATGGGAGCCAACAGTCACGGAAGGTTTTTGATTATCATTCAGTAACGATGCAGCAGCTTGAATCCATACGAAACGAGGGCCCAGAGCCTCACCTCGCTGGAGACCGACCATCGAAGCACCTTAAGCTCGTTTTCATTCGGCATTGCTTGCGAGCACTTCGACTTCCTAGAATTTCAATAGACCTAATGGAATCGCCACTCCCTAATCTTTCCGGAGAGGCCTTATCGCCGACGGCAACTGCCAAAGACGAGATTACTCAGATGATACTAAAAAGTGCCGCAAGGTCCGAATTAGGAATGTATGTTTCGAAGAGACAGGAATTCTATCTTCGAAGAGCGCGTAGGCGGCGTAAGTTTGCGTGGAAGCCGGTTTTGCAGAGCATCTCCGAGATGAAGCCTGTCATGGAATTCCACACTCCGATGGCTTACCGGGATAGTGGGTCTCCGCCGAAGAACGCCTCTACCCCATCCTTACCTGGCCCGAAGAACATTTCACCGCCACGACAAGTGAGTGTCCCGCAAAGGAGCAGTCCTCCGCCGAAGAACGTCTCACCACCTCCCCAGCCCGCATTTGTAGCGCGGACTGCGTCGAAGTATTCTGCTGCATCTCAGCAAGTTCAACGAAATCGAGGCAACGCGAAATCTCTTTATATGGCGTAGTTTGTGTCTCGACTGAACTCCTATCTATTCCCCCATCGAGATAACTGCATTCGTTGGATAAATTTCTCCAACATTTTTGCTCTTCATCCTCAAGCAGCTCCTCAATGGCCAGTAATATGTTACGACATTGTGCACAACTCCAATTACGTAGCGTTATTCTGTAACCCACGTTCATCGAGGTATCAAGGAATGGCGCAGTAAGCACTGCTACTTTGTGCTTTGGTATCCCGTTGTGACGAGATGTCATGTCGCACCGTGCCTATCAGTGGGATTTTCTTGAGCGCAGATCTTGCTTCCGCAGTTTGTTTCATAACGTTTTGGTTCGTAGGGGGCCTAGACGGTACTATCAAGCAATGAGAAGTGTGCTGGTGTGGATTTGACAGCAATCTTTTGGAGGATTGTCTTTCCTATGTAGAACATAGCGAGGACACTTGCGCCTGGTGGGCACATCCCATAGAACATAGTGCTTCACTTCTGGGTTGTTCACCACTAGGATCATATGACCTTCTCATCTATTTTCGGGCTTTGTTTCGAGCTCATGTACCATCGACTAGCGTCACTTTGACTGCGGTGATAATCGTTTTGTCAATTTAGTGGAGCTTTGTAGATGATAGATGCCATTTGTACAGTAGCTTGGATGCTGTTTACAAGATAGCGGCAGCTAGAAGCCTTAAACCTTTAGCTACCATGTATTATTTAAACCTATATGAAGTGAACGGCTGTGCAGATATTGCCGTTAACGC Nucleotide sequence of full-length MPK-4from Physcomitrella patens (SEQ ID NO:23)ATCCCGGGCGGTCGAGTCGTATTAGGTGTTGTTTCATTGTAAGGGTTCGGAAGCACGGGGCACGGCGTATATACCGTTCCCCTTGAACGTTGATCTCACCTTTGGAAGACCTGAATTGAGTAGCGTGCGGAAGCTGCATCGATCCGGAAGAGACGATGAGTAGGAGAGTGAGAAGGGGAGGTCTTCGCGTCGCGGTGCCGAAGCAAGAGACTCCCGTCAGCAAATTTTTGACTGCCAGTGGAACTTTCCAGGATGATGATATCAAGCTCAACCACACCGGGCTTCGCGTCGTCTCTTCAGAACCTAACCTTCCTACGCAGACGCAGTCTAGCTCCCCAGATGGGCAACTGTCAATAGCAGACCTGGAGTTAGTGCGGTTCTTGGGAAAGGGTGCGGGTGGAACCGTGCAGCTTGTCCGGCACAAATGGACCAATGTCAATTATGCACTGAAGGCGATACAAATGAATATCAACGAAACAGTGAGGAAGCAGATTGTTCAGGAGCTGAAAATCAACCAAGTGACGCACCAGCAGTGCCCTTATATCGTGGAATGCTTCCACTCCTTCTACCACAACGGCGTCATATCCATGATCCTAGAGTACATGGACAGGGGCTCGTTGTCCGACATTATTAAGCAACAAAAGCAGATACCTGAGCCGTATTTGGCCGTCATTGCTAGTCAAGTTCTGAAGGGATTGGAATACCTACACCAAGTCAGGCACATCATACATCGTGATATAAAGCCCTCCAACCTCCTCATCAATCACAAGGGTGAGGTCAAAATATCTGATTTTGGTGTCAGTGCTGTGTTGGTTCATTCCTTGGCCCAGCGAGACACGTTCGTTGGGACTTGCACATATATGTCGCCAGAACGCCTTCAGGGGCGTTCGTATGCATACGACAGTGACCTATGGAGTTTAGGATTGACTCTTTTGGAGTGTGCGTTGGGTACCTTCCCATACAAACCAGCTGGAATGGAAGAGGGTTGGCAAAATTTCTTCATCCTCATGGAATGTATAGTTAATCAACCCCCCGCAGCCGCATCCCCTGACAAATTCTCCCCCGAATTTTGTTCTTTTATTGAATCCTGCATCCGGAAATGTCCCAGTGAACGACCATCAACTACTGATTTACTTAAACATCCGTTCCTGCAAAAGTACAACGAGGAAGAGTACCATTTGAGCAAGATTTTGTAACTTAAAGTTAGCCTCGCATGGCGTGCAGAGACTGTCACTACCACAAGCCTGATCCACCACTGAACTTCAAGGGACTTTACCAAAAGCATGGTCGAACTACCTCGCCAATCCGCCACTTTCTCAATGCCTTTTCCTTATATAGTCATATGTGGTCAAGTTGAGAACGATATCAAATCAGATTGACGGAAAAAACATCTTCAACGCCGTTTCCCAACCTTATAGAAAGTGGAGTTTTCTCAATGAGCCCCATTTGTCGCTGAGAACGTGCAGCTCATGAAACAATCCATAAGTGTGTTAATCGGGGTCTTATATTATCATCACCATGCTAGCTTTTTATGTTACCTGCACTTTTTCTTTCCTTATTGCACAGCATCGAACACTTCTTCGATACCCAAAACAATATTTCCATCTTCTTTCTTCTTTTTTTCACGTCTTGCGACAAGGAATTTCCTCACGGAGATTTTTCAACACTTTTCTCAAATGTTTTTAGAGTTTTTAAACTGACAATTGAAGAGGTCGGACCTACCGGACTCGC Nucleotide sequence of full-length MPK-5from Physcomitrella patens (SEQ ID NO:24)ATCCCGGGAGAGGCTGATCTGATGCTACAGTTTCGTGTGCAGCTAGTCTTTAGAGATTCGGGCAACGCACTTGTTGAAGATCGGAAACTTTCAAAATCGGTCGAGTCGTATTAGGTGTTGTTTCATTGTAAGGGTTCGGAAGCACGGGGCACGGCGTATATACCGTTCCCCTTGAACGTTGATCTCACCTTTGGAAGACCTGAATTGAGTAGCGTGCGGAAGCTGCATCGATCCGGAAGAGACGATGAGTAGGAGAGTGAGAAGGGGAGGTCTTCGCGTCGCGGTGCCGAAGCAAGAGACTCCCGTCAGCAAATTTTTGACTGCCAGTGGAACTTTCCAGGATGATGATATCAAGCTCAACCACACCGGGCTTCGCGTCGTCTCTTCAGAACCTAACCTTCCTACGCAGACGCAGTCTAGCTCCCCAGATGGGCAACTGTCAATAGCAGACCTGGAGTTAGTGCGGTTCTTAGGAAAGGGTGCGGGTGGAACCGTGCAGCTTGTCCGGCACAAATGGACCAATGTCAATTATGCACTGAAGGCGATACAAATGAATATCAACGAAACAGTGAGGAAGCAGATTGTTCAGGAGCTGAAAATCAACCAAGTGACGCACCAGCAGTGCCCTTATATCGTGGAATGCTTCCACTCCTTCTACCACAACGGCGTCATATCCATGATCCTAGAGTACATGGACAGGGGCTCGTTGTCCGACATTATTAAGCAACAAAAGCAGATACCTGAGCCGTATCTGGCCGTCATTGCTAGTCAAGTTCTGAAGGGATTGGAATACCTACACCAAGTCAGGCACATCATACATCGTGATATAAAGCCCTCCAACCTCCTCATCAATCACAAGGGTGAGGTCAAAATATCTGATTTTGGTGTCAGTGCTGTGTTGGTTCATTCCTTGGCCCAGCGAGACACGTTCGTTGGGACTTGCACATATATGTCGCCAGAACGCCTTCAGGGGCGTTCGTATGCATACGACAGTGACCTATGGAGTTTAGGATTGACTCTTTTGGAGTGTGCGTTGGGTACCTTCCCATACAAACCAGCTGGAATGGAAGAGGGTTGGCAAAATTTCTTCATCCTCATGGAATGTATAGTTAATCAACCCCCCGCAGCCGCATCCCCTGACAAATTCTCCCCCGAATTTTGTTCTTTTATTGAATCCTGCATCCGGAAATGTCCCAGTGAACGACCATCAACTACTGATTTACTTAAACATCCGTTCCTGCAAAAGTACAACGAGGAAGAGTACCATTTGAGCAAGATTTTGTAACTTAAAGTTAGCCTCGCATGGCGTGCAGAGACTGTCACTACCACAAGCCTGATCCACCACTGAACTTCAAGGGACTTTACCAAAAGCATGGTCGAACTACCTCGCCAATCCGCCA GAGCTCA Nucleotidesequence of full-length CPK-1 from Physcomitrella patens (SEQ ID NO:25)ATCCCGGGTGTAGGCGGGCGAGGTTCGATGCAATGGGGCAGTGTTATGGAAAGTTTGATGATGGAGGCGAAGGGGAGGATTTGTTTGAGCGGCAGAAAGTGCAGGTTTCTAGGACGCCAAAGCATGGATCGTGGAGCAATAGCAACCGAGGGAGCTTCAACAATGGCGGGGGGGCCTCGCCTATGAGAGCCAAGACGTCGTTCGGGAGCAGCCATCCGTCCCCGCGGCATCCCTCAGCTAGTCCGCTCCCTCACTACACGAGCTCCCCAGCGCCTTCGACCCCGCGACGGAACATTTTCAAAAGGCCTTTTCCTCCTCCTTCTCCCGCGAAGCACATTCAGTCCAGTCTCGTGAAACGGCATGGCGCGAAGCCGAAAGAAGGAGGGGCGATCCCTGAGGCTGTCGATGGTGAGAAGCCCTTGGATAAGCATTTCGGCTATCACAAGAACTTCGCTACTAAGTATGAGCTGGGGCATGAAGTCGGTCGCGGGCACTTCGGTCACACATGTTACGCGAAAGTACGGAAGGGCGAGCATAAGGGACAAGCCGTGGCAGTGAAGATAATCTCGAAAGCGAAGATGACGACTGCTATTGCGATCGAGGACGTGGGACGAGAAGTGAAAATTTTGAAGGCTCTGACGGGACACCAGAATTTGGTTCGATTCTACGATTCCTGCGAGGACCATCTAAATGTGTACATTGTTATGGAATTATGTGAAGGAGGTGAATTATTGGATCGAATTTTGTCTCGGGGAGGGAAGTACTCGGAGGAAGACGCCAAGGTTGTTGTGCGGCAGATTTTGAGCGTTGTTGCGTTTTGTCACCTGCAAGGCGTTGTTCACCGAGATCTTAAGCCTGAGAATTTTCTGTTTACCACGAAGGATGAATATGCTCAGCTTAAGGCCATTGATTTTGGATTGTCAGATTTCATCAAACCCGATGAAAGACTGAACGATATCGTTGGAAGCGCATACTACGTTGCGCCGGAGGTATTGCATAGGTTATATTCAATGGAAGCTGACGTATGGAGCATTGGAGTCATCACGTACATTTTGTTATGTGGTAGTCGACCGTTTTGGGCGCGGACCGAGTCGGGCATTTTTCGTGCGGTGTTGAGGGCTGACCCGAGCTTTGAAGAAGCCCCTTGGCCTTCCATCTCTCCCGAAGCCAAGGATTTCGTGAAGCGTCTCCTGAATAAGGATATGCGGAAACGCATGACTGCTGCACAAGCTTTAACTCATCCATGGATTCGAAGTAACAACGTGAAGATACCTCTGGATATCTTAGTGTACAGACTTGTGAGGAATTATCTTCGTGCATCATCCATGAGAAAGGCTGCTTTGAAGGCCCTGTCAAAGACTTTAACCGAAGACGAGACTTTTTATCTACGTACTCAATTTATGCTGCTAGAACCAAGTAACAACGGTCGTGTTACTTTTGAGAATTTCAGACAGGCACTGCTGAAAAATTCAACAGAGGCCATGAAAGAGTCACGGGTTTTTGAAATTCTGGAATCGATGGATGGTCTTCATTTCAAGAAAATGGACTTTTCAGAGTTCTGTGCAGCGGCCATTAGTGTTCTCCAGTTAGAAGCCACAGAACGATGGGAGCAGCATGCTCGCGCAGCTTACGACATATTTGAGAAAGAGGGTAACCGAGTCATTTATCCTGATGAACTTGCGAAAGAGATGGGACTAGCACCAAATGTACCAGCCCAAGTGTTTCTAGATTGGATTAGACAGTCTGATGGTCGGCTGAGTTTCACTGGGTTCACCAAGCTGCTACATGGAATTTCCAGCCGTGCTATCAAAAATCTCCAGCAGTGATTCTTTGCATCGTACAGTTCGGAATGGAGTTTTTAAGCTCTTTTAGTTTCACTTCCGTCTTCAACTGCTGCTTCGCCTCGTCTCTGAGCTGTGATAGCGTATCTCAAGCATATGCACAACTCGCATTTTTGCTGAAGTGATTTGTCACCTCACATTAGTCGGGCCTCTGGAACTTTCACTTATTTGGATTATTTATGTAGAAGTCCAGATCAAAAGCGAAAAGGAATGGCTAGATATTGTCACAAGAAGTAACATAGTCAAATTCAGGAGCACTTAAGCACACATTGAGTGCTTTTTATTGGAATTCTTAGATATGGAACTGATGTTTCCAAGGGAAGGGTCTATGAGGCAGAGAGTGGAATGTATAGACTGGCATATGGTTAAGTGATCATTGGACTGCCGTTCTACTCCGGTTGTCGTTAAC GC Nucleotidesequence of full-length CPK-2 from Physcomitrella patens (SEQ ID NO:26)ATCCCGGGCGAACTGCGATCTGAGATTCCAACTTGGAAGGGCCTCGCGTAAGACCGGATCTCGTTTCTTACGCTTTTGCGCCTCGCGATATTTGTACATTGTTTCCTCTGGTTTTATTCGATTCCGCCTCTGAAAATGTGAACGGGCTGCAAGCTTGGTTTTGGAGCAACGTTGGAGCATTGAAGGGTTGCGCTCGTCCCTGCCCATTCCTCGCTTCTGCTCTGGCCTATGTCATGACGACGTGAAGGAGAGGATTTGAGGGTTTTGTAAGTGATATAATCCTCCCCGAGGAGATTTCTGTGAGTTGATTAACTTGGATCAGCGACATGGGGAACACTAGTTCGAGGGGATCGAGGAAGTCCACTCGGCAGGTGAATCAGGGAGTCGGGTCTCAAGACACCCGAGAGAAGAATGATAGCGTCAATCCAAAGACGAGACAGGGTGGTAGCGTTGGCGCAAACAACTATGGCGGAAAGCCAAGCAGTGGTGCTCAGGCCGGAGAACGATCCACCTCTGCGCCCGCTGCTCTGCCGAGGCCGAAGCCAGCATCGAGGTCAGTATCCGGTGTTTTGGGTAAGCCGCTGTCAGATATTCGTCAATCTTACATCCTGGGACGGGAGCTTGGCCGAGGGCAGTTCGGAGTGACTTACTTGTGTACTGACAAGATGACGAATGAGGCGTACGCGTGCAAGAGCATCGCCAAACGGAAACTGACCAGTAAGGAGGATATCGAGGATGTTAAGCGGGAGGTTCAGATTATGCATCACCTGTCGGGGACACCCAATATCGTGGTGTTAAAGGATGTGTTCGAGGACAAGCATTCCGTGCATCTTGTGATGGAGCTCTGTGCAGGTGGCGAGCTCTTCGATCGCATCATTGCCAAGGGGCATTACAGTGAGCGCGCCGCTGCCGATATGTGCAGAGTCATCGTCAATGTGGTGCACAGATGCCACTCATTAGGGGTCTTCCATCGGGATCTCAAGCCAGAGAATTTTCTGTTGGCCAGCAAGGCTGAGGATGCGCCTCTGAAGGCCACAGACTTCGGTCTGTCAACTTTCTTTAAGCCAGGAGATGTGTTCCAGGATATTGTTGGAAGTGCGTATTACGTGGCCCCTGAAGTTTTGAAGAGAAGTTATGGTCCTGAAGCTGATGTTTGGAGTGCAGGCGTGATTGTGTACATTCTGCTGTGTGGTGTACCCCCCTTCTGGGCTGAAACTGAGCAGGGTATCTTTGACGCTGTGCTCAAAGGGCACATAGACTTCGAGAACGATCCATGGCCGAAAATCTCCAACGGGGCTAAGGATTTGGTGAGGAAAATGCTAAACCCTAACGTGAAGATACGTCTGACGGCACAGCAGGTGTTGAACCATCCATGGATGAAGGAAGATGGTGATGCTCCAGACGTGCCACTCGACAATGCGGTGTTGACCAGACTGAAAAATTTCTCAGCCGCCAACAAGATGAAAAAGCTGGCGCTGAAGGTGATTGCAGAGAGTCTGTCGGAGGAAGAGATCGTGGGGTTGAGGGAGATGTTCAAATCCATAGATACAGACAACAGCGGCACGGTGACGTTCGAGGAGCTTAAGGAAGGGTTGCTGAAGCAGGGCTCAAAACTTAATGAATCGGACATCAGGAAACTAATGGAAGCTGCAGATGTCGATGGAAACGGCAAGATCGACTTCAACGAGTTCATATCGGCAACAATGCACATGAACAAGACGGAGAAAGAGGATCACCTTTGGGCAGCATTCATGCATTTCGACACGGACAATAGCGGGTATATCACCATCGACGAGCTTCAGGAAGCAATGGAGAAGAATGGAATGGGAGATCCTGAGACCATCCAAGAGATCATCAGCGAGGTGGACACAGACAACGACGGAAGAATAGACTACGACGAGTTCGTAGCCATGATGCGCAAGGGCAATCCTGGCGCTGAAAACGGAGGAACGGTGAACAAGCCCAGACACAGGTAGTAGCTCCTGGTTGCCAATTTGACGACGGGTTTGGCAAGGCAACAGTAGTTGTTGTTAGCTTTCAGATTCAGGTTCGGTATTGTTCATGCCCTCCTTTGTCTCGAACAATGGACTCTAGGCCTTTCCAATGGAAAAGCTATTCCAACAGGGTTTGCATAACGTGTAGTAGAATGAAAGCATTGCCTGGGGGGTGTACAGTGCCTGTGATCTTGTGGAGTTCTCGTAGGATGGCTTCGGTTGGATCTCGTTAACGC Deduced amino acid sequence of PK-6 fromPhyscomitrella patens (SEQ ID NO:27)MGVDMKAPAKQSLGVGLLLCSVVILSVVSSVYGQVQTDPVDTTGLISMWYDLKQSQSLTGWTQNASNPCGQQWYGVVCDGSSVTEIKIGSRGLNGNFNPSYFQNAFKKLRIFDASNNNIEGNIPQQFPTSLTQMILNNNKLTGGLPQFDQLGALTVVNLSNNNLTGNMNPNYFNVIVNVETFDVSYNQLEGTLPDSILNLAKLRFLNLQNNKFNGKLPDDFSRLKNLQTFNIENDQFTGNYPSGLPSNSRVGGNRLTFPPPPAPGTPAPRTPSPSGTSNGSSSHLPLGAIIGIAAGGAVLLLLLALGICLCCRKRSKKALGDPEATTSSRRPWFTPPLSAKSQSDPSKSIDKTTKRNIFGSSKSEKKSSKHRVFEPAPLDKGAADEPVVKASPPVKVLKAPPSFKGISGLGAGHSKATIGKVNKSNIAATPFSVADLQAATNSFSQDNLIGEGSMGRVYRAEFPNGQVLAVKKIDSSASMVQNEDDFLSVVDSLARLQHANTAELVGYCIEHDQRLLVYEYVSRGTLNELLHFSGENTKALSWNVRIKIALGSARALEYLHEVCAPPVVHHNFKSANILLDDELNPHVSDCGLAALAPSGSERQVSAQMLGSFGYSAPEYAMSGTYTVKSDVYSFGVVMLELLTGRKSLDSSRPRSEQSLVRWATPQLHDIDALARMVDPSLKGIYPAKSLSRFADIVALCVQPEPEFRPPMSEVVQALVRLMQRASLSKRRSESAVGIESNEPSETSL Deduced amino acidsequence of PK-7 from Physcomitrella patens (SEQ ID NO:28)MSVSGMDNYEKLEKVGEGTYGKVYKARDKRSGQLVALKKTRLEMEEEGVPSTALREVSLLQMLSHSMYIVRLLCVEHVEKGSKPMLYLVFEYMDTDLKKYIDLHGRGPSGKPLPPKVVQSFMYQLCTGLAHCHGHGVMHRDLKPQNLLVDKQTRRLKIADLGLGRAFTVPMKSYTHEIVTLWYRAPEVLLGATHYSLPVDIWSVGCIFAELVRKMPLFTGDSELQQLLHIFRLLGTPNETIWPGVSQHRDWHEFPQWRPQDLSLAVPGLSAVGLDLLAKMLVFEPSKRISAKAALSHTYF ADVDKTAT Deducedamino acid sequence of PK-8 from Physcomitrella patens (SEQ ID NO:29)MADAKEELALRTEMHWAVRSNDVGLLRTILKKDKQLVNAADYDKRTPLHIAASLDCVPVAKVLLAEGAELNAKDRWGKSPRGEAESAGYMEMVKLLKDYGAESHAGAPRGHVESLIQVAPPLPSNRDWEIAPSEIELDTSELIGKGAFGEIRKALWRGTPVAVKTIRPSLSNDRMVIKDFQHEVQLLVKVRHPNIVQFLGAVTRQRPLMLVTEFLAGGDLHQLLRSNPNLAPDRIVKYALDIARGMSYLHNRSKPIIHRDLKPRNIIVDEEHELKVGDFGLSKLIDVKLMHDVYKMTGGTGSYRYMAPEVFEHQPYDKSVDVFSFGMILYEMFEGVAPFEDKDAYDAATLVARDDKRPEMRAQTYPPQMKALIEDCWSPYTPKRPPFVEIVKKLEVMYEDCLLRLPKDRRHLRDILHLRRNPADS Deduced amino acid sequence of PK-9 fromPhyscomitrella patens (SEQ ID NO:30)MKRYQRRKVQRLGREGQVLLERTLFKQLRPSPFVPHLLATPIDSDNVALVLNCVLAGPLELLLRSPLDENSARFLVANVVLAVELLHKDGVVYRGISPDVLMIDRKGRLQLVDFRFAKQMSDERTFTVCGMADFLAPEIIQGQGHGLASDWWAVGVLMYFMLQTELPFGSWRDNELEIFGRIARRQLTFPSSFSPEAVDLIDKLLVVDPTKRLGCDSHGSLAIREHPWFRGINWDKHLDCSVEVPSEIMTRLQLAIDFLPVDDSYQVFDLQPDEDDPPWLDGW Deduced amino acid sequence of CK-1from Physcomitrella patens (SEQ ID NO:31)MDLGGDRMRAPQRQSREYQYRSLDVFTEQHEQLQKQQQQDEYQRTELKLETLPKMLSNATVSSSPRSSPDGRRLRTVANKYAVEGMVGSGAFCKVYQGSDLTNHEVVGIKLEDTRTEHAQLMHESRLYNILRGGKGVPNMRWFGKEQDYNVMVLDLLGPNLLHLFKVCGLRFSLKTVTMLGYQMIDRVEYVHSRGLVHRDLKPDNFLMGCGRQGNQVFIIDFGLAKEYMDPATRRHIPYRDRKSFTGTARYASRNQHRGIEHSRRDDIESLGYILMYFLRGNLPWQGKGGQRLTDQKQHEYMHNKIKMNTTVEELCDGYPSQFADFLHHARSLGFYEQPDYCYLRSLFRDLFIQKKFQLDHVYDWTVYTQLPQNGSLQSVRSQNSAASSHLQNRPSNVSY CPPLTKSEFRREVVAANDeduced amino acid sequence of CK-2 from Physcomitrella patens (SEQ IDNO:32) MEPRVGNKYRLGRKIGSGSFGEIYLGTNVQTNEEVGIKLESIKTKHPQLLYESKLYRILQGGTGIPNIRWFGIEGDYNVLVLDLLGPSLEDLFNFCSRKFSLKTVLMLADQLINRVEYVHAKSFLHRDIKPDNFLMGLGRRANQVYIIDFGLAKKYRDPSTHQHIPYRENKNLTGTARYASINTHLGIEQSRRDDLESLGYVLMYFLRGSLPWQGLKAGTKKQKYEKISEKKMSTPIEVLCKNYPSEFASYFHYCRSLRFDDKPDYAYLKRIFRDLFIREGFQFDYVFDWTILKYQQSQISGGSSTRLGASAGQTSGALGTGATGSRDLQRPTEPMDPSRRRLPGGANGSGVANALDSSKHKSPGLDESAKDSALAVVSEPERMHTSSYATRGGSSSRRAVLSSSRPSGASAEVVDSSRTGSSKLGPTSLRSSAGMQRSSPVTSDPKRISSRHPQPPSANLRIYEAAIKGVESLSVEVDQSRYK Deduced amino acid sequence of CK-3from Physcomitrella patens (SEQ ID NO:33)MSKARVYTDVNVQRPKDYWDYEALTVQWGDQDDYEVVRKVGRGKYSEVFEGVNAVNSERCVMKILKPVKKKKIKREIKILQNLCGGPNIVKLLDIVRDQQSKTPSLIFEYVNNTDFKVLYPTLTDFDIRYYIHELLKALDYCHSQGIMHRDVKPHNVMIDHEQRKLRLIDWGLAEFYHPGKEYNVRVASRYFKGPELLVDLQDYDYSLDMWSLGCMFAGMIFRKEPFFYGHDNYDQLVKIAKVLGTDELNSYLNKYRLELDPHLEALVGRHSRKPWSKFINADNQRLVVPEAVDFLDKLLRYDHQDRLTAKEAMAHPYFYPVKVSEVSNRRSA Deduced amino acid sequence of MPK-2from Physcomitrella patens (SEQ ID NO:34)METSSGTPELKVISTPTYGGHYVKYVVAGTDFEVTARYKPPLRPIGRGAYGIVCSLFDTVTGEEVAVKKIGNAFDNRIDAKRTLREIKLLRHMDHENVVAITDIIRPPTRENFNDVYIVYELMDTDLHQIIRSNQALTEDHCQYFLYQILRGLKYIHSANVLHRDLKPTNLLVNANCDLKIADFGLARTLSETDFMTEYVVTRWYRAPELLLNCSAYTAAIDIWSVGCIFMELLNRSALFPGRDYVHQLRLITELIGTPEDRDLGFLRSDNARRYIKHLPRQSPIPLTQKFRGINRSALDLVEKMLVFDPAKRITVEAALAHPYLASLHDINDEPASVSPFEFDFEEPPISEEHIKDLIWREALDCSLGPDDMVQ Deduced amino acid sequence of MPK-3 fromPhyscomitrella patens (SEQ ID NO:35)MGLTPFSCVTVQGYVRVVYPDGHVENLSKSCSVHDLLLGNPDYYVCGSTPYTITNRMAAEEVLEYGVTYFVCATPNAQPFLERQPKVVHRGSKILPRFSKHGVHYRELRSPTHGSQQSRKVFDYHSVTMQQLESIRNEGPEPHLAGDRPSKHLKLVFIRHCLRALRLPRISIDLMESPLPNLSGEALSPTATAKDEITQMILKSAARSELGMYVSKRQEFYLRRARRRRKFAWKPVLQSISEMKPVMEFHTPMAYRDSGSPPKNASTPSLPGPKNISPPRQVSVPQRSSPPPKNVSPPPQPAFVARTASKYSAASQQVQRNRGNAKSLYMA Deduced amino acid sequence of MPK-4from Physcomitrella patens (SEQ ID NO:36)MSRRVRRGGLRVAVPKQETPVSKFLTASGTFQDDDIKLNHTGLRVVSSEPNLPTQTQSSSPDGQLSIADLELVRFLGKGAGGTVQLVRHKWTNYNYALKAIQMNINETVRKQIVQELKINQVTHQQCPYIVECFHSFYHNGVISMILEYMDRGSLSDIIKQQKQIPEPYLAVIASQVLKGLEYLHQVRHIIHRDIKPSNLLINHKGEVKISDFGVSAVLVHSLAQRDTFVGTCTYMSPERLQGRSYAYDSDLWSLGLTLLECALGTFPYKPAGMEEGWQNFFILMECIVNQPPAAASPDKESPEFCSFIESCIRKCPSERPSTTDLLKHPFLQKYNEEEYHLSKIL Deduced amino acidsequence of MPK-5 from Physcomitrella patens (SEQ ID NO:37)MSRRVRRGGLRVAVPKQETPVSKFLTASGTFQDDDIKLNHTGLRVVSSEPNLPTQTQSSSPDGQLSIADLELVRFLGKGAGGTVQLVRHKWTNVNYALKAIQMMNINETVRKQIVQELKINQVTHQQCPYIVECFHSFYHNGVISMILEYMDRGSLSDIIKQQKQIPEPYLAVIASQVLKGLEYLHQVRHIIHRDIKPSNLLINHKGEVKISDFGVSAVLVHSLAQRDTFVGTCTYMSPERLQGRSYAYDSDLWSLGLTLLECALGTFPYKPAGMEEGWQNFFILMECIVNQPPAAASPDKFSPEFCSFIESCIRKCPSERPSTTDLLKHPFLQKYNEEEYHLSKIL Deduced amino acidsequence of CPK-1 from Physcomitrella patens (SEQ ID NO:38)MGQCYGKFDDGGEGEDLFERQKVQVSRTPKHGSWSNSNRGSFNNGGGASPMRAKTSFGSSHPSPRHPSASPLPHYTSSPAPSTPRRNIFKRPFPPPSPAKHIQSSLVKRHGAKPKEGGAIPEAVDGEKPLDKHFGYHKNFATKYELGHEVGRGHFGHTCYAKVRKGEHKGQAVAVKIISKAKMTTAIAIEDVGREVKILKALTGHQNLVRFYDSCEDHLNVYIVMELCEGGELLDRILSRGGKYSEEDAKVVVRQILSVVAFCHLQGVVHRDLKPENFLFTTKDEYAQLKAIDFGLSDFIKPDERLNDIVGSAYYVAPEVLHRLYSMEADVWSIGVITYILLCGSRPFWARTESGIFRAVLRADPSFEEAPWPSISPEAKDFVKRLLNKDMRKRMTAAQALTHPWIRSNNVKIPLDILVYRLVRNYLRASSMRKAALKALSKTLTEDETFYLRTQFMLLEPSNNGRVTFENFRQALLKNSTEAMKESRVFEILESMDGLHFKKMDFSEFCAAAISVLQLEATERWEQHARAAYDIFEKEGNRVIYPDELAKEMGLAPNVPAQVFLDWIRQSDGRLSFTGFTKLLHGISSRAIKNLQQ Deduced amino acidsequence of CPK-2 from Physcomitrella patens (SEQ ID NO:39)MGNTSSRGSRKSTRQVNQGVGSQDTREKNDSVNPKTRQGGSVGANNYGGKPSSGAQAGERSTSAPAALPRPKPASRSVSGVLGKPLSDIRQSYILGRELGRGQFGVTYLCTDKMTNEAYACKSIAKRKLTSKEDIEDVKREVQIMHHLSGTPNIVVLKDVFEDKHSVHLVMELCAGGELFDRIIAKGHYSERAAADMCRVIVNVVHRCHSLGVFHRDLKPENFLLASKAEDAPLKATDFGLSTFFKPGDVFQDIVGSAYYVAPEVLKRSYGPEADVWSAGVIVYILLCGVPPFWAETEQGIFDAVLKGHIDFENDPWPKISNGAKDLVRKMLNPNVKIRLTAQQVLNHPWMKEDGDAPDVPLDNAVLTRLKNFSAANKMKKLALKVIAESLSEEEIVGLREMFKSIDTDNSGTVTFEELKEGLLKQGSKLNESDIRKLMEAADVDGNGKIDFNEFISATMHMNKTEKEDHLWAAFMHFDTDNSGYITIDELQEAMEKNGMGDPETIQEIISEVDTDNDGRIDYDEFVAMMRKGNPGAENGGTVNKPRHR

1. A transgenic plant cell transformed with an expression vectorcomprising an isolated polynucleotide encoding a full-length polypeptidehaving casein kinase II activity.
 2. The plant cell of claim 1, whereinthe isolated polynucleotide encodes a polypeptide selected from thegroup consisting of: a) a polypeptide having a sequence as set forth inamino acids 1 to 333 of SEQ ID NO:33; b) a polypeptide having a sequenceas set forth in Swiss-Prot Accession Number O64816, Swiss-Prot AccessionNumber Q9ZR52, Swiss-Prot Accession Number P28523, Swiss-Prot AccessionNumber Q9SN18, or Swiss-Prot Accession Number Q08466; and c) apolypeptide having at least about 87% sequence identity to thepolypeptides of a) or b).
 3. The plant cell of claim 2, wherein thepolynucleotide encodes the polypeptide having the sequence as set forthin amino acids 1 to 333 of SEQ ID NO:33.
 4. The plant cell of claim 2,wherein the polynucleotide encodes the polypeptide having the sequenceas set forth in Swiss-Prot Accession Number O64816, Swiss-Prot AccessionNumber Q9ZR52, Swiss-Prot Accession Number P28523, Swiss-Prot AccessionNumber Q9SN18, or Swiss-Prot Accession Number Q08466.
 5. The plant cellof claim 2, wherein the polynucleotide encodes the polypeptide having atleast about 87% sequence identity to the polypeptide having the sequenceas set forth in amino acids 1 to 333 of SEQ ID NO:33.
 6. The plant cellof claim 1, wherein the polynucleotide is selected from the groupconsisting of: a) a polynucleotide having a sequence as set forth innucleotides 1 to 1217 of SEQ ID NO:20; b) a polynucleotide encoding apolypeptide having a sequence as set forth in amino acids 1 to 333 ofSEQ ID NO:33; and c) a polynucleotide which hybridizes to thepolynucleotide of a) or to the poly nucleotide of b) in 6×SSC at about45° C., followed by one or more washes in 0.2×SSC and 0.1% SDS at 50-65°C.
 7. The plant cell of claim 6, wherein the polynucleotide has thesequence as set forth in nucleotides 1 to 1217 of SEQ ID NO:20.
 8. Theplant cell of claim 6, wherein the polynucleotide encodes thepolypeptide having a sequence as set forth in amino acids 1 to 333 ofSEQ ID NO:33.
 9. The plant cell of claim 6, wherein the polynucleotidehybridizes to the polynucleotide having the sequence as set forth innucleotides 1 to 1217 of SEQ ID NO:33 in 6×SSC at about 45° C., followedby one or more washes in 0.2×SSC and 0.1% SDS at 50-65° C.
 10. Atransgenic plant transformed with an expression cassette comprising anisolated polynucleotide encoding a full-length polypeptide having caseinkinase II activity.
 11. The plant of claim 10, wherein the isolatedpolynucleotide encodes a polypeptide selected from the group consistingof: a) a polypeptide having a sequence as set forth in amino acids 1 to333 of SEQ ID NO:33; b) a polypeptide having a sequence as set forth inSwiss-Prot Accession Number O64816, Swiss-Prot Accession Number Q9ZR52,Swiss-Prot Accession Number P28523, Swiss-Prot Accession Number Q9SN18,or Swiss-Prot Accession Number Q08466; and c) a polypeptide having atleast about 87% sequence identity to the polypeptides of a) orb). 12.The plant of claim 11, wherein the polynucleotide encodes thepolypeptide having the sequence as set forth in amino acids 1 to 333 ofSEQ ID NO:33.
 13. The plant of claim 11, wherein the polynucleotideencodes the polypeptide having the sequence as set forth in Swiss-ProtAccession Number O64816, Swiss-Prot Accession Number Q9ZR52, Swiss-ProtAccession Number P28523, Swiss-Prot Accession Number Q9SN18, orSwiss-Prot Accession Number Q08466.
 14. The plant of claim 11, whereinthe polynucleotide encodes the polypeptide having at least about 87%sequence identity to the polypeptide having the sequence as set forth inamino acids 1 to 333 of SEQ ID NO:33.
 15. The plant of claim 10, whereinthe polynucleotide is selected from the group consisting of: a) apolynucleotide having a sequence as set forth in nucleotides 1 to 1217of SEQ ID NO:20; b) a polynucleotide encoding a polypeptide having asequence as set forth in amino acids 1 to 333 of SEQ ID NO:33; and c) apolynucleotide which hybridizes to the polynucleotide of a) or to thepoly nucleotide of b) in 6×SSC at about 45° C., followed by one or morewashes in 0.2×SSC and 0.1% SDS at 50-65° C.
 16. The plant of claim 15,wherein the polynucleotide has the sequence as set forth in nucleotides1 to 1217 of SEQ ID NO:20.
 17. The plant of claim 15, wherein thepolynucleotide encodes the polypeptide having a sequence as set forth inamino acids 1 to 333 of SEQ ID NO:33.
 18. The plant of claim 15, whereinthe polynucleotide hybridizes to the polynucleotide having the sequenceas set forth in nucleotides 1 to 1217 of SEQ ID NO:33 in 6×SSC at about45° C., followed by one or more washes in 0.2×SSC and 0.1% SDS at 50-65°C.
 19. The plant of claim 10, wherein the plant is a monocot.
 20. Theplant of claim 20, wherein the plant is a dicot.
 21. The plant of claim10, wherein the plant is selected from the group consisting of maize,wheat, rye, oat, triticale, rice, barley, soybean, peanut, cotton,rapeseed, canola, manihot, pepper, sunflower, tagetes, potato, tobacco,eggplant, tomato, Vicia species, pea, alfalfa, coffee, cacao, tea, Salixspecies, oil palm, coconut, perennial grasses, and a forage crop plant.22. A seed which is true breeding for a transgene comprising apolynucleotide encoding a full-length polypeptide having casein kinaseII activity.
 23. The seed of claim 22, wherein the polypeptide isselected from the group consisting of: a) a polypeptide having asequence as set forth in amino acids 1 to 333 of SEQ ID NO:33; b) apolypeptide having a sequence as set forth in Swiss-Prot AccessionNumber O64816, Swiss-Prot Accession Number Q9ZR52, Swiss-Prot AccessionNumber P28523, Swiss-Prot Accession Number Q9SN18, or Swiss-ProtAccession Number Q08466; and c) a polypeptide having at least about 87%sequence identity to the polypeptides of a) or b).
 24. The seed of claim23, wherein the polynucleotide encodes the polypeptide having thesequence as set forth in amino acids 1 to 333 of SEQ ID NO:33.
 25. Theseed of claim 23, wherein the polynucleotide encodes the polypeptidehaving the sequence as set forth in Swiss-Prot Accession Number O64816,Swiss-Prot Accession Number Q9ZR52, Swiss-Prot Accession Number P28523,Swiss-Prot Accession Number Q9SN18, or Swiss-Prot Accession NumberQ08466.
 26. The seed of claim 23, wherein the polynucleotide encodes thepolypeptide having at least about 87% sequence identity to thepolypeptide having the sequence as set forth in amino acids 1 to 333 ofSEQ ID NO:33.
 27. The seed of claim 22, wherein the polynucleotide isselected from the group consisting of: a) a polynucleotide having asequence as set forth in nucleotides 1 to 1217 of SEQ ID NO:20; b) apolynucleotide encoding a polypeptide having a sequence as set forth inamino acids 1 to 333 of SEQ ID NO:33; and c) a polynucleotide whichhybridizes to the polynucleotide of a) or to the poly nucleotide of b)in 6×SSC at about 45° C., followed by one or more washes in 0.2×SSC and0.1% SDS at 50-65° C.
 28. The seed of claim 27, wherein thepolynucleotide has the sequence as set forth in nucleotides 1 to 1217 ofSEQ ID NO:20.
 29. The seed of claim 27, wherein the polynucleotideencodes the polypeptide having a sequence as set forth in amino acids 1to 333 of SEQ ID NO:33.
 30. The seed of claim 27, wherein thepolynucleotide hybridizes to the polynucleotide having the sequence asset forth in nucleotides 1 to 1217 of SEQ ID NO:33 in 6×SSC at about 45°C., followed by one or more washes in 0.2×SSC and 0.1% SDS at 50-65° C.31. An isolated nucleic acid comprising a polynucleotide selected fromthe group consisting of: a) a polynucleotide having a sequence as setforth in SEQ ID NO:20; and b) a polynucleotide encoding a polypeptidehaving a sequence as set forth in SEQ ID NO:33.
 32. The isolated nucleicacid of claim 31, wherein the polynucleotide has the sequence as setforth in SEQ ID NO:20.
 33. The isolated nucleic acid of claim 31,wherein the polynucleotide encodes the polypeptide having the sequenceas set forth in SEQ ID NO:33.
 34. A method of producing adrought-tolerant transgenic plant, the method comprising the steps of:a) transforming a plant cell with an expression vector comprising apolynucleotide encoding a full-length polypeptide having casein kinaseII activity; b) growing the transformed plant cell to generatetransgenic plants; and c) screening the transgenic plants generated instep b) to identify a transgenic plant that expresses the polypeptideand exhibits increased tolerance to drought stress as compared to a wildtype variety of the plant.
 35. The method of claim 34, wherein thepolypeptide is selected from the group consisting of: a) a polypeptidehaving a sequence as set forth in amino acids 1 to 333 of SEQ ID NO:33;b) a polypeptide having a sequence as set forth in Swiss-Prot AccessionNumber O64816, Swiss-Prot Accession Number Q9ZR52, Swiss-Prot AccessionNumber P28523, Swiss-Prot Accession Number Q9SN18, or Swiss-ProtAccession Number Q08466; and c) a polypeptide having at least about 87%sequence identity to the polypeptides of a) or b).
 36. The method ofclaim 35, wherein the polynucleotide encodes the polypeptide having thesequence as set forth in amino acids 1 to 333 of SEQ ID NO:33.
 37. Themethod of claim 35, wherein the polynucleotide encodes the polypeptidehaving the sequence as set forth in Swiss-Prot Accession Number O64816,Swiss-Prot Accession Number Q9ZR52, Swiss-Prot Accession Number P28523,Swiss-Prot Accession Number Q9SN18, or Swiss-Prot Accession NumberQ08466.
 38. The method of claim 35, wherein the polynucleotide encodesthe polypeptide having at least about 87% sequence identity to thepolypeptide having the sequence as set forth in amino acids 1 to 333 ofSEQ ID NO:33.
 39. The method of claim 34, wherein the polynucleotide isselected from the group consisting of: a) a polynucleotide having asequence as set forth in nucleotides 1 to 1217 of SEQ ID NO:20; b) apolynucleotide encoding a polypeptide having a sequence as set forth inamino acids 1 to 333 of SEQ ID NO:33; and c) a polynucleotide whichhybridizes to the polynucleotide of a) or to the poly nucleotide of b)in 6×SSC at about 45° C., followed by one or more washes in 0.2×SSC and0.1% SDS at 50-65° C.
 40. The method of claim 39, wherein thepolynucleotide has the sequence as set forth in nucleotides 1 to 1217 ofSEQ ID NO:20.
 41. The method of claim 39, wherein the polynucleotideencodes the polypeptide having a sequence as set forth in amino acids 1to 333 of SEQ ID NO:33.
 42. The method of claim 39, wherein thepolynucleotide hybridizes to the polynucleotide having the sequence asset forth in nucleotides 1 to 1217 of SEQ ID NO:33 in 6×SSC at about 45°C., followed by one or more washes in 0.2×SSC and 0.1% SDS at 50-65° C.